Data Analytics and Mathematical Models to Facilitate Disease Prevention in the U.S. by Apergi, Lida Anna
ABSTRACT
Title of dissertation: DATA ANALYTICS AND MATHEMATICAL
MODELS TO FACILITATE DISEASE
PREVENTION IN THE U.S.
Lida Anna Apergi
Doctor of Philosophy, 2020
Dissertation directed by: Professor John Baras
Institute for Systems Research
Professor Bruce Golden
Robert H. Smith School of Business
The U.S. is leading in healthcare expenditures worldwide, but health outcomes in the
U.S. are not reflective of the level of spending. Prevention plays a crucial role in improv-
ing the health of individuals in the U.S., since it helps people live longer and healthier
lives. Preventive services include actions that prevent diseases from ever occurring, detect
diseases at an early stage, and manage diseases that have already been diagnosed. In this
dissertation, we use data analytics and mathematical modeling techniques to better under-
stand factors that influence disease prevention and help provide efficient solutions.
In the first part of this dissertation, we study two problems of disease prevention at
the public health level. First, we investigate the impact of state-level vaccination exemp-
tion policy and of the highly publicized Disneyland measles outbreak on MMR vaccination
rates of young children. At the same time, we highlight the impact that the choice of socioe-
conomic factors can have on measurement results. We estimate the impact of these policies
using multiple linear regression. Furthermore, we study the sensitivity of the results by
examining a number of different approaches for the selection of socioeconomic control
variables. Second, we utilize big data to estimate the additive cost of chronic diseases and
study their cost patterns. We model the cost based on a cost hierarchy; that is, the cost of
each condition is modeled as a function of the number of other more expensive chronic con-
ditions the individual has. Using large scale claims data, we identify members that suffer
from one or more chronic conditions and estimate their healthcare expenditures. Through
our analysis, we categorize the chronic conditions into different expenditure groups based
on the characteristics of their cost profiles.
In the second part of this dissertation, we study two problems of disease prevention
at the healthcare provider level, focusing in the area of cardiology. First, we study the
adoption of conversational agent technology by patients with heart failure. Conversational
agents can help patients with heart failure to manage their condition and provide frequent
feedback to their healthcare providers. We analyze data from two studies, with each study
focusing on a different type of conversational agent. We compare the two types of conver-
sational agent technologies in terms of patient engagement, and investigate which patient
characteristics are important in determining the patient engagement. Second, we tackle the
problem of outpatient scheduling in the cardiology department of a large medical center.
The outpatients have to go through a number of diagnostic tests and treatments before they
can complete the final procedure. We develop an integer programming model to schedule
2
appointments that are convenient for the outpatients by minimizing the number of visits
that the patients have to make to the hospital and the time they spend waiting in the hospi-
tal. Furthermore, we investigate whether scheduling outpatients in groups can lead to better
schedules for the patients.
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Κάλλιον το προλαμβάνειν ή το θεραπεύειν.
- Prevention is better than cure -
Hippocrates of Kos, 460-370 BC
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The national health expenditures in the U.S. in 2018 were $3.6 trillion, which cor-
responds to 17.7% of the gross domestic product (GDP). During the 2000 to 2018 time
period, the average annual increase in national health spending was 5.7%, with a total
increase of 167% from 2000 to 2018. In particular, the per capita annual expenditures
increased from $4,855 1 in 2000 to $11,172 in 2018 [34]. Based on the current rate of
increase, projections estimate that by 2027, the annual health expenditures will reach $6.0
trillion, and correspond to 19.4% of the GDP [35]. Thus, based on U.S. population pro-
jections [31], the per capita annual expenditures in 2027 will be $17,207. Increases in
health expenditures in the U.S. are mostly attributed to the increasing prices of healthcare
services and goods [8], but also, to a smaller extent, to the aging population and the popu-
lation growth [42]. On the other hand, disease prevalence is not as strongly associated with
the increase in expenditures in the U.S., and for some conditions it has been found to even
have a negative association with total health expenditures [42].
Across all OECD (Organization for Economic Co-operation and Development) coun-
1All amounts in 2018 dollars
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tries, the U.S. has the highest per capita health expenditures and the highest percentage of
GDP associated with health expenditures. However, the U.S. is not associated with im-
proved health outcomes. In particular, the U.S. is the only OECD country that spends more
than the OECD average but has lower than average life expectancy and higher than average
avoidable mortality rates (i.e., deaths that could have been avoided through public health or
medical interventions [119]). Furthermore, the U.S. is associated with lower than average
healthcare coverage and fewer doctors than the OECD average [120]. Comparing the U.S.
with 10 high-income countries (i.e., Australia, Canada, Denmark, France, Germany, Japan,
the Netherlands, Sweden, Switzerland, and the United Kingdom), yields similar results,
with the U.S. having the highest percentage of GDP spent on healthcare but the lowest life
expectancy and the highest infant mortality across the 11 countries [125].
From the above, we see that improvements can be made to the U.S. healthcare system,
both in terms of healthcare expenditures, and health outcomes. In order to reduce health-
care expenditures, proposed actions that could be taken include reducing the prices for
prescription drugs, administration fees, and hospital services [40, 41]. On the other hand,
in order to improve health outcomes it is crucial to focus more on preventive care, which
can help prevent or treat a condition at an early stage. Treating a condition early means
that it is more likely that future, more complex, and expensive treatments will be avoided
[40]. There is no clear evidence that prevention initiatives lead to lower healthcare expen-
ditures, with one reason being that prevention leads to increased longevity, which increases
the likelihood of developing other conditions [115]. Nevertheless, prevention is crucial in
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improving the health of individuals in the U.S., since it helps people live longer and lead
healthier lives [52]. For that reason, it is critical to identify areas that require prevention
interventions and investigate ways to make it easy for people to use existing preventive
services.
1.2 Facilitating disease prevention
There are three levels of preventive services [115]. In primary prevention, the goal is
to prevent a disease before it occurs. Examples of primary prevention include vaccinating
children against an infectious disease, educating the population about sexually transmitted
diseases, promoting healthy foods and regular exercise, and banning smoking in restau-
rants. In secondary prevention, the goal is to detect a disease at an early stage, which will
make it easier to stop its further development. Examples of secondary prevention include
mammogram screenings, bone density tests, and and regular blood pressure testing. Finally,
in tertiary prevention, the goal is to manage a disease that has been diagnosed in order to
stop or slow its progression and minimize its symptoms. Examples include screening for
complications, rehabilitation, and surgery.
Prevention can be promoted both at the state level, through public health policy and
interventions, and at the healthcare provider level, by helping patients manage their con-
ditions, promoting screenings, and even creating a positive healthcare experience for the
patients, such that the patients will not avoid seeking necessary treatment in the future
[61]. In this dissertation, we study four prevention-related problems, starting with two
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problems at the public health level, and continuing with two problems at the healthcare
provider level. These are introduced below.
First, we study a problem in vaccination uptake, which is an example of primary pre-
vention. Vaccines not only help save lives but also contribute to economic growth, and
efficient healthcare systems. Increasing the percentage of the population that is healthy,
means that more people are able to work or get an education, which leads to immediate
and future productivity gains. Furthermore, vaccination decreases the number of disease
outbreaks in a society, which helps to maintain more stable levels of resource requirements
in the healthcare system [138]. In the U.S., it was estimated that the economic burden of
unvaccinated adults suffering from vaccine-preventable diseases was $7.1 billion during
one year (2015) [124]. Thus, it is important to identify factors that influence vaccination
uptake in the U.S.
In this dissertation, we focus on measles vaccination uptake across the U.S. The cost of
a measles outbreak can be broken down into three categories [157]. First, the immunologic
costs have to do with the measles infection as well as post-infection implications which
can last up to a few years. Second, the financial cost of dealing with measles can be up
to $142,000 for each individual infection if we also take into account the cost of tracking
down people that were exposed to the infection, putting people in quarantine, and inform-
ing the public about measles prevention. Third, the stress imposed on the public health
system during an outbreak can affect the capability of the system to cope with other po-
tential infections. It is estimated that a 5% decrease in the current measles coverage in the
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U.S. would triple the number of annual measles cases of children 2 to 11 years old. That
would correspond to an additional cost of $2.1 million in the public sector [92]. In our
study, we investigate how vaccination exemption policies and media coverage of previous
outbreaks impact the measles vaccination rates. Furthermore, we demonstrate that different
approaches in the way that socioeconomic controls (i.e., education, health, community, and
economic characteristics) are chosen can lead to considerably different conclusions, which
can have serious implications for policy studies.
Second, we study the costs related to the management of chronic conditions. In the
U.S., one in two adults is diagnosed with at least one chronic condition [171], with the
direct costs associated with the treatment of chronic conditions equal to $1.1 trillion in
2016 [173]. If the economic burden of lost productivity is also taken into account, the total
costs of chronic conditions increases to $3.7 trillion, which was the equivalent of nearly
20% of the GDP during that year [173]. A number of chronic conditions are considered
to be preventable since they can be avoided or treated by following more healthy lifestyles
and going through the necessary screenings [11]. Examples include many types of heart
conditions, cancers, pulmonary conditions, diabetes, and hypertension, which together cost
over $433 billion in 2013 [143]. From the above, we see that it is crucial to investigate ways
to prevent chronic conditions. In order to decide where to direct the prevention efforts, it
is critical to better understand the costs associated with each condition and the effect that
combinations of chronic conditions have on the healthcare expenditures.
In our work, we study the healthcare costs of multiple chronic conditions. About one
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in four adults in the U.S. have multiple (at least two) chronic conditions [171]. Thus, it is
important to understand how the healthcare expenditures for each type of chronic condition
change when other conditions are also present. This information can be used to better
estimate the effect of preventive programs and policies on the healthcare expenditures of a
population and, thus, help to decide on the direction of the interventions. In our study, we
expand our analysis to 69 chronic condition categories, which is a larger set of conditions
compared to previous studies. We propose a novel approach to model the cost based on
a cost hierarchy, where the cost of each condition is modeled as a function of the number
of other more expensive chronic conditions the individual has. Furthermore, based on the
results of our model, we categorize the chronic conditions into different expenditure groups
based on their cost behavior characteristics.
The other two studies in this dissertation focus on promoting prevention at the health-
care provider level. Both studies deal with problems in tertiary prevention, since they
investigate ways of helping patients to manage and treat their conditions as necessary. Fur-
thermore, both studies are dealing with the management of heart conditions, which are the
chronic conditions associated with one of the highest annual healthcare expenditures in the
U.S. In particular, the cost of heart conditions in 2013 was equal to $147 billion and was
second only to the cost of mental disorders ($201 billion) [143].
In our third study, we focus on the management of heart failure. Heart failure is a
condition with high prevalence and high hospitalization and readmission rates [179]. The
direct annual healthcare costs of heart failure are estimated at over $30 billion in the U.S.
6
and are expected to increase over time [75]. Thus, it is important to investigate ways to help
patients manage their condition. A crucial factor for the successful management of heart
failure is self-care, which includes taking medication, limiting salt intake, and also looking
for symptoms that might cause concern [141]. One approach to help with the management
of the condition at home is through telehealth. With telehealth, the healthcare provider can
get daily feedback from the patient and understand whether the patient is following the
provided instructions correctly, whether there are any concerning symptoms present, and
whether intervention is necessary.
In this dissertation, we investigate the use of conversational agent technology by pa-
tients with heart failure. The advantage of using this type of technology for telehealth
is that the patient can hear the questions and answer them through speech. This allows
patients with limited experience with technology to participate in telehealth, since it is
more intuitive to use speech to answer questions instead of, for example, entering answers
through a screen. In our work, we compare two types of conversational agent technologies,
one is based on the Amazon Alexa technology and only uses voice, while the other uses
an Avatar to ask questions through a tablet, combining voice and image. Furthermore, we
examine which patient characteristics are linked to higher levels of technology usage.
In our fourth and final study, we focus on making access to healthcare services as ef-
fortless as possible for patients, in order to ensure that they will not avoid seeking treatment
when necessary. For example, if long waiting times are observed in an emergency center of
a hospital, then some patients may decide to leave before being seen by a physician [145].
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This can be dangerous for the health of the patients and can cause an additional burden to
the hospital in the future, since treating patients will become more difficult and expensive
if the health of the patients deteriorates. Similarly, people who have experienced long wait-
ing times in the past in a hospital or a physician’s office may avoid going to the doctor in
the future or may be more likely to not show up for an appointment [158]. Therefore, it is
crucial to make the experience of visiting a healthcare provider as efficient as possible in
terms of patient waiting times. This can be achieved through scheduling.
In particular, in this dissertation, we investigate the problem of multi-appointment
scheduling for outpatients. We focus on outpatients who plan to have an elective pro-
cedure in cardiology. These patients have to first complete a number of diagnostic tests
and/or treatments before they are ready for the final procedure. This means that they have
to travel to the hospital on multiple occasions and have to spend time waiting from one ap-
pointment to the next. Since some of these patients may depend on someone else to drive
them to and from the hospital, it is important to generate schedules that are convenient for
them and match their availability. This is currently done manually by the scheduling staff,
which can be complicated and time consuming. We propose a mathematical programming
formulation in order to help obtain better solutions to this problem. The patients in this
case would not have to travel to the hospital more often than necessary or have to wait in
the hospital for long periods of time.
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1.3 Summary of contributions
The rest of the dissertation is organized as follows.
Chapter 2 investigates factors that are linked with high or low measles vaccination rates
at the state level in the U.S. The main contributions of this chapter are that we examine
the effect of allowing personal belief exemptions on vaccination rates of younger children,
who do not necessarily attend school, and study the impact of the Disneyland outbreak
on vaccination rates of subsequent years. Furthermore, we demonstrate the importance of
socioeconomic control selection in policy studies.
Chapter 3 examines the contribution of different types of chronic conditions to the total
healthcare cost of individuals. We contribute to the existing literature by proposing a novel
approach to model the cost of chronic conditions, when more than one conditions might be
present in the patient. This allows us to expand the number of chronic conditions and their
combinations taken into account, and thus examine the cost patterns of multiple chronic
conditions.
Chapter 4 discusses the use of conversational agents by patients with heart failure. In
particular, the contribution of this chapter is twofold. First, we compare two types of con-
versational agent technologies with respect to patient engagement. Second, we identify
patient characteristics (including demographic, clinical, and technology-related character-
istics) that impact engagement with conversational agent technology.
Chapter 5 studies the problem of multi-appointment scheduling for outpatients in cardi-
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ology. The contributions of this chapter include proposing an IP formulation for scheduling
outpatients in a cardiology setting, and providing formulation improvements that can be ap-
plied to other scheduling problems following a similar formulation approach. Finally, we
study whether and how patients should be grouped when scheduling under different sce-
narios of resource availability and external demand.
Finally, Chapter 6 concludes the dissertation and presents potential directions for future
research.
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Chapter 2: MMR vaccination rates of 19-35 months old children: The im-
portance of socioeconomic factor selection
2.1 Introduction
In this chapter, we study factors influencing the measles vaccination uptake in the U.S.,
which is a problem at the primary prevention level. Measles is an infectious disease, which
has caused millions of deaths in the past. A vaccine for measles was first introduced in
the U.S. in 1963 and led to a drastic decrease in the number of measles cases reported per
year [106]. Currently, in most instances, the measles vaccine is distributed in combination
with vaccines against two other diseases. The resulting vaccine is called MMR (measles,
mumps, and rubella) and is the one most commonly used to protect against measles. It is
recommended that children get their first MMR dose before the age of 15 months, and the
second dose between the ages of 4 and 6 years [29].
Some medical conditions that cause a weak immune system may prohibit the vaccina-
tion of a child. For example, children going through chemotherapy cannot get the MMR
vaccine. These children still get protected from the infection through herd immunity. This
means that if enough people in a community get vaccinated, even if some people are not
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able to get vaccinated, they will still get protected from the infection [177], as the infection
is unable to spread from one person to the next. In the case of measles, for herd immunity
to work, at least 96% of the population has to be vaccinated [17]. If the vaccination cov-
erage drops below that, measles outbreaks can occur in the population. Children must be
vaccinated in order to attend school; however, exemptions due to medical reasons are al-
lowed in all U.S. states and some states allow religious and personal belief (philosophical)
exemptions as well [114].
Some parents choose to not vaccinate their children, even if their child does not meet
the requirements for a medical exemption. Those parents usually believe that vaccines are
unsafe for their children, that they do not work, or that the diseases they protect from are
very rare and not too dangerous [20]. A now infamous and discredited [32, 159] study
published in 1998 [170] linked the MMR vaccination to autism. Later, the original article
was retracted. However, many parents still believe that MMR vaccinations increase the risk
for autism spectrum disorders, which has led to a decrease in the vaccination rates. Studies
have shown that states with easier exemption procedures have higher non-medical exemp-
tion rates [16, 122], and states allowing personal belief exemptions have higher exemptions
and lower vaccination rates [122, 151]. Similarly, states that have easier procedures for
obtaining a medical exemption have significantly higher exemption rates [156].
A reduction in vaccination rates has led to a decrease in the percentage of the population
that is immune to measles, which has led to a number of outbreaks [19]. Figure 2.1 includes
the number of reported measles cases in the U.S. from 2006 to 2017 [27] and the monthly
12










































Figure 2.1: Measles cases in the U.S. and popularity in the news and Google searches per month.
The bars show the number of annual measles cases. The number of news articles were obtained
from the Lexis Uni [89] database after searching for the word measles, and filtering for articles in
the U.S.. The Google searches were obtained through Google trends (trends.google.com). Both are
normalized to a maximum value of 100.
media coverage of measles as well as the Google searches of the word measles from 2006
to 2017. The most publicized measles outbreak originated in Disneyland, California, and
started in late December 2014 and continued into early February 2015 [180]. In total,
125 measles cases were reported in connection with this outbreak, affecting people from
several states. Even though there were worse outbreaks around the time of the Disneyland
outbreak, resulting in a larger number of measles cases, the Disneyland outbreak was the
event that worried or, at the very least, interested the most people. In other words, in early
2015 a large portion of the U.S. population found out about the effects of measles and how
low vaccination rates can lead to outbreaks.
Prior research has linked media coverage of the MMR vaccine to vaccination rates. In
Wales, there were significantly lower vaccination rates in a region where a newspaper was
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publishing articles against MMR vaccination [99]. A study conducted in Denmark covering
the period 1997 to 2014 found a positive correlation between MMR vaccination rates and
pro-vaccination or neutral media coverage in the period 1997 to 2004 [63]. A study utilizing
data from the National Immunization Survey (NIS) from 1995 to 2004 found a limited
association between media coverage and MMR vaccination in the U.S. [154]. There has
been limited research into the impact of the Disneyland outbreak. A survey in Colorado
found that women with children had a more positive attitude towards MMR vaccines after
the Disneyland outbreak [22]. However, very few women planning to not vaccinate their
children changed their intention.
Controlling for socioeconomic factors is critical when studying policy effects on health
outcomes, as socioeconomic factors influence health care choices, health care utilization,
and lifestyle choices [103, 116, 132] just to name a few. Socioeconomic factors that have
been shown to influence childhood vaccination rates include education, material depriva-
tion, and population density [177].
In the age of big and easily accessible data, there is access to a wide range of socioe-
conomic controls, with numerous correlated indicators available. As an example, the state
of the economy (which has been linked to healthcare utilization and health outcomes in
numerous studies) can be represented by the unemployment rate [161], average or median
wages [88], income inequality [129], affordable housing [131], and others. Simply includ-
ing all available socioeconomic factors in a model is not a good solution as it can lead to
multicollinearity, increasing variability in the model’s estimates, and, potentially, to incor-
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rect conclusions. The selection of socioeconomic factors is, therefore, a complex modeling
question, which has not been fully addressed in the literature. In this chapter, we will
demonstrate its importance. At the same time, there is significant under-reporting on the
socioeconomic factors included in the vaccination policy literature and on the method of
selection. For example, in papers studying the impact of vaccination policies on childhood
vaccination rates in the U.S., it is common for the complete output of the model, including
information about which socioeconomic factors are used, their corresponding coefficients
and statistical significance to be missing [19, 151, 156]. In addition, the reporting of the ex-
planatory power of the corresponding models is often missing, limiting the understanding
as to what extent the included factors drive the outcome.
The goal of this study is threefold. First, we seek to understand whether exemption
regulations for school age children translate to infants and young toddlers. Prior studies
of the vaccination and exemption rates in the U.S. focus on children going to kindergarten
[16, 19, 122, 151, 156]; the impact of these policies on vaccination rates of younger children
has not been studied. Second, we aim to understand the effect of the Disneyland outbreak
on vaccination rates at the national level. To the best of our knowledge, there is no study of
MMR vaccination focusing on the period after the Disneyland outbreak [151]. Finally, we
demonstrate the importance of carefully selecting socioeconomic factors for health policy
studies. We show that the outcome of the study is highly sensitive to the selection; small
changes can lead to different results and conclusions, highlighting the importance of careful




We used state level data (all 50 states and the District of Columbia (DC)) from 2011 to
2017. The data were obtained from a number of sources, as detailed below.
The dependent variable is the annual percentage of children 19 to 35 months old that
have gotten at least one dose of the MMR vaccine, obtained from the Centers for Disease
Control and Prevention’s (CDC’s) ChildVaxView database [26]. These percentages were
estimated based on the annual NIS - Child survey [28]. This annual survey uses telephone
interviews as well as immunization histories. The state level estimation rate is estimated
based on the answers obtained from those surveyed.
Independent variables were created to reflect the vaccination exemptions in each state
using information from the National Conference of State Legislatures [114]. Exemptions
allowed in each state are either only medical, medical and religious, or medical, religious,
and personal belief exemptions. There were changes in the exemption policy of two of
the states in 2015, which were accounted for. California stopped allowing religious and
personal belief exemptions, while Vermont removed personal belief exemptions. In 2017,
three states only allowed medical exemptions, 29 states and DC allowed medical and reli-
gious exemptions, and 18 states allowed medical, religious, and personal belief exemptions.
The independent variable used in our analysis is a binary variable showing whether a state
allowed personal belief exemptions in a specific year or not.
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We account for nationwide changes in underlying vaccination rates by including annual
control variables. The annual control variable for 2015 is of special interest to understand
the impact that the Disneyland outbreak may have had on overall vaccination rates. We
hypothesize that the increased awareness of measle outbreaks would lead to higher vacci-
nation rates in 2015.
The socioeconomic independent variables in our analysis come from the Opportunity
Index database (OID) [123]. The data include a number of variables covering education,
economics, community, and healthcare (see Table 2.1 for the variables and their descrip-
tions). Where the OID data did not include full information for our study period, addi-
tional data were collected. Specifically, information on the number of medical doctors (per
100,000 population) in each state in 2016 and 2017 was gathered from the Association
of American Medical Colleges [1], and the percentage of the population without health
insurance in each state from 2011 to 2015 was collected from the American Community
Survey [3]. The OID also includes indices for overall education, economics, community,
and healthcare in each state, which are averages of the rescaled underlying factors (see
[123] for additional information). In our analysis, we consider the individual factors as
well as the indices for the economy, education, and community dimensions.
Additionally, we incorporated demographic information for each state, obtained from
the Henry J. Kaiser Family Foundation [77]. In particular, our dataset includes separate
variables for the population percentage of white, black, Hispanic, Asian, American In-
dian/Alaska Native, Native Hawaiian/Pacific Islander, and multiracial. In total, the data
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Table 2.1: Variables obtained from the Opportunity Index database.
Variable Description
Jobs Unemployment rate
Wages Median household income
Poverty Pct. of population below the federal poverty level
Income Inequality Ratio of household income at the 80th percentile to that
at the 20th percentile
Access To Banking Services Banking institutions per 10,000 population
Affordable Housing Pct. of households spending less than 30% of their in-
come on housing
Preschool Enrollment Pct. of 3- and 4-year-olds attending preschool
High School Graduation Pct. of on-time high school graduations
Postsecondary Education Pct. of adults with Associate’s degree or higher
Health Insurance Coverage Pct. of population without health insurance
Access to Medical Care Medical doctors per 100,000 population
Volunteering Pct. of adults who volunteered during the previous year
Youth Disconnection Pct. of youth not in school and not working
Violent Crime Incidents of violent crime per 100,000 population
Access to Healthy Food Grocery stores and produce vendors per 10,000 popula-
tion
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contains 32 independent variables and 357 observations, corresponding to information for
all 50 states and DC over the seven-year study period.
2.2.2 Methodology
We use multiple linear regression to model the impact of state exception policies and
other factors on annual vaccination rates, using different approaches for the selection of so-
cioeconomic factors. In addition to socioeconomic factors, all models include the exemp-
tion policy of each state, annual indicator variables (using 2011 as a reference category),
and the percentages of white, black, Hispanic, and Asian populations. The goodness-of-fit
of the various models is reported using R2. All analysis was conducted in R, version 3.5.3,
using the olsrr package for variable selection models.
A number of approaches exist to address multicollinearity [43, 55], ranging from manu-
ally selecting a few key factors to running principal component regression. We apply expert
selection as our base model. Using an econometric approach, key socioeconomic factors
were manually selected based on past research findings. The advantage of this approach
is that the factors are pre-selected, enabling the study of a specific set of socioeconomic
factors. This is the most common approach used in the health policy literature, including
the papers studying the effect of state policy on vaccination rates [19, 151, 156]. The so-
cioeconomic controls chosen were poverty rates, on-time high school graduations, lack of
insurance coverage, and access to medical care.
As sensitivity analysis, we implemented multiple different approaches to understand
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the sensitivity of the results to the socioeconomic factor selection, each discussed below.
We examined all regression models for multicollinearity using the variance inflation factor
(VIF). As a rule of thumb, a VIF value larger than 10 indicates an issue with multicollinear-
ity [6].
2.2.2.1 Manual index creation
As a first alternative, we implemented an econometric approach using the OID indices.
Instead of adding individual socioeconomic factors as independent variables, one can sum-
marize factors into indices and combine the socioeconomic factors into a few socioeco-
nomic indices. We utilized the OID indices for education, economy, and the community.
This is a knowledge-driven approach, since the indices are estimated based on the un-
derlying factors that are known to be linked to the state of the education, economy, and
community of a state.
2.2.2.2 Variable selection methods
Next, we applied variable selection methods. Variable selection methods include or ex-
clude variables from the model based on statistical measures of the variable’s influence on
the outcome (for example the p-values of the regression coefficients). As a result, variables
are automatically selected based on the data and not based on prior domain knowledge.
These models typically have fewer variables while retaining predictive power, facilitating
interpretability.
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Variable selection methods have been widely applied in the health policy literature,
with studies focusing on the impact of healthcare campaigns [70], on online healthcare
adoption [152], and on hospital readmission [110]. In our analysis we implemented forward
selection, backward elimination, stepwise selection, and the best subset methods (based
on the adjusted R2 value). For each model, all the individual socioeconomic factors are
initially included in the analysis (the OID indices were excluded).
2.2.2.3 Principal Component approach
Fundamentally, principal component analysis uses transformations to convert a set of
correlated variables into a set of values of linearly uncorrelated variables called princi-
pal components. We included the principal components in the regression in the place of
socioeconomic controls. Principal component analysis has been used in the literature to
summarize information on socioeconomic characteristics in order to, for example, explain
mortality rates in rural areas [53] and evaluate the effect of population-based payment mod-
els on health care quality and spending [155]. The principal components were generated
based on the 15 socioeconomic factors included in the study (see Table 2.1). The number
of components was selected based on the cumulative proportion of the variance accounted
for using the scree test [2]. The advantage of using principal components is that it is en-
sured that there will not be any multicollinearity issues, since the resulting variables (or
components) are uncorrelated. However, the disadvantage is lack of interpretability.
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2.2.2.4 All possible combinations
In addition to the above models, in order to highlight the potential variability in policy
and annual estimates based on which socioeconomic factors are included, we built a linear
regression model for each possible combination of socioeconomic factors. As there are 15
factors, this corresponds to 32,767 unique regression models. We examined the value of
each regression coefficient and its level of significance in every model. We focus on the
impact of the exemption policy as well as the annual indicator variables.
2.3 Results
2.3.1 Correlation analysis
In order to highlight the correlations within socioeconomic factors, we ran a correlation
analysis. Figure 2.2 shows the correlations between every pair of continuous independent
variables. We note that some of the variables are strongly correlated. For example, the
poverty rate is strongly negatively correlated with the median household income in a state.
Similarly, the percentage of the population that is white is negatively correlated with the
variables for other populations. These correlations highlight the importance of considering
multicollinearity. Summary statistics of the continuous variables can be found in Table A.1
in Appendix A.
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Figure 2.2: Correlations of all continuous independent variables in the dataset. White circles in-
dicate positive correlation and black circles indicate negative correlation, the size of the circles
indicates the magnitude of the correlation.
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Table 2.2: Econometric model for predicting MMR vaccination rates (R2 = 22.2%).
Variable Coefficient p-value VIF
(Intercept) 90.545 <0.001
Policy
Allow medical, religious, and personal belief exemptions -0.972 0.001 1.14
Socioeconomic
Poverty -0.091 0.124 2.11
Access To Medical Care 0.000 0.906 2.90
Health Insurance Coverage -0.178 0.005 4.89
High School Graduation 0.071 0.016 2.50
Demographic
Pct. of Asian population -0.025 0.744 9.60
Pct. of black population 0.055 0.136 9.20
Pct. of Hispanic population 0.031 0.408 8.47
Pct. of white population -0.014 0.745 26.8
Year
2012 -0.411 0.406 1.75
2013 0.075 0.882 1.84
2014 -0.059 0.911 1.98
2015 0.115 0.830 2.04
2016 -1.026 0.063 2.17
2017 -1.180 0.039 2.32
2.3.2 Regression results
2.3.2.1 The Base Model
The linear regression model for the econometric approach has an R2 of 22.2%. The
complete output can be found in Table 2.2.
The regression results highlight that states that allow personal belief exemptions have
lower MMR vaccination rates compared to states that do not, but are otherwise similar. The
corresponding coefficient in the model is -0.972, (p-value <0.01).
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There was a small increase in the observed vaccination rates in 2015 compared to both
2014 and 2016. However, none of the annual regression coefficients between 2012 and
2016 are statistically significantly different from the base year of 2011. Only the annual
control for 2017 is statistically significant and shows on average vaccination rates in 2017
were a full percentage point lower after accounting for all other variables in the model
(-1.180, p-value <0.05). Further, the difference between the estimated coefficients from
2012 to 2015 are minor, within half a percent. In contrast, in both 2016 and 2017, the rates
decreased below the 2011 levels. In other words, we do not observe a significant increase
in vaccination rates following the 2015 Disneyland outbreak.
In the econometric model, the socioeconomic factors that were statistically significant
were the percentage of population without medical insurance and the percentage of on-time
high school graduations. States with a higher percentage of the population being unin-
sured tend to have lower vaccination rates (-0.178, p-value <0.01) and states with higher
percentages of on-time high school graduations have higher vaccination rates (0.071, p-
value <0.05). The coefficients corresponding to the percentage of the population below the
poverty level and the access to medical doctors were not significant in the model.
In the econometric model, the VIF for the percentage of the white population equals
26.8, indicating possible issues with multicollinearity, caused by the strong negative cor-
relation between the percentage of the white population and the percentages of the other
demographic groups. Removing this variable from this model resolved the multicollinear-
ity issue, and had minimal impact on the remaining coefficients (the resulting model is
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included for comparison in Table 2.3).
Table 2.3: Econometric model (excluding pct. of white population) for predicting MMR vaccination
rates (R2 = 22.1%).
Variable Coefficient p-value VIF
(Intercept) 89.298 <0.001
Policy
Allow medical, religious, and personal belief exemptions -0.979 0.001 1.14
Socioeconomic
Poverty -0.092 0.122 2.11
Access To Medical Care 0.000 0.863 2.83
Health Insurance Coverage -0.172 0.004 4.35
High School Graduation 0.069 0.016 2.38
Demographic
Pct. of Asian population -0.002 0.948 1.34
Pct. of black population 0.066 <0.001 2.12
Pct. of Hispanic population 0.042 0.015 1.78
Year
2012 -0.410 0.406 1.75
2013 0.081 0.872 1.83
2014 -0.043 0.935 1.96
2015 0.137 0.796 2.01
2016 -0.990 0.067 2.08
2017 -1.134 0.040 2.18
2.3.2.2 Other modeling approaches
We summarize the results from the different modeling approaches in Figure 2.3. From
the top panel of the figure, we note that the models built based on the variable selection
methods have slightly higher R2 compared to the other models. In particular, the R2 of
the data-driven approaches ranges from 27.4% (stepwise selection) to 31.1% (backward
elimination and best subset). In the econometric approach using the OID indices, the R2
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Figure 2.3: Summary of the different approaches (the dashed horizontal lines in the lower panels
indicate statistical significance at the 5% level).
principal components, which account for about 84% of the variation in the socioeconomic
data. The resulting R2 from the principal component regression was 23.9%. The results
highlight the improved fit of the data-driven models compared to the manual approach, as
well as the fact that a large part of the variation in the vaccination rates is not explained by
the data. The complete output of the regression models can be found in Tables 2.4 through
2.9.
The lower left panel of Figure 2.3 summarizes the value and the significance of the re-
gression coefficient for the indicator variable for personal belief exemptions. The variable
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was selected in all data-driven approaches. For all models, we note that regression coef-
ficient is negative and statistically significant. The magnitude of the impact ranges from
-0.744 (stepwise selection) to -0.992 (econometric approach using the OID indices) or a
relative difference of 28%.
The annual control variable for 2015, the year after the outbreak in Disneyland, was also
selected by all the data-driven approaches. However, as highlighted in the lower right panel
of Figure 2.3, the magnitude and statistical significance is not consistent across the various
models. In particular, the coefficient ranges from negative (-0.246, p-value = 0.685 in the
principal component regression) to positive values (0.963, p-value <0.05 in the best subset
approach). It is worth pointing out that all the models based on variable selection methods
have similar coefficients for the 2015 control, which is positive and statistically significant.
This highlights that depending on the modeling approach chosen, the conclusion about the
effect of the Disneyland outbreak can vary considerably.
Regarding the socioeconomic controls, in the econometric approach using the OID
indices, the only statistically significant OID index is the education index. The coefficient
equals to 0.106 (p-value <0.001), indicating that the higher level of education in a state is
linked to higher MMR vaccination rates.
The variable selection models have similarities in terms of the variables included and
their coefficient values. Variables that were selected by all four methods were the number
of banking institutions per 10,000, where the coefficient ranges from 0.545 to 0.664 (p-
value <0.01), the percentage of affordable housing, with the coefficient ranging from -0.220
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Table 2.4: Regression model for predicting MMR vaccination rates based on the forward selection
method (R2 = 30.3%).
Variable Coefficient p-value VIF
(Intercept) 110.669 <0.001
Policy
Allow medical, religious, and personal belief exemptions -0.804 0.005 1.24
Socioeconomic
Affordable Housing -0.186 <0.001 3.38
Access To Banking Services 0.630 0.001 2.37
Access To Medical Care 0.004 0.193 6.29
Health Insurance Coverage -0.078 0.170 4.43
Preschool Enrollment -0.014 0.614 3.49
High School Graduation 0.027 0.328 2.54
Postsecondary Education -0.133 0.022 7.50
Youth Disconnection -0.398 <0.001 5.30
Violent Crime -0.003 0.033 3.90
Volunteering -0.042 0.252 2.54
Demographic
Pct. of American Indian/Alaska Native population 0.161 0.014 2.06
Pct. of black population 0.102 <0.001 4.05
Pct. of Hispanic population 0.039 0.056 2.71
Year
2012 -0.466 0.221 1.15
2015 0.772 0.040 1.12
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Table 2.5: Regression model for predicting MMR vaccination rates based on the backward elimina-
tion method (R2 = 31.3%).
Variable Coefficient p-value VIF
(Intercept) 130.351 <0.001
Policy
Allow medical, religious, and personal belief exemptions -0.868 0.002 1.15
Socioeconomic
Median household income 0.000 0.094 16.1
Poverty -0.293 0.059 16.2
Affordable Housing -0.185 <0.001 3.30
Access To Banking Services 0.545 0.005 2.42
Access To Medical Care 0.006 0.059 7.88
Health Insurance Coverage -0.101 0.088 4.92
High School Graduation 0.036 0.193 2.48
Postsecondary Education -0.151 0.007 7.03
Youth Disconnection -0.314 0.003 6.66
Violent Crime -0.004 0.010 4.17
Demographic
Pct. of Asian population -0.225 <0.001 4.78
Pct. of Hispanic population -0.054 0.012 3.05
Pct. of white population -0.142 <0.001 11.6
Year
2012 -0.514 0.172 1.14
2015 0.737 0.050 1.14
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Table 2.6: Regression model for predicting MMR vaccination rates based on the stepwise selection
method (R2 = 27.4%).
Variable Coefficient p-value VIF
(Intercept) 104.326 <0.001
Policy
Allow medical, religious, and personal belief exemptions -0.744 0.007 1.13
Socioeconomic
Affordable Housing -0.123 <0.001 1.45
Access To Banking Services 0.561 0.001 1.81
Youth Disconnection -0.376 <0.001 1.69
Volunteering -0.086 0.005 1.70
Demographic
Pct. of black population 0.049 0.001 1.48
Year
2015 0.893 0.013 1.01
Table 2.7: Regression model for predicting MMR vaccination rates based on the best subset method
(R2 = 31.3%).
Variable Coefficient p-value VIF
(Intercept) 123.319 <0.001
Policy
Allow medical, religious, and personal belief exemptions -0.855 0.002 1.20
Socioeconomic
Affordable Housing -0.220 <0.001 3.43
Access To Banking Services 0.664 <0.001 2.28
Health Insurance Coverage -0.146 0.008 4.18
High School Graduation 0.032 0.256 2.59
Postsecondary Education -0.107 0.025 5.21
Youth Disconnection -0.378 <0.001 5.01
Volunteering -0.053 0.135 2.41
Violent Crime -0.003 0.024 2.99
Demographic
Pct. of Asian population -0.320 <0.001 13.6
Pct. of Hispanic population -0.044 0.051 3.36
Pct. of multiracial population 0.212 0.090 7.35
Pct. of white population -0.111 <0.001 8.38
Year
2014 0.455 0.217 1.10
2015 0.963 0.010 1.11
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Table 2.8: Econometric model with OID indices for predicting MMR vaccination rates (R2 = 21%).
Variable Coefficient p-value VIF
(Intercept) 83.244 <0.001
Policy
Allow medical, religious, and personal belief exemptions -0.992 0.001 1.10
Socioeconomic
Economy Dimension 0.002 0.960 2.84
Education Dimension 0.106 <0.001 2.75
Community Dimension 0.052 0.102 3.06
Demographic
Pct. of Asian population 0.026 0.309 1.12
Pct. of black population 0.045 0.005 1.72
Pct. of Hispanic population 0.011 0.463 1.33
Year
2012 -0.520 0.292 1.72
2013 -0.131 0.791 1.74
2014 -0.209 0.683 1.86
2015 0.124 0.809 1.88
2016 -0.395 0.506 2.50
2017 -0.306 0.615 2.63
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Table 2.9: Principal Component regression for predicting MMR vaccination rates (R2 = 23.9%).
Variable Coefficient p-value VIF
(Intercept) 91.350 <0.001
Policy
Allow medical, religious, and personal belief exemptions -0.876 0.002 1.12
PCA of Socioeconomic factors
1st component -0.559 <0.001 1.59
2nd component -0.123 0.273 3.01
3rd component 0.174 0.193 1.85
4th component 0.446 0.006 1.71
5th component 0.150 0.450 2.10
Demographic
Pct. of Asian population 0.005 0.873 1.67
Pct. of black population 0.069 0.001 3.03
Pct. of Hispanic population 0.037 0.056 2.22
Year
2012 -0.637 0.201 1.82
2013 -0.238 0.646 1.96
2014 -0.473 0.405 2.36
2015 -0.246 0.685 2.69
2016 -1.298 0.045 3.04
2017 -1.381 0.046 3.49
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to -0.185 (p-value <0.01), and the percentage of youth not in school or working, where
the coefficient ranges from -0.398 to -0.314 (p-value <0.01). Furthermore, the variables
corresponding to the percentage of adults with higher education (coefficient ranges from
-0.151 to -0.107), and the incidents of violent crime per 100,000 population (coefficient
ranges from -0.004 to -0.003) were included in three out of the four models and are in
all cases statistically significant at the 5% level. Other variables that were included in
three of the four models were the percentage of adults who volunteer, where the coefficient
ranges from -0.086 to -0.042, only statistically significant in the stepwise selection model
(-0.086, p-value <0.01), the percentage of population without health insurance, where the
coefficient ranges from -0.146 to -0.078, only statistically significant in the best subset
model (-0.146, p-value <0.01), and the percentage of on-time high school graduations,
where the coefficient ranges from 0.027 to 0.036, but is not statistically significant in any
of the models.
From the above, we see that education is linked in general to higher MMR vaccination
rates. Nevertheless, populations with a higher percentage of postsecondary education are
linked to lower vaccination rates. While this might be surprising, it is similar to the results
of [177]. Factors that are associated with economic prosperity are also linked to higher
vaccination rates. However, affordable housing is an exception since it is associated with
lower MMR rates in the models discussed above.
Multicollinearity is observed in some models resulting from variable selection methods.
In the backward elimination model, the variable corresponding to the percentage of white
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population in a state has a VIF equal to 11.6. This is similar to the multicolinearity observed
in the econometric model, since this variable is strongly negatively correlated with the
other two demographic variables included in the model. Some multicollinearity is also
observed in the demographic variables in the best subset model. Again in the backward
elimination model, the variables corresponding to the median household income and the
percentage of the population below the federal poverty level have increased VIF values.
Those two variables were identified to be strongly negatively correlated in the correlation
analysis. Since the above models were chosen based on variable selection methods, we did
not remove any of the variables. Nevertheless, this shows that the commonly used variable
selection methods do not fully safeguard against multicollinearity.
2.3.2.3 All possible combinations
Figure 2.4 summarizes the regression coefficients for all possible combinations of so-
cioeconomic factors; each model controlled for a different set of socioeconomic factors. In
all possible regressions, the coefficient for allowing personal belief exemptions was neg-
ative and statistically significant at the 5% level. Thus, we can safely conclude that the
states that allow personal belief exemptions have statistically significantly lower MMR
vaccination rates. However, the range of the coefficient varies significantly between -0.62
and -1.21. The regression coefficient for 2015 in some cases was negative but not sta-
tistically significant. In other cases, the coefficient was positive, sometimes statistically
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Figure 2.4: Coefficients and significance observed for various combinations of socioeconomic con-
trols (the dashed lines indicate statistical significance at the 5% level).
itive and statistically significant coefficient for year 2015, which corresponds to less than
4% of all possible combinations. Taking a closer look at this subset of models, two vari-
ables commonly appear; the percentage of affordable housing and the number of banking
institutions. Out of the 1,269 models, 1,027 models included both variables, 87 included
affordable housing but not banking, and 109 included banking and not affordable housing.
In total, the above corresponded to over 96% of the models with a positive and statistically
significant coefficient for 2015.
2.4 Discussion
This study focused on the vaccination rates of children between 19 and 35 months old.
Independent of the modeling approach taken, the coefficient of allowing personal exemp-
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tions was negative and statistically significant. From our baseline model, we estimate the
impact of allowing personal exception to be −0.97 percentage points. The impact was
estimated to be between −0.74 and −0.99 percentage points when using other modeling
approaches commonly applied in the literature. Allowing for selection of any socioeco-
nomic controls the estimated impact is between −0.62 and −1.21 percentage points. Our
study demonstrated the sensitivity of the choice of socioeconomic factors on policy im-
pact estimates, highlighting the importance of carefully selecting socioeconomic factors in
regression modeling aimed at estimating policy effects.
Our study population does not necessarily attend preschool [113] and is, therefore, not
directly influenced by school vaccination requirements. However, we observe that young
children living in states where personal belief exemptions are not allowed get vaccinated at
higher rates. This shows the significance of the vaccination exemption policies on MMR
immunization rates in young children. This is important because it is crucial for young
children to get vaccinated, since children younger than 5 years old have a higher risk of
serious measles complications [175].
Our empirical study of Google searches and media coverage suggests great interest in
measles following the Disneyland outbreak. This was an outbreak that affected people
from numerous states and was extensively discussed in the media. However, we cannot
draw any clear conclusions from our regression analyses about the effect of the Disneyland
outbreak on the vaccination rates. Our baseline model does not find the indicator variable
for 2015 to be statistically significant. Some of the other modeling approaches resulted in
37
a positive and statistically significant effect on vaccination rates in the year of the outbreak.
The sensitivity analysis further highlights the differences in the results, which depend on
the selected socioeconomic controls.
Most of the models that resulted in a positive and statistically significant annual in-
dicator variable for 2015 included at least one of two specific socioeconomic controls,
affordable housing and the access to banking institutions. Notably, those two controls were
also selected by all the variable selection methods, which all resulted in regression models
with a positive and statistically significant annual indicator variable for 2015. Both controls
are linked to the overall prosperity of a state, and they are correlated (ρ = 0.50). Interest-
ingly, while access to banking institutions is positively correlated with vaccination rates,
affordable housing is negatively correlated with vaccination rates.
In this work, we report the R2 for each model, which highlights that socioeconomic,
demographic, and exemption policies only explain up to 31% of the variation in state level
vaccination rates. Therefore, together with the inherent variability in the survey results that
this study is based on, variability in other state specific factors or personal factors appears
to drive more than half of state level variability in vaccination rates. Such factors could, for




One goal of this chapter was to study the effect of the vaccination exemption policy
on the vaccination rates of young children. A second goal was to study the effect of the
highly publicized Disneyland outbreak on vaccination rates in subsequent years. The re-
sults showed that personal belief exemptions were linked to lower vaccination rates, which
agrees with the results of previous studies focusing on children attending kindergarten.
However, the magnitude of the policy impact changed based on the modeling approach
used. We could not conclude whether the Disneyland outbreak had any effect on future
vaccination rates, since different models provided contradictory results.
The above highlights the importance of choosing appropriate socioeconomic controls
in regression analysis. When studying retrospective data, there is no one superior approach
to controlling for complex phenomena such as “the economy,” and as our study shows,
the different methods commonly applied in the literature can reach different conclusions.
We, therefore, argue that minimally, it is crucial to present complete regression models,
including information about the choice of socioeconomic factors, for both replicability and
model evaluation. Further, this study suggests the importance of studying the sensitivity of
the results with respect to socioeconomic factors, as the choice can significantly influence
the estimate of the policy impact.
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Chapter 3: The cost of multiple chronic conditions: A study of chronic
cost burden using a condition hierarchy
3.1 Introduction
In this chapter, we introduce a new modeling approach to study the cost of chronic
conditions. Understanding the costs of chronic conditions can help in designing better
prevention interventions.
Roughly half of the U.S. adult population is estimated to have at least one chronic
condition, with one in four adults having multiple (two or more) chronic conditions [171].
The healthcare utilization patterns of those with chronic conditions are characterized by
more frequent outpatient, and emergency department visits [133, 139], and the resulting
and often high cost burden of chronic disease is well documented [10, 30, 51, 153]. In
addition to higher costs, chronic conditions have been linked to worse health outcomes and
to the prevalence of other chronic conditions [4, 59, 62, 146].
It is, therefore, unsurprising that a large literature focuses on the impact of disease
burden on healthcare costs and the correlation between chronic diseases. Typically these
studies focus on one condition at a time. For example, diabetic patients have been found
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to be at higher risk of depression, and the combination of diabetes and depression is linked
to increased total healthcare costs [45]. Similarly, diabetics who have a thyroid disease
have higher healthcare expenditures compared to those who do not have a thyroid disease
[137]. Cancer survivors are more likely to get (multiple) chronic conditions, and have
higher medical costs for those chronic conditions (e.g., heart disease, stroke) compared to
people without a history of cancer [59]. Depression is another condition studied in the
literature; depression is linked to higher non-mental health costs in patients with chronic
conditions, while at the same time chronic conditions are more prevalent in people with
depression [174]. Other studies that focus on disease burden and costs include studies of
chronic obstructive pulmonary disease [15], rheumatoid arthritis [62], and autism spectrum
disorders [168]. A summary of the existing literature focusing on costs linked to multiple
chronic conditions can be found in [146].
There are a handful of papers that study the cost of combinations of chronic condi-
tions. The cost of four chronic conditions, arthritis, diabetes mellitus, heart disease, and
hypertension, is studied in [104]. The study concludes that adults with all four chronic con-
ditions have the highest cost. In the cases where only two or three conditions are present,
combinations including arthritis, diabetes mellitus, and/or heart disease lead to the highest
overall costs. Combinations of two and three chronic conditions are studied in [95], and
ordered based on prevalence and cost. In particular, the authors focus on 69 chronic con-
ditions and generate all possible combinations of conditions (of size 2 or 3), gender, and
age group. This allows them to investigate the burden of combination of conditions in the
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population studied, compare the results with the national numbers, and identify subsets of
the population that might cause concern. In this population, the most common dyad is hy-
pertension and hyperlipidemia, and the most common triad is diabetes, hypertension, and
hyperlipidemia. The cost of 10 common chronic conditions and all combinations of two
of the conditions is studied in [38]. For most combinations of two chronic conditions a
super-additive effect is observed, which indicates that the sum of the cost of having each
condition separately is lower than the cost of having both conditions. However, some com-
binations have the opposite effect. For example, the combination of cancer and stroke leads
to lower costs than the sum of the costs of the individual conditions.
Improved understanding of the chronic disease cost burden will aid in the design of
policy and programs. For example, in value-based payment schemes, cost-based models
are often used as the justification for clinical outreach and interventions. A deeper under-
standing of the chronic cost burden can help develop insights for these targeted programs
[95, 135]. While it is well known that chronic diseases generally increase utilization and
cost, limited knowledge exists about the interactions and the cost implication of multiple
chronic diseases.
The presence of comorbid conditions may affect both the severity of other conditions
and the course of treatment. More specifically, the aggressiveness of the treatment of each
chronic disease (and, therefore, potentially the associated costs) may be affected by the
number of other more serious diseases that are present. In this chapter, we aim at building
a comprehensive picture of the costs of multiple chronic conditions. We introduce a novel
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approach to model the cost of chronic conditions as a function of each condition’s place in a
cost hierarchy, and study a larger set of chronic conditions than previously in the literature.
Our modeling approach enables the study of how each condition contributes to the overall
cost based on the number of other (more costly) conditions that the person has.
3.2 Methodology
3.2.1 Data
This study is based on claims data, provided by two large insurance companies in the
Rochester area of New York State. The dataset is a repository of fully de-identified HIPAA
compliant data containing several years of historical claims records. The repository is
administered by the Finger Lakes Health Systems Agency, and comprises data from com-
mercial accounts, Medicare Advantage and Medicaid Managed Care accounts, and account
data for which the two insurers serve as third-party administrators. The repository contains
more than 300 million claims records related to outpatient, inpatient, and pharmacy ser-
vices. The data extends from 2007 through 2013.
Important to this study is the fact that the total cost of each service is averaged across all
providers to protect proprietary pricing information, and can be separated into: (1) group
costs, which are the total costs attributed to hospital resources utilized during a patient’s
inpatient stays (such as room charges); and (2) claim costs, which are the total costs at-
tributed to physician services provided by medical staff either in an inpatient setting (such
as the services delivered by an anesthesiologist not employed by the hospital) or outpa-
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tient settings. In this study, we combine the group and claim costs as well as the costs of
pharmaceutical claims, as the total healthcare cost of members. Note that the cost is not
limited to the expenses related to the chronic conditions under study, but is the total annual
healthcare cost for the member.
3.2.2 Chronic condition identification and inclusion criteria
A number of approaches and definitions have been used to determine which conditions
are considered to be chronic [12, 146]. With our goal of building a comprehensive picture
of chronic cost burden, we adapted the algorithm provided in [94], which summarizes di-
agnosis codes for 69 chronic conditions. This algorithm has been used to identify chronic
conditions in a number of recent studies [64, 166, 169]. For certain clinical conditions,
we augmented the algorithm with additional codes as detailed in Appendix B. This was
done in order to improve the sensitivity of the algorithm and ensure that no diagnoses are
overlooked. Table 3.1 includes the chronic conditions included in the study and the corre-
sponding abbreviations used in figures and tables throughout the chapter. It also includes
the number of members identified with each condition. This study focuses on explaining
the overall healthcare costs in 2012. Therefore, a member was considered to have a chronic
condition if (s)he had at least one claim with a corresponding diagnoses code in 2012,
and a second claim with a diagnoses code (for the same condition) at least three months
apart (in 2012 or earlier). This ensured the exclusion of short term treatment of chronic
conditions, or potentially erroneous diagnoses coding of claims associated with diagnostic
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testing. Sensitivity analysis of the inclusion criteria is provided in Appendix D. Note that
all diagnoses codes were considered (not only primary) as secondary (or other) diagnosis
codes are considered as a confirmation of the existence of the chronic condition. Finally,
only members that are at least 18 years old in 2012 are included in the study.
Table 3.1: Chronic condition studied and the number members identified.
Chronic Conditions Abbreviations Member Count
Allergy, ENT and other upper respiratory disorders allergy 50,740
Anemia and other non-cancer heme disorders anemia 9,709
Aneurysm aneurysm 3,993
Anxiety disorders anxiety 45,914
Asthma, COPD, other chronic lung disease asthma 46,364
Coronary atherosclerosis athero 38,324
Back problems back 27,075
Behavior disorders behavio 9,555
Benign neoplasm benign 537
Bipolar disorder bipol 7,494
Benign prostatic hypertrophy (BPH) bph 19,586
Breast non-cancer breast 1,284
Cerebrovascular Disease cerebro 14,164
Congestive heart failure chf 11,435
Chronic Infectious and Parasitic Diseases chroninf 1,120
Other central and peripheral nervous system disorders cnspns 29,651
Congenital Heart Disease concard 2,213
Non-cardiac congenital disorder congen 6,668
Cystic fibrosis cystic 51
Organic brain problem (dementia) dem 7,840
Dental and mouth disorders dental 14
Depression and depressive disorders depress 65,975
Diabetes mellitus dm 68,641
Conduction disorder or cardiac dysrhythmia dysrhy 35,208
Epilepsy epilepsy 2,891
Esophageal disorder and GI ulcers esoph 50,353
Degenerative eye problem (glauc/eye) eye 87,833
Female infertility and GU anatomic disorders (e.g.
prolapse, endometriosis)
femalegu 21,211
Diverticulosis, diverticulitis, enterocolitis, intestinal
malabsorption
gi 20,838
continued . . .
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. . . Table 3.1 continued
Chronic Conditions Abbreviations Member Count
Gout or other crystal arthropathy gout 8,248
Chronic Hepatitis hep 1,749
Human immunodeficiency virus hiv 913
Hypertension htn 188,613
Hyperlipidemia hyprlip 179,822
Immunity disorder immun 3,019
Kidney and Vesicoureteral Disorders (excl. renal fail-
ure)
kidney 11,870
Chronic Liver Disease (excl. chronic hepatitis) liver 5,155
Lupus lupus 3,416
Male GU excluding BPH malegu 6,666
Malignant neoplasm malig 30,323
Malnutrition (not obesity/overweight)-includes disor-
ders of metabolism
malnutr 48,801
Menopause and perimenopause menop 9,456
Acute myocardial infarction mi 1,313
Migraines migrain 12,040
Misc mental health miscmh 1,064
Multiple sclerosis ms 2,208
Obesity obesity 30,229
Osteoarthritis osteo 58,626
Other endocrine othendo 72,465
Other MSK including osteoporosis othmsk 31,774
Chronic pancreatitis panc 295
Paralysis para 941
Parkinson’s disease parkin 1,891
Peripheral atherosclerosis periph 8,728
Personality disorder persnal 2,546
Pulmonary heart disease pulmhrt 1,322
Chronic renal failure renal 11,757
Rheumatoid arthritis rheum 7,376
Schizophrenia and Psychotic Disorders schiz 3,039
Sickle cell anemia sickle 126
Chronic skin ulcer skin 14,596
Sleep disorders sleep 21,233
Sexually Transmitted Infections sti 497
Cardiomyopathy and Structural Heart Disease strctht 10,556
Substance-use Disorders subst 36,407
Tuberculosis tb 1
continued . . .
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. . . Table 3.1 continued
Chronic Conditions Abbreviations Member Count
Thrombosis and Embolism thrombemb 400
Heart valve disorder valve 15,440
Non-thrombotic, non-athlerosclerotic vascular disease vasc 5,167
3.2.3 Model formulation
As previously discussed, the cost of chronic conditions is affected by the presence of
other chronic conditions. Previous work has focused on studying the cost of comorbid
conditions in isolation, or studying all combinations of a small set of conditions. When
studying a large set of chronic conditions, the number of possible combinations grows
exponentially (considering all combinations of two, three, or four combinations of any of
the 69 chronic conditions results in over 900,000 combinations). Therefore, we utilize cost
as a surrogate for severity and model the cost of any chronic condition as a function of
whether the condition is the one that is the most expensive the member has, the second
most expensive, and so forward. As an example, the model captures the cost of obesity
when it is the most costly condition the person has, the second most costly condition, and
so forth. This formulation enables us to study whether the cost of each condition increases
or decreases with disease burden.
To support this analysis, we order the conditions in decreasing order of cost. The cost
for each condition is the average annual cost across all members with each chronic con-
dition and no other chronic conditions. In order to estimate the effect that each chronic
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condition has on healthcare cost as a function of its cost order (or rank) for each mem-
ber, we formulate the problem using linear regression. The dependent variable (y) is the
member’s annual healthcare cost in 2012, and the model is specified as follows:







β jlx jl + ε, (3.1)
where N is the number of chronic conditions taken into account (i.e., N = 69), and
xi jl =

1, if condition j is ranked as the lth costliest condition for member i, where l < L j
0, otherwise
xi jL j =

1, if condition j is ranked as the lth costliest condition for member i, where l ≥ L j
0, otherwise.
Thus, the independent variables show whether a member has each type of chronic con-
dition, and also how this condition is ranked (based on how expensive it is to treat) com-
pared to all other chronic conditions that the member has. We refer to a condition of a
specific rank as the order that it appears for a member. For example, a condition ranked as
the third most expensive condition in an individual, appears in order 3 for this individual.
The parameters L j are a threshold for each condition j, which limits the cost level of
the model. Setting L j = 1 for all j would result in a model that would simple regress
the total healthcare cost on each condition (i.e., the xi jl would be binary indicators of the
presence of the chronic conditions under study). Increasing L j allows for more detailed
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analysis. However, there are practical limitations to how large L j can be, even with a large
data set. For example, if L j = 10 for all j, we would attempt to estimate the cost of each
chronic condition when it is the most expensive condition for a member, all the way to the
tenth most costly condition. As most members suffer from a limited number of chronic
conditions, for high values of l there are very few (if any) observations for most conditions.
In addition, it is important to note that for rare conditions, there may not be a large enough
population to estimate its impact when it is the lth most costly condition that a person
suffers from. For example, there are only 8 people in our data that have dental and mouth
disorders as their fifth most expensive condition, and when the corresponding variable is
included in the regression it leads to a coefficient that is not statistically significant.
Note that the costliest conditions also have a limit to the value that L j can take. For
example, in our data, cystic fibrosis is ranked as the most expensive condition. For cystic
fibrosis, L j = 1, since either a member has cystic fibrosis as the number one ranked condi-
tion or not. Similarly, for conditions ranked second, third, and fourth the maximum value
that L j can take is at most 2, 3, and 4, respectively.
As a result, L j is set for each condition through an iterative process, to ensure the
statistical significance of the regression coefficients. We first set L j = Lmax for all condi-
tions, with two exceptions. First, for the conditions that are ordered as the Lmax− 1 most
expensive conditions, we set their L j equal to their place in the cost hierarchy. Second,
for rare conditions, we observe their maximum position in the hierarchy. For example, in
our data, chronic infectious and parasitic diseases appear as the most expensive condition
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for some individuals, up to the fourth most expensive condition in others. Thus, for this
type of condition L j ≤ 4, regardless of the value of Lmax. After setting the initial L j for
all conditions j, we run a number of regression models to remove variables that are not
statistically significant. From the initial run, we study the regression coefficients of all
conditions with L j = Lmax, and in particular on β jLmax (their coefficient corresponding to
the condition when it is the Lmax most expensive condition for the patient or higher). If
β jLmax is not statistically significant, we update L j = L j−1 and update the data accordingly
(i.e., xi j(Lmax−1) = xi j(Lmax−1)+ xi j(Lmax)). We then rerun the analysis, and in the next iter-
ation focus on the statistical significance of the β j(Lmax−1) for those conditions that have
L j = Lmax− 1. We continue this process, until β jL j is statistically significant for all con-
ditions. For example, based on the model resulting from our data, chronic infectious and
parasitic diseases include coefficients β j4, and β j3, which are not statistically significant .
Thus, after applying the algorithm, this type of condition consists of two coefficients (i.e.,
β j1, and β j2), since the information from variable x j4 was merged to x j3, and in the sub-
sequent iteration the resulting variable was merged to x j2. This procedure is detailed in
Algorithm 1.
3.2.3.1 Condition hierarchy example
In this section, we use an example to illustrate the different values that the variables
of our model may take. Table 3.2 shows the values that variables take in our condition
hierarchy model, before we apply Algorithm 1. In this case, we have set Lmax = 5. For the
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Data: Initial set of variables x1 = {x1i jl ∀ i, j, l}.
Result: Reduced set of variables xL = {xLi jl ∀ i, j, l}.
Initiation: m = {Lmax,Lmax−1, ...,2}
L j equals Lmax (with exceptions discussed in the main text);
Build a linear regression model based on x1, and obtain initial set of coefficients
β 1 = {β 1jl ∀ j, l};
Updates: for n = {2,3, ...,Lmax} do
xn = xn−1;
m̄ = mn−1;
for each chronic condition j do
if (L j = m̄ )
AND (β n−1jm̄ is not statistically significant at the 5% level) then





remove xnjm̄ = {xni jm̄∀i} from xn;
set L j = m̄−1;
end
end
Build a linear regression model based on the updated xn, and obtain set of
coefficients β n;
end
Algorithm 1: Reducing the variable set based on statistical significance.
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Table 3.2: Example showing the values of the variables in our model (before Algorithm 1).
j Ordered
Conditions
L j i Conditions Variables
1 cystic 1 1 hiv x1,2,1 = 1,
2 hiv 2 and x1, j,l = 0 for all other j, l
3 thrombemb 3 2 panc x2,9,1 = 1,
4 ms 4 and x2, j,l = 0 for all other j, l
5 hep 5 3 thrombemb, ms, renal x3,3,1 = 1, x3,4,2 = 1, x3,8,3 = 1,
6 mi 5 and x3, j,l = 0 for all other j, l
7 benign 5 4 thrombemb, ms, mi, x4,3,1 = 1, x4,4,2 = 1, x4,5,3 = 1,
8 renal 5 benign, panc, rheum x4,7,4 = 1, x4,9,5 = 1, x4,10,5 = 1,
9 panc 5 and x4, j,l = 0 for all other j, l
10 rheum 5 ... ... ...
... ... ...
Table 3.3: Example showing the values of the variables in our model (after applying Algorithm 1).
j Ordered
Conditions
L j i Conditions Variables
1 cystic 1 1 hiv x1,2,1 = 1,
2 hiv 1 and x1, j,l = 0 for all other j, l
3 thrombemb 1 2 panc x2,9,1 = 1,
4 ms 2 and x2, j,l = 0 for all other j, l
5 hep 2 3 thrombemb, ms, renal x3,3,1 = 1, x3,4,2 = 1, x3,8,2 = 1,
6 mi 5 and x3, j,l = 0 for all other j, l
7 benign 4 4 thrombemb, ms, mi, x4,3,1 = 1, x4,4,2 = 1, x4,5,3 = 1,
8 renal 2 benign, panc, rheum x4,7,4 = 1, x4,9,5 = 1, x4,10,3 = 1,
9 panc 5 and x4, j,l = 0 for all other j, l
10 rheum 3 ... ... ...
... ... ...
purpose of this example, we assume that there exist enough members in our data set, such
that each of the presented conditions appears first, up to at least the fifth most expensive
condition in a member. Thus, L j = 5, for all conditions. The only exceptions are the four
most expensive conditions in our data. Table 3.3 shows the corresponding values after we
apply Algorithm 1. We see that for some conditions the value of L j has decreased, due to
some variables not being statistically significant. This has also affected the corresponding
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values that the variables take in the last column of the table.
3.2.4 Model fitting
The dependent variable is the annual healthcare cost of the members. Since the distri-
bution of healthcare costs is skewed with non-negative values, we use a gamma regression
with log link [38, 96], a common approach with data that has these characteristics. Note
that the log link is not the same as a logarithmic transformation of the dependent variable.
The log link is a function of the mean of the dependent variable, while a regression with
a logarithmic transformation gives the relationship with the mean of the natural logarithm
of the dependent variable. Thus, using the log link makes it easier to transform back to the
original dollars, since there is no need to correct the retransformation bias [146].
3.2.5 Model interpretation
The regression coefficients β jl in our regression model can be interpreted as the per-
centage change in the expected annual healthcare cost of the individual member when a
specific chronic condition is the lth most expensive condition, when l ≤ L j (and if l = L j
the interpretation is the percentage change when the condition is at least the L j most expen-
sive condition). Because the underlying costs of someone with no other chronic conditions
vs. someone with, say, four other conditions is quite different, then the same percentage
increase can correspond to very different cost impacts. As a result, in order to compare
cost impact across positions in the cost hierarchy for the same condition, we transform the
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coefficients to reflect the change in actual dollars. For this translation, we use the average
healthcare cost corresponding to individuals that have a specific condition in a specific or-
der as our estimate. In particular, the dollar contribution of each condition in each order is
estimated as c jl = e
β jl−1
eβ jl
c̄ jl , where β jl is the coefficient corresponding to condition j ap-
pearing in order l, and c̄ jl is the average annual cost of people having condition j in order
l.
The above cost contribution is estimated in the following manner. Since we have a
logarithmic relationship between the dependent variable and the mean of the independent
variables in our model, condition j appearing in order l (i.e., xi jl = 1) leads to a total annual
cost that is eβ jl times the total annual cost we would get if condition j did not appear in
order l (i.e., xi jl = 0). Since we are interested in the contribution of condition j appearing
in order l (i.e., the difference in cost between having condition j in order l and not having
this condition in order l), we have c jl = c̄ jl− 1
eβ jl
c̄ jl = e
β jl−1
eβ jl




proportion of the average annual cost that is explained by a member having condition j
appearing in order l.
3.2.6 Characterizing cost patterns
We summarize the results of the regression model from three different angles.
First we summarize the average cost contribution (across all possible orders) of each
condition 1 as well as the corresponding variance. Specifically, the average cost contribu-
1Unweighted average (not weighted by the number of members with condition in each order)
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tion for a condition j equals 1L j ∑
L j










As a second step in summarizing the cost characteristics of the different chronic con-
ditions, we fit a simple linear regression model to each condition to capture whether the
cost is (on average) increasing or decreasing as a function of the number of other more ex-
pensive conditions the member has. Specifically, for each condition j we fit the following
regression model:
c j = γ j +δ jo j + ε j, (3.2)
where o j = {o jl ∀l = 1, ...,L j} is the independent variable consisting of the possible orders
in which a condition j can appear in our model, and the dependent variable c j = {c jl ∀l =
1, ...,L j} is the cost contribution of condition j appearing in each possible order o j, which
is estimated based on the coefficient values of this particular condition, as described in
Subsection 3.2.5. The δ j (the slope for each condition) is an indicator of whether the cost
is increasing or decreasing in the order o j.
Third, we apply k-means clustering in order to group conditions together that have
similar cost characteristics. In order to decide on the number of clusters, we computed
multiple cluster metrics that reflect the quality of the resulting clusters, such as the silhou-
ette [144], the Hubert index [71], the D index [84], and others. The k was determined by
a majority rule of the different metrics, which was done through the NbClust package in
R. The attributes used in the clustering reflect the curves formed by the resulting regres-
sion coefficients for each condition. More specifically, the attributes used in the clustering
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algorithm are the change in cost contribution from one coefficient to the next divided by
the total range of values for this condition. Thus, for a condition j with cost contribution
c j = {c jl ∀l = 1, ...,L j}, the attributes used in the clustering analysis will be equal to vec-
tor a j = {
c j(l+1)−c jl
maxl c jl−minl c jl ∀l < L j}. These features capture the direction and the magnitude
of the change as the condition goes from being the most expensive, to the second most
expensive, and so on. Furthermore, with this approach, all attributes take values in [−1,1].
All the analysis was conducted in R version 3.5.3. utilizing packages NbClust, Rmisc,
rsq and ggplot2. The research plan for the study was reviewed and approved by the Insti-
tutional Review Board (IRB) at the University of Maryland College Park (UMCP).
3.3 Results
3.3.1 Population Statistics
We identified 409,238 members with at least one chronic condition in 2012, with the
number of members diagnosed with each type of condition presented in Table 3.1. The
average age of members with at least one chronic condition was 55.7 years old, 58% were
female, about 28% of our population were enrolled in Medicare, and 8% in Medicaid in
2012. The average number of chronic conditions per member was 3.76 (with a standard
deviation of 2.79), and the number of members with each number of conditions decreased
exponentially as the number of chronic conditions increased, as depicted in Figure 3.1.
Figure 3.2 shows the relationship between the number of conditions a member has, and the













Figure 3.1: Counts of members with each number of chronic conditions.
plots showing the distribution of the number of conditions broken down by age groups.
As expected, older members have a higher number of conditions, on average. The bottom
panel shows the annual healthcare cost associated with the number of chronic conditions a
member has, highlighting that the median annual healthcare cost increases with the number
of conditions. Notable, for members with more than 23 conditions, we do not observe a
clear increase in the median. This can either be a result of the small number of members
(we have 10, 4, and 2 members with 23, 24, and 25 conditions, respectively) as in those
cases can easily be affected by only a few observations, or potentially indicating a flattening




























































































































































































































































































































































































































































































































































































































































































































Figure 3.2: Box plots of: number of chronic conditions for each age group (top panel), and annual
cost based on number of chronic conditions (bottom panel). Note that in the bottom panel there are















































































































Figure 3.3: Scatter plot of percentage of female population against average age, colored by the
percent on Medicaid. The names of conditions that have a higher than 25% of their population
covered by Medicaid, an average population age outside the 50 to 80 range, and more than 75% or
less 25% of their population being female are labelled.
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Figure 3.3 includes a scatter plot of the 69 chronic conditions studied, showing in-
formation about the average age of members with the condition, the percentage of the
population with the condition that is female, and the percentage that is covered by Medi-
caid. The figure reflects that our population is 58% female, with the majority of chronic
conditions diagnosed in higher percentages in women. Furthermore, we see that some con-
ditions strictly affect women (breast non-cancer, menopause and perimenopause, female
infertility and Genitourinary (GU) anatomic disorders) or men (male GU, benign prostatic
hypertrophy). Note that tuberculosis (TB) is also a female-only condition in our data, as
the one member with TB in 2012 happened to be female. Other conditions that are more
common in women (over 75% female), include lupus, migraines, multiple sclerosis (MS),
rheumatoid arthritis, and some musculoskeletal (MSK) disorders (including osteoporosis).
Specific conditions were also linked to higher percentages of Medicaid coverage. Those
included sickle cell anemia, dental and mouth disorders, human immunodeficiency virus
(HIV), sexually transmitted infections (STI), schizophrenia and psychotic disorders, bipo-
lar disorder, and substance-use disorders. Finally, we see from the figure that the majority
of conditions have an average population age between 50 and 80 years old. The only con-
dition with an average age above 80 is organic brain problem (dementia), while conditions
with an average age below 50 include cystic fibrosis, female infertility and GU anatomic
disorders, HIV, STI, substance-use disorders, sickle cell anemia, migraines, anxiety disor-
ders, behavior disorders, bipolar disorder, and other mental health disorders.
As discussed in Subsection 3.2.3, we order the conditions in decreasing order of their
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Table 3.4: Ordering of conditions and corresponding costs.
Chronic Order Average Cost (and Std Dev) Average Cost (and Std Dev)
Condition members with only this cond. all members with this cond.
cystic 1 18,245 (15,919) 32,056 (24,196)
hiv 2 17,094 (10,167) 24,392 (17,381)
thrombemb 3 16,177 (24,393) 27,853 (34,436)
ms 4 15,599 (15,205) 23,994 (21,190)
hep 5 12,423 (29,036) 21,076 (36,295)
mi 6 12,136 (16,907) 30,792 (33,213)
benign 7 8,473 (16,587) 12,453 (14,776)
renal 8 7,481 (17,098) 23,470 (31,909)
panc 9 7,323 (6,346) 19,722 (21,869)
rheum 10 7,309 (9,896) 13,766 (17,321)
osteo 23 3,626 (5,881) 12,327 (16,707)
dm 33 3,180 (4,426) 11,252 (17,601)
othendo 39 2,822 (5,139) 9,320 (15,281)
asthma 42 2,742 (3,930) 12,526 (18,963)
esoph 43 2,738 (3,491) 10,660 (15,808)
depress 46 2,420 (3,056) 9,570 (15,115)
anxiety 53 2,157 (2,897) 8,921 (14,358)
allergy 55 2,068 (2,914) 7,962 (12,341)
malnutr 56 2,044 (3,660) 9,867 (17,186)
eye 57 2,011 (3,316) 9,602 (14,456)
chf 60 1,958 (2,544) 25,987 (29,871)
menop 61 1,952 (2,132) 7,379 (10,708)
aneurysm 62 1,948 (2,093) 15,961 (21,645)
htn 63 1,925 (3,774) 9,070 (14,753)
periph 64 1,900 (2,646) 20,442 (26,943)
bph 65 1,892 (2,891) 10,001 (15,045)
hyprlip 66 1,669 (2,605) 8,351 (13,736)
gout 67 1,387 (2,116) 13,641 (21,916)
tb 68 1,058 (0) 1,058 (0)
dental 69 706 (479) 14,033 (16,699)
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cost in order to generate the variables included in our model. Table 3.4 includes the 10
conditions with the highest, and the 10 conditions with the lowest order, as well as 10 con-
ditions with high occurrence in our population (complete version of table can be found in
Table C.1, Appendix C). The table also includes the average annual cost (and standard de-
viation) of the members in our data that have only been diagnosed with each condition, and
none of the other chronic conditions, as well as the average cost (and standard deviation)
of all members with each condition.
3.3.2 Modeling Results
3.3.2.1 Overview of resulting coefficients
As discussed in Section 3.2.3, a value for the parameter Lmax needs to be set. To strike
a balance between a large enough value of Lmax in order to observe potential cost patterns
in the cost, and at the same time have sufficient sample sizes, we selected Lmax = 5. The
full regression model is reported in Table C.2 in the Appendix, and has an R2 of 42.5% 2.
A number of conditions have fewer than Lmax regression coefficients. In particular,
four of the conditions have fewer than five coefficients because they were ranked as one
of the four most expensive conditions (cystic fibrosis, HIV, thrombosis and embolism, and
MS), and 13 have fewer than five coefficients because there were no members in our data
that happened to have them in a specific order (benign neoplasm, chronic infectious and
parasitic diseases, dental and mouth disorders, GI problems, chronic hepatitis, malignant
2R2 for GLM [111], estimated through the rsq package in R
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neoplasm, acute myocardial infarction, chronic pancreatitis, Parkinson’s disease, chronic
renal failure, rheumatoid arthritis, sickle cell anemia, tuberculosis). Furthermore, since
our data set consists of members who have at least one chronic condition, each member
will have exactly one chronic condition ranked as first. Thus, if we include all variables
corresponding to a condition being ranked as first in a member, we would have linearly de-
pendent variables. For that reason, we set gout or other crystal arthropathy as the baseline
first condition. Additionally, in our data set a single member had acute myocardial infarc-
tion as the third condition and chronic renal failure as a fourth condition. In addition, this
member was the only member having acute myocardial infarction as a third, and chronic
renal failure as a fourth condition. Including both variables in the model would result in
linear dependence. For that reason, the variable corresponding to having chronic renal fail-
ure as a fourth condition was removed from the regression model. Finally, an additional 60
variables were removed for not being statistically significant by applying Algorithm 1.
Figure 3.4 includes examples of different cost patterns. Figure 3.4a (coronary atheroscle-
rosis) shows a large increase in the cost contribution when the condition is the second most
expensive, compared to when it was the most expensive. However, after that the contri-
bution remains relatively stable, or even a small decrease is observed, when we compare
the cost of the condition being the third, fourth, or fifth most expensive to the condition
being the second most expensive. In contrast, Figure 3.4b (obesity) shows a relatively sta-
ble increase in cost with an increase in the number of more expensive conditions. In other
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(d) Chronic renal failure
Figure 3.4: Cost contribution based on the regression coefficients for four chronic conditions
chronic conditions a member has. From Figures 3.4c and 3.4d, we see that some condi-
tions have L j < Lmax, as discussed above. From Figure 3.4c, we see a clear decrease in
the cost contribution, when pulmonary heart disease appears on third order or higher. Fi-
nally, chronic renal failure in Figure 3.4d is estimated to have a large increase in cost if the
member has at least one additional more expensive chronic condition. From Figure 3.4, it
is clear that various conditions have very different cost characteristics as the number other
more expensive chronic conditions increases. We summarize the regression coefficients of
the different conditions below, first by applying regression analysis, followed by clustering.
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3.3.2.2 Average, Variance, and Slope
Figure 3.5 is a scatter plot highlighting the relationship between the average and the
variance of the cost contributions of each condition, with each cost contribution given an
equal weight in the estimation of the measurement. For the conditions that have L j equal
to one (only have a single regression coefficient) we set the variance to 0. Of the eleven
conditions that are identified to have the highest average cost contribution (based on the
value of their coefficients), nine were ranked among the eleven most expensive conditions
based on the results of Table C.1. The two additional conditions are sickle cell anemia
and pulmonary heart disease, which were ranked as the 12th and 34th most expensive con-
ditions, respectively. On the other hand, benign neoplasm, and rheumatoid arthritis were
ranked as 7th and 10th based on the results of Table C.1, but were actually the 15th and 12th
conditions based on the average cost contribution of their coefficients.
Figure 3.6 summarizes the resulting slopes for all conditions for which L j is at least 2
(the minimum requirement to be able to estimate a slope). From the figure, we note that
the majority of the conditions have a positive slope, meaning that the higher the number
of other more expensive chronic conditions, the higher the estimated cost contribution to
the annual healthcare. The conditions that have a negative slope are Parkinson’s disease,
pulmonary heart disease, and rheumatoid arthritis. The conditions with L j equal to 1, and,
therefore, a single cost estimate from equation (3.1) are excluded from the figure. Those
conditions are benign neoplasm, cystic fibrosis, dental and mouth disorders, chronic hep-






















































































































































Figure 3.6: Slopes for each chronic condition.
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thrombosis and embolism. From the figure, we can summarize the conditions based on
the direction and magnitude of their estimated slopes. For example, chronic renal failure,
sickle cell anemia, paralysis, anemia and other non-cancer heme disorders, STI, and im-
munity disorder are conditions with high positive slope. This means that as the number
of more expensive condition that the person has increases, the cost contribution of those
conditions to the total healthcare cost of the member increases drastically. We note that
the conditions identified with the highest variance in Figure 3.5, are the conditions with the
largest absolute slopes.
3.3.2.3 Clustering based on the curve form
Finally, we apply clustering to group the chronic conditions together based on their cost
characteristics. Note that, as discussed in Subsection 3.3.2.1, not all conditions have five
regression coefficients. Thus, we conduct separate clustering analysis based on the number
coefficients that each condition corresponds to. We exclude from the analysis conditions
only corresponding to one or two coefficients. In total, 18 of the 69 conditions are excluded
from the clustering analysis. We use the majority approach discussed in Subsection 3.2.6
on conditions with an equal number of coefficients. In each case, it was recommended to
use two centers. After applying the k-means clustering algorithm with k = 2 on conditions
with an equal number of coefficients, we get the clusters presented in Table 3.5.
For conditions corresponding to five coefficients, the first cluster includes mostly condi-
tions that either have a small decrease in the contributing cost when the individuals have an
68






5 1 10 Coronary atherosclerosis | Back problems | Benign
prostatic hypertrophy (BPH) | Non-cardiac congen-
ital disorder | Diabetes mellitus | Conduction dis-
order or cardiac dysrhythmia | Esophageal disorder
and GI ulcers | Kidney and Vesicoureteral Disor-
ders (excl. renalfailure) | Other endocrine | Non-
thrombotic, non-athlerosclerotic vasculardisease
2 16 Aneurysm | Anxiety disorders | Asthma, COPD,
other chronic lung disease | Congestive heart fail-
ure | Other central and peripheral nervous system
disorders | Congenital Heart Disease | Depression
and depressive disorders | Hypertension | Immu-
nity disorder | Malnutrition (not obesity/overweight)-
includesdisorders of metabolism | Obesity | Pe-
ripheral atherosclerosis | Sleep disorders | STI |
Cardiomyopathy and Structural Heart Disease |
Substance-use Disorders
4 1 6 Anemia and other non-cancer heme disorders | Or-
ganic brain problem (dementia) | Chronic Liver Dis-
ease (excl. chronic hepatitis) | Osteoarthritis | Pul-
monary heart disease | Chronic skin ulcer
2 8 Behavior disorders | Bipolar disorder | Breast non-
cancer | Epilepsy | Female infertility and GU
anatomic disorders | Gout or other crystal arthropa-
thy | Hyperlipidemia | Misc mental health
3 1 7 Allergy, ENT and other upper respiratory disorders
| Degenerative eye problem (glauc/eye) | Malignant
neoplasm | Menopause and perimenopause | Mi-
graines | Schizophrenia and Psychotic Disorders |
Heart valve disorder
2 4 Diverticulosis, diverticulitis, enterocolitis, intestinal
malabsorption | Other MSK including osteoporosis |
Paralysis | Personality disorder
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increased number of more expensive conditions, or the contributing cost remains relatively
stable after a relatively large increase from the first to the second order. One representa-
tive example for this cluster is included in Figure 3.7a (back problems), where we see that
after an initial increase in the cost contribution, the cost decreases. Another example in
this cluster is esophageal disorder and GI ulcers (Figure 3.7b), which has a large increase
in cost from the first to the second order, and then the cost remains relatively stable (there
is a small increase observed). On the other hand, conditions consisting of five coefficients
that were included in the second cluster have a more stable increase as the number of other
more expensive conditions increases. One example from this cluster is cardiomyopathy
and structural heart disease, which is included in Figure 3.7c.
For conditions corresponding to four coefficients, the first cluster again includes condi-
tions that have a decrease in their contributing cost, or a relatively stable cost contribution
after an initial increase observed when the condition is the second most expensive. One
of the conditions included in this cluster is anemia and other non-cancer heme disorders
(Figure 3.7d), which has a constant cost when there is at least one more expensive condi-
tion present, and organic brain problem (dementia) (Figure 3.7e), which has a decrease in
the cost. On the other hand, the majority of conditions included in the second cluster have
an increase in the contributing cost as the number of more expensive conditions that are
present increases. For example, this is the case with behavior disorders, included in Figure
3.7f. Nevertheless, two of the conditions included in this cluster (female infertility and GU
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Figure 3.7: Chronic conditions representing common patterns observed in each cluster.
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since their costs fluctuate from one order to the next.
Finally, for conditions consisting of three coefficients, the first cluster includes condi-
tions which have an increase in the contributing cost when the condition goes from being
the most expensive to being the second most expensive, and a decrease in the cost from hav-
ing one more expensive condition to having two more expensive conditions present. This
can be seen from Figure 3.7g, which includes the costs for schizophrenia and psychotic
disorders. On the other hand, the conditions included in the second cluster have a constant
increase in cost as the order in which they appear increases. An example of such a con-
dition is GI problems (diverticulosis, diverticulitis, enterocolitis, intestinal malabsorption),
which is included in Figure 3.7h.
The different cost behavior of each cluster is also summarized in Figure 3.8, where each
subgraph includes box plots showing the relative cost contribution across all conditions in
the same cluster. In particular, for each condition, all cost contributions are normalized to
take values between 0 and 1. The lowest cost contribution of a specific condition takes the
value 0, the highest the value 1, and all other costs are normalized to take values in between.
This allows us to get a better overview of the cost curves of conditions belonging to the
same cluster. For all clusters, we see that there is an increase in the cost contribution from a
condition being the most expensive that a person has to the condition being the second most
expensive. However, when the number of more expensive conditions increases, different
clusters behave in a different manner. In general, all the 2nd-type clusters (Figures 3.8b,
3.8d, and 3.8f) show in most cases an increase in the normalized cost as the number of more
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expensive conditions increases. On the other hand, all 1st-type clusters (Figures 3.8a, 3.8c,
and 3.8e) in most cases show a decrease with an increase in the number of more expensive
conditions that are present, if we exclude the relationship between the condition being the
first and the second most expensive for an individual.
Compared to the slopes presented in Figure 3.6, the clustering analysis provides more
information regarding the cost behavior of different conditions. For example, the estimated
slopes could not capture as well the decrease in the cost contribution observed in some of
the conditions when there are two or more costlier conditions present. Additionally, an
important observation is that there seems to be an increase in the cost contribution across
all conditions, when the condition goes from being the most expensive to being the second
most expensive. This may be a sign of overall worse health. Nevertheless, in some cases,
the slope analysis and the clustering analysis highlight the same observations. For example,
of the 22 conditions with the highest slope presented in Figure 3.6, only four were included
in one of the clusters that indicated a decrease/non-increase in the cost as the number of
more expensive conditions increases. Those were anemia and other non-cancer heme dis-
orders, schizophrenia and psychotic disorders, chronic skin ulcer, and chronic liver disease
(excluding chronic hepatitis). On the other hand, the one condition with a negative slope
that was part of the clustering analysis (pulmonary heart disease), was included in a clus-
ter that had conditions with a decreasing cost. Furthermore, of the 11 conditions with the
smallest positive slope, only two (hyperlipidemia, and female infertility and GU anatomic
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(f) 2nd cluster: conditions with 3 coefficients
Figure 3.8: Box plots of the normalized cost contributions of the conditions in each cluster.
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the number of more expensive conditions increases.
3.4 Discussion
In this chapter, we present a method for estimating the contribution of different chronic
conditions to individuals’ annual healthcare costs. We estimate the cost for each condition
as a function of the number of more expensive chronic conditions that the person has,
focusing on 69 different chronic conditions. The methodology we use allows us to model
the healthcare cost of individuals with multiple chronic conditions in more detail than the
well established literature on the cost of chronic conditions. Based on the results of our
estimation model, we group together conditions that have similar cost characteristics.
The clustering analysis highlights that different chronic conditions behave in different
ways in terms of their cost contribution. For conditions with a constant increase in cost, it
seems that they impose an additional complexity to the treatment of the member leading
to an increase to the total healthcare cost. The complexity becomes more distinct as the
number of more expensive conditions that the member has increases. On the other hand,
for some conditions, as the number of more expensive conditions that the member has
increases, the cost that these conditions contribute to the annual healthcare cost starts de-
creasing. Further study is required to determine the contributing factors, but one hypothesis
is that the treatment focus is on other more serious conditions.
The information and the proposed methodology of this chapter can be utilized by re-
searchers and policymakers, to better estimate the effect of interventions on the healthcare
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cost of patients with specific chronic conditions, and help make better healthcare cost pre-
dictions for people with chronic conditions. Furthermore, it can help identify conditions
that are linked to lower costs, and by extension lower healthcare utilization, as the number
of other more expensive conditions that the person has increases. This information could
be utilized by healthcare providers. A decrease in the cost contribution could be justified by
other conditions of the individual or could raise concern since it indicates a need to focus
more on a specific sub-population of patients, who are not getting the necessary treatment.
This could help improve the quality of healthcare of individuals with chronic conditions.
3.4.1 Limitations
This study focused on the population of a specific geographical region and the corre-
sponding healthcare costs during one calendar year. However, different states have been
found to have different prevalence of specific chronic conditions and different hospitaliza-
tion rates [135]. Thus, our findings cannot necessarily be extrapolated to other states in the
U.S. Nevertheless, we expect many of the patterns observed to be similar across states.
Furthermore, our model was built on specific chronic condition specifications. The
diagnosis codes used were organized in predetermined groups based on the algorithm pro-
vided in [94], with each group consisting of multiple types of conditions in most cases.
While diagnoses belonging under the same chronic condition category had similarities to
each other, in some cases, we expect to find differences in their treatment costs. For exam-
ple, asthma and COPD (chronic obstructive pulmonary disease) are included in the same
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condition category in the analysis, but the mean annual cost per patient is estimated at
$3,100 for asthma [117], and at about $6,200 for COPD [126]. Thus, future research could
focus on more specific conditions instead of groups of conditions and, thus, expand the
identified cost behaviors to more than 69 conditions. However, in order to achieve that, a
larger sample size is required, with enough individuals who that have other chronic con-
ditions present at the same time. This would make it possible to draw significant results
about the cost behavior of the specific conditions.
3.5 Conclusions
In this work, we studied the cost behavior of 69 chronic conditions. Through the pro-
posed modeling approach, we separated the cost contributions of the various chronic condi-
tions depending on the order in which they appear in individuals. This allowed us to study
the cost behavior of each condition, based on the number of more expensive conditions
that are present. The results indicate that conditions can be divided into two main groups.
The first included conditions that do not show a clear increase in the cost contribution as
the number of more expensive conditions that are present increases. In particular, in most
cases there was an increase in cost when the condition went from being the most expensive
to the second most expensive in an individual, and then the cost either remained constant or
decreased. The second group included conditions with a relatively stable increase in cost
as the number of more expensive conditions increases.
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Chapter 4: Conversational agent technology adoption by patients with heart
failure
4.1 Introduction
In this chapter, we study the use of two different types of conversational agent technolo-
gies by patients with heart failure (HF). This is a problem at the tertiary prevention level,
since the goal is to help people better manage their condition. HF is a condition in which
the heart of the patient is not able to pump enough blood and oxygen to the organs. HF has
high prevalence, affecting over 26 million people worldwide, and it is associated with high
mortality, and healthcare utilization [148]. Due to the aging population, the prevalence of
HF is expected to increase in the future. In the U.S., there are currently 6.2 million adults
with HF, with this number expected to increase to over 8 million by 2030 [167]. Individuals
with HF are projected to make up about 2.97% of the U.S. adult population in 2030 [167],
with the total (medical and indirect) costs associated with the condition estimated to reach
$70 billion [68]. Currently in the U.S., there are about 800,000 annual hospitalizations for
the primary diagnosis of HF, and, after each hospitalization, the 28-day and 1-year mortal-
ity is 10.4% and 29.5%, respectively [167]. Thus, it is crucial to support people with HF to
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manage their conditions once discharged from the hospital.
The treatment for HF is closely associated with self-care. In addition to taking medi-
cations, a patient is advised to reduce salt and fluid intake [25], monitor their weight daily,
stay active through appropriate physical activity, and to look for symptoms that could cause
concern such as swelling in ankles, weight increase, or shortness of breath [141]. One ap-
proach for frequent information exchange is utilizing telehealth. Telehealth allows health-
care providers to get daily feedback from the patients, enabling them to promptly intervene
when necessary.
A number of telehealth approaches for HF have been examined. For example, struc-
tured telephone-monitoring, allows patients to answer a set of prerecorded questions re-
garding their symptoms through their telephone keypad [33]. Increased internet access
has allowed the development of numerous technologies [7, 48, 81, 87, 97], with some ex-
amples presented below. Patients can log in to a designated website to enter information
about their daily symptoms, which allows nurses to monitor any changes [97]. Through an
Xbox gaming platform, HF patients can navigate through screens, answer multiple-choice
questions regarding their symptoms, read further instruction about their self-care, and learn
more about their condition [48]. Tablets connected to a weight scale and a blood pres-
sure wrist monitor allow patients to send daily readings to their healthcare provider [87].
Similarly, through an Android phone app, patients can submit daily symptoms, and auto-
matically transmit vital readings, including weight, blood pressure, and glucose levels [7].
A recent review of studies on telehealth adoption by patients with HF can be found in [54].
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Across the studies discussed, main factors that are identified to negatively influence tele-
health adoption include difficulties with using the required technology, not remembering to
use the technology every day, and considering the telehealth procedure to be redundant or
boring. It can, therefore, be concluded that a critical component of any telehealth applica-
tion is its ease of use. Conversational agent technology that uses speech is potentially one
such solution, since it can ask questions of the patients through speech and understand the
patients’ answers through speech recognition.
Conversational agents have been used in numerous healthcare settings, with the litera-
ture extensively focusing on mental health applications [83, 134]. However, the conversa-
tional agent technology has also been used to help support behavior change and promote
a healthy lifestyle [91]. Furthermore, in a few studies, the technology has also been rec-
ommended for patients with HF, in order to collect information about their symptoms and
help with managing their conditions. In particular, proposed designs for conversational
agent technology in patients with HF can be found in [47, 178]. A study on a small cohort
of HF patients, investigating their satisfaction and engagement with conversational agent
technology, found high user satisfaction and engagement levels [107].
The contribution of our work is twofold. First, we compare two types of conversational
agent technologies, to study differences with respect to patient engagement. Both technolo-
gies use speech recognition, and were used by HF patients. The first technology utilized the
Amazon Alexa technology and only communicated with the patient through speech (audio
only). We will refer to this implementation as the Alexa+ throughout this chapter. The sec-
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ond technology was an app run on a tablet that used an avatar, thus combining audio and
visuals. We will refer to this second implementation as the Avatar throughout this chapter.
Second, we investigate which patient characteristics are important factors in determining
the patient engagement. To the best of our knowledge, this is the first study examining
factors that influence conversational agent technology uptake in patients with HF.
4.2 Methods
4.2.1 Conversational agent technologies
Alexa is a virtual assistant AI technology developed by Amazon. Alexa is voice ac-
tivated, and has a number of functions, including sending messages, playing music and
giving traffic updates. The original capabilities of Alexa were expanded for the purpose
of this study, in order to be able to ask patients with HF a series of questions regarding
their condition which resulted to an augmented technology (Alexa+). We used Echo Dot
devices, which are smart speakers that can be used to access Alexa+. The retail price for an
Echo Dot (see Figure 4.1a) is $50 per unit, making this technology relatively affordable.
The Avatar was developed by ObEN [118]. This technology generates avatars, which
have customizable appearance, and can speak in different languages, and can potentially
be used in a number of different health care settings. In our study, the avatar was used
to ask the patients a series of questions related to their HF treatment and symptoms. The
avatar application was saved on tablets which had no other applications. An example of the
Avatar technology is presented in Figure 4.1b.
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(a) Echo Dot (b) Avatar on tablet
Figure 4.1: Conversational agent technology used.
Note that one difference between the two conversational agent technologies, in addition
to the way that information is presented, is that the Alexa+ technology allows patients to
set-up daily reminders. Thus, at a specific time during the day patients participating in
the Alexa+ study had the option to receive reminders in order to fill out the questionnaire.
However, the tablets used in the Avatar study did not have this option.
Both Alexa+ and the Avatar follow the exact same script. In the first stage of the script,
the conversational agent asks the HF patients 11 questions, which can be potentially ex-
panded to 13 questions, depending on the answers that the patients give. Patients answer
each question separately with yes or no. The answer that the patient gives to each question,
affects the type of comment that the conversational agent makes right after the answer, as
82
well as the next question. The 11-item questionnaire is divided into three components:
compliance (questions 1-3), mild HF symptoms (questions 4-6) and moderate/severe HF
symptoms (questions 7-11). The compliance questions have to do with whether the pa-
tients weighed themselves, took their HF medication, and avoided eating high-salt food.
Answering negatively to any of those questions raises a yellow flag. The mild HF symptom
questions are intended to find out if the patient has shortness of breath with regular activity,
cough, or swollen ankles. If the patients answer positively to any of the mild HF symptoms
questions an orange flag is raised for that question. The moderate/severe HF symptoms
questions have to do with weight increase, and shortness of breath at rest or while sleeping.
If the patient answers yes to any of the moderate/severe HF symptoms questions, a red flag
is raised. The raised flags can result in alerts, as we will discuss in Section 4.2.4 (Moni-
toring), and the red flags affect the tailored advice that the conversational agent gives the
patient once the questionnaire is completed. This is done in the second stage of the script,
where the agent in addition to the advice summarises the answers provided by the patient.
The detailed script including the questions asked, their order, and the comments that the
conversational agents make in each case can be found in Tables E.1 and E.2 of Appendix
E.
4.2.2 Patient enrollment and training
Thirty patients were enrolled in each of the two studies by using the same eligibility
criteria. In particular, in order to participate, the patients should have been admitted or
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treated for Chronic HF at MedStar Washington Hospital Center or a MedStar Heart Failure
Clinic. Further, the patients had to be 18 or older, and live in a house with wifi access.
Finally, the patients could not participate in the studies if they had had a heart transplant or
if they had a ventricular assist device (VAD). The participation was optional for the patients.
Patients declined the offer to participate for multiple reasons, including: not wanting to take
the daily surveys, not wanting another “device” in their lives, or lack of interest.
Participants randomized to the Alexa+ study group were provided an Amazon account,
equipped with an Echo Dot configured to access the Alexa+ application, and were provided
training on the Alexa Echo Dot including Alexa voice training. Voice training consisted of
a session of 25 phrase repetitions that allows Alexa to improve its voice recognition ca-
pabilities for the target user. The patients participating in the Avatar study were provided
tablets with the Avatar application. They were shown how to use the technology. Further-
more, patients participating in both studies completed their first questionnaire during their
training, in order to make sure that the device was working properly and to ensure that the
patients understood how to do it.
4.2.3 Demographic and technology survey
Before the patients started using the conversational agent that was assigned to them,
they filled out a demographic and technology survey. This allowed us to identify patient
characteristics that were associated with low or high conversational agent technology adop-
tion in subsequent analysis. In particular, the demographic section of the survey included
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questions about: age, gender, marital status, race, Hispanic heritage, annual household in-
come, education, insurance coverage, number of years with HF, number of medications
to manage HF, and visual impairment. The technology section of the survey included
questions about: the type of mobile phone they use, whether they use their phone to text
messages, whether they access social media, and browse the Internet though their phone,
and how confident they feel using computers, or other electronic devices.
4.2.4 Monitoring
Once enrolled, patients were instructed to complete the questionnaire on a daily basis
for 90 days. For participants who answered in a manner that indicated HF stability, the re-
sponse was coded green and no alert was generated. For questions answered in a clinically
undesirable manner, the responses were divided into yellow, orange, and red answers to
correspond to the compliance questions, mild HF symptom questions, and moderate/severe
HF symptom questions, respectively. Alerts were generated for the red questions. The
alerts resulted in an immediate text and email to the study nurse, who monitored the alerts
each day, including weekends and holidays. The texts contained the participant identifi-
cation number and contained the following alert: “We have received a concerning daily
response from patient [PatientID] that warrants your attention: [QuestionID] yes”. In
total, 281 alerts were generated for the Alexa+ group, and 404 for the Avatar group. Infor-
mation about the answers was also summarized as a color display (see example in Figure
4.2).
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A baseline was established based on the first time that the participants completed the
questionnaire. The study nurse reviewed alerts daily and evaluated participant’s stability
compared to baseline. Thus, any changes were evaluated based on their initial answers.
As part of the general care practices at the study institution, each HF patient is assigned
a nurse navigator, who is responsible for coordinating the clinical care of the participant.
A change in status was defined as a change in the moderate/severe HF symptom questions
from baseline, multiple red flag responses, or persistent red flag responses. For patients
with a change in status, the nurse navigator at the study institution was informed of the
alert, as well as the PI and the study physician.
Every three weeks the study coordinator would contact participants who did not com-
plete the questionnaire to check on the participant status and reeducate or encourage com-
pletion. In some cases, participants would call and inform the study coordinator that they
were traveling out of state/country or on vacation and unable to complete the questionnaire.
A weekly phone check-in was completed by the study coordinator to answer any questions
and provide additional training to the participants on how to initiate and communicate with
the device.
4.2.5 Analysis
We use descriptive statistics to characterize demographic and clinical characteristics of
the patients, as well as their experience and confidence in using technology. In particular,
we estimate means and standard deviations for the continuous variables, and counts and
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Weigh Medica.. Medica.. Medica.. Salt TiredAc.. Cough AnkleS.. Weight.. TiredR.. LieFlat Proppe.. WakeUp
Figure 4.2: Example of color display used in the monitoring of patients.
corresponding percentages for the categorical variables. Furthermore, we report the number
of missing values for each variable. We compare the patient populations participating in
the Alexa+ study to that of the Avatar study based on the aforementioned characteristics.
We use chi-squared tests to compare the counts in the different categories between the
two populations for each the 12 categorical variables, and two-sample t-tests to test the
difference between the two population means for the 3 continuous variables. We report the
corresponding P-values for each variable.
Note that the information discussed above comes from the survey discussed in Subsec-
tion 4.2.3. However, in some cases data regarding demographic and clinical characteristics
were also retrieved from the electronic health records of the patient in order to decrease the
number of missing values.
Patients’ engagement is defined as the number of days during the study period that the
patient used the corresponding conversational agent to answer the questionnaire. We use
visualizations to show the levels of engagement in each study.
We model the relationship between the engagement level and the patient’s characteris-
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tics using multiple linear regression on the entire population (combining both studies). In
particular, the dependent variable is the number of days that the patient utilized the con-
versational agent technology during the 90-day study period. The independent variables
consist of the demographic, clinical, and technology-related characteristics of the patient.
Of those, categorical variables consisting of more than two categories were also trans-
formed to binary variables. In particular, we generated a binary variable for patients that
have a smartphone, for patients that are very confident to use technology, for patients that
have only a little or not at all confidence to use technology, for patients that have college
education or higher, for patients that have a high school education or less, for patients with
an annual household income higher than $100,000, for patients with an annual household
income less than $50,000, and for patients that are married. Finally, in order to differentiate
between the two studies, we generated a binary variable taking the value 1 for patients that
participated in the Avatar study, and 0 for patients of the Alexa+ study. In order to select
which variables to include in the regression model we use the best subsets method, based
on the adjusted R2 value. Given the small sample size, variables need to be carefully se-
lected, and therefore we chose to use this method in order to generate a model that explains
the variation in the patient’s engagement as well as possible based on our available data.
However, like any reduced model, the interpretation of the coefficients may be biased if
important variables are excluded from the model.
Finally, in order to more closely study the impact of the patient characteristics on the
technology usage of each type of conversational agent, we build a separate model for each
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study population. We use a subset of the variables selected in the general model described




Three patients out of the thirty initially enrolled in the Avatar study were subsequently
withdrawn from the study, because it was not possible to reach the patients after they pro-
vided the initial participation consent. Table 4.1 shows the demographic, clinical, and
technology-related characteristics of the patients participating in each study. We see from
the table that patients participating in the Alexa+ study were taking a statistically signifi-
cantly (P-value = 0.0075) different number of medications to manage HF compared to the
patients of the Avatar study. In particular, patients in the Alexa+ study were taking more
medications, with a mean of 8.7 (standard deviation 4.0), while patients that participated
in the Avatar study were taking a mean of 5.8 (standard deviation 3.4) medications. For
the remaining variables there were no statistically significant differences between the two
patient populations.
Overall, both populations were predominantly male (60% in the Alexa+, 63% in the
Avatar), black (60% in the Alexa+, 63% in the Avatar), had an average age of about 55
years (mean age 54 for Alexa+, and 56.5 for Avatar), and had had HF for an average of
about 7 years (mean of 7.5 for Alexa+, and 7.3 for Avatar). Furthermore, the majority of
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patients in both studies had experience in using smartphones, and had confidence in using
similar technology.






Age, mean (SD) 54.0 (11.7) 56.5 (12.1) 0.45
Missing 2 1
Gender, n(%) 1
Male 18 (60.0%) 17 (63.0%)
Female 10 (33.3%) 10 (37.0%)
Missing 2 (6.7%) 0 (0.0%)
Marital status, n(%) 0.80
Single, never married 7 (23.3%) 6 (22.2%)
Married 11 (36.7%) 15(55.6%)
Living together, not married 3 (10.0%) 1 (3.7%)
Separated/Divorced/Widowed 6 (20.0%) 5 (18.5%)
Missing 3 (10.0%) 0 (0.0%)
Race, n(%) 0.54
Black 18 (60.0%) 17 (63.0%)
Asian 0 (0.0%) 1 (3.7%)
White 7 (23.3%) 8 (29.6%)
Other 4 (13.3%) 1 (3.7%)
Missing 1 (3.3%) 0 (0.0%)
Hispanic heritage, n(%) 1
Yes 1 (3.3%) 0 (0.0%)
No 27 (90.0%) 27 (100%)
Missing 2 (6.7%) 0 (0.0%)
Annual household income, n(%) 0.28
$0-$50,000 19 (63.3%) 9 (33.3%)
$50,001-$100,000 2 (6.7%) 5 (18.5%)
More than $100,000 5 (16.7%) 8 (29.6%)
Missing 4 (13.3%) 5 (18.5%)
Education level, n(%) 0.49
Some high school/ High school graduate 11 (36.7%) 9(33.3%)
Some college 10 (33.3%) 7 (25.9%)
College graduate 3 (10.0%) 2 (7.4%)
Post-graduate degree 2 (6.7%) 6 (22.2%)
Missing 4 (13.3%) 3 (11.1%)
Years with HF, mean (SD) 7.5 (8.1) 7.3 (6.4) 0.95
continued . . .
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Number of medications to manage HF, mean
(SD)
8.7 (4.0) 5.8 (3.4) 0.0075
Missing 2 1
Visually impaired or blind, n(%) 0.11
Yes 4 (13.3%) 0 (0.0%)
No 22 (73.3%) 25 (92.6%)
Missing 4 (13.3%) 2 (7.4%)
Type of mobile phone, n(%) 0.41
Basic 1 (3.3%) 2 (7.4%)
Smart 25 (83.3%) 22 (81.5%)
None 0 (0.0%) 1 (3.7%)
Missing 4 (13.3%) 2 (7.4%)
Uses phone to text, n(%) 1
Yes 25 (83.3%) 24 (88.9%)
No 1 (3.3%) 1 (3.7%)
Missing 4 (13.3%) 2 (7.4%)
Uses phone for social media, n(%) 0.58
Yes 15 (50.0%) 17 (63.0%)
No 11 (36.7%) 8 (29.6%)
Missing 4 (13.3%) 2 (7.4%)
Uses phone to browse the Internet, n(%) 0.23
Yes 24 (80.0%) 20 (74.1%)
No 2 (6.7%) 5 (18.5%)
Missing 4 (13.3%) 2 (7.4%)
Confidence in using technology, n(%) 0.87
Very 11(36.7%) 12(44.4%)
Somewhat 13 (43.3%) 10 (37.0%)
Only a little 2 (6.7%) 2 (7.4%)
Not at all 0 (0.0%) 1 (3.7%)
Missing 4 (13.3%) 2 (7.4%)
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Figure 4.3: Box plot showing number of interactions in each study
4.3.2 Technology engagement
In both cases some patients did not complete the study. In particular, from the patients
participating in the Alexa+ study, five patients decided to withdraw from the study, two
patients had issues with their wifi connection, and two patients never responded to contact
attempts. One participant of the Avatar study did not respond to any contact attempts. Thus,
from the Alexa+ study we obtained information about the use of the conversational agent
technology for 21 out of the 30 patients, and the Avatar study for 26 out of the 27 patients.
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Figure 4.3 highlights the variations in the levels of engagement for patients participat-
ing in each study. For both technologies we see that there is a large range of values in the
number of times that patients interacted with the conversational agent during the 90-day
time period. While there are some patients in both studies that engaged with the conver-
sational agent technology almost daily, the majority of participants used the technology a
lot less. Furthermore, we observe a difference between the two technologies, with patients
participating in the Alexa+ study appearing to interact more frequently with the technology.
In particular, it is estimated that Alexa+ patients used the technology a mean of 31.8 times
(standard deviation 22.9), while the Avatar patient used it a mean of 20.2 times (standard
deviation 22.5).
4.3.3 Regression results
Based on the best subsets method, the highest adjusted R2 value is obtained by the
model presented in Table 4.2, which consists of six variables. The model has an adjusted
R2 of 28.9%. We see from the resulting coefficients that the older patients are linked to
higher use of the technology (0.6974, P-value <0.05), while black patients used the tech-
nology fewer times compared to non-black patients of otherwise similar characteristics
(−25.5295, P-value <0.005). Furthermore, patients that take an increased number of medi-
cations to manage HF, are associated with a lower use of the technology (−3.8529, P-value
<0.05). Finally, patients that participated in the Avatar study completed the questionnaire
is lower numbers (−27.0030, P-value <0.005) compared to patients of similar character-
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Table 4.2: Linear regression model for predicting the number of times that the patient used the
conversational agent technology.
Variable Coefficient 95% CI P-value
(Intercept) 39.5291 -0.5772 79.6354 0.0532
Age 0.6974 0.0272 1.3677 0.04189
Black -25.5295 -40.6311 -10.4279 0.0016
Household income higher than $100,000 2.3765 -12.9982 17.7512 0.75514
Number of medications to manage HF -3.8529 -7.0922 -0.6136 0.02119
Confidence in using technology 7.4847 -7.0128 21.9822 0.30118
Avatar study participant -27.0030 -44.8163 -9.1898 0.00411
istics that participated in the Alexa+ study. The variables for high household income and
high confidence in using technology were also included in the model. Both had positive
coefficients but were not statistically significant.
We also built two separate linear regression models, one for each study population.
Both models consisted of the exact same variables, which were based on the ones selected
for the model of Table 4.2. In particular, compared to the model of Table 4.2, we re-
moved the variable showing whether a patient participated in the Avatar study, since this
is no longer necessary with the populations being separate. Furthermore, we excluded the
variable indicating whether the patient has a high household income because it was not
statistically significant in the model of Table 4.2, and the smaller separate cohorts fewer
variables are preferred. We selected to contain the variable showing confidence in technol-
ogy, which has been identified as a concern of patients participating in similar telehealth
studies [108, 136]. The resulting models are included in Table 4.3. The adjusted R2 for the
Alexa+ model is 38.1%, and for the Avatar 20%. The coefficient corresponding to the age
of the patient is positive (0.7543 for the Alexa+, and 0.4373 for the Avatar), but not statisti-
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Table 4.3: Linear regression model for each population separately.
Alexa+ Avatar
Variable Coefficient P-value Coefficient P-value
(Intercept) 75.9747 0.0257 8.4326 0.7578
Age 0.7543 0.0848 0.4373 0.3487
Black -33.9386 0.0082 -24.6938 0.0148
Number of medications to manage HF -7.1885 0.0047 -0.3584 0.8349
Confidence in using technology -4.8618 0.6394 9.7999 0.3170
cally significant in either of the two models. Both models indicate that black patients used
the technology fewer times compared to non-black patients of similar characteristics, with
the coefficients being negative (−33.9386 for the Alexa+, and −24.6938 for the Avatar)
and statistically significant. An increased number of medications has a negative effect in
the number of interactions with the conversational agent in both models (−7.1885 for the
Alexa+, and −0.3584 for the Avatar), but it is only statistically significant in the Alexa+
model. Finally, the coefficient for the variable showing confidence in technology is not
statistically significant in either model. In particular, while in the model for the Avatar pop-
ulation the effect is positive (9.7999) as in the model of Table 4.2, for the Alexa+ population
the effect is negative (−4.8618).
4.4 Discussion
4.4.1 Comparing the two technologies
Patients participating in the Alexa+ study engaged on average more with the conver-
sation agent. This is highlighted by linear regression model, where we controlled for a
number of patient characteristics (demographic, clinical, and technology-related). The in-
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dicator variable identifying patients that participated in the Avatar study was selected to
be included in the model by the best subsets method, and was negative and statistically
significant. In particular, patients using the Avatar technology used the conversational day
27 fewer days on average during the 90-day study period, compared to the patients using
the Alexa+ technology, after accounting for patient characteristics.
The circumstances under which the patients were enrolled, trained, and monitored were
almost identical for the two studies, and both conversational agent types used the exact
same script to interact with the patients. Thus, the difference in the levels of engagement
is most likely attributed to the characteristics of each technology. The Alexa+ technology
allows for patients to set up daily reminders to answer the questionnaire. This is not sup-
ported by the Avatar technology. Forgetting to interact with the system has been identified
as a crucial factor of hindering telehealth uptake in previous studies [54]. Furthermore, the
conversational agent using the Alexa+ technology, could potentially be easier to use since
it is voice activated and the patient can interact with it by simply being in the same room.
However, there is no clear evidence that using the Avatar technology was difficult for the
patients, since the factor showing the confidence in using technology was not statistically
significant. This result is also supported by the models focusing on each study population
separately, which do not reveal a significant impact of technology experience on the num-
ber of interactions for either type of technology. In the literature, it has been suggested that
confidence and experience with technology can be used as a selection criterion for patients
participating in telehealth [108]. However, we do not find this to be an issue for this type
96
of technology. Thus, overall, the conversational agent technology seems to be easy to use,
since confidence in using technology did not affect the levels of engagement.
4.4.2 Patient characteristics
Older patients were linked to higher levels of engagement. This agrees with findings
from previous studies, where the age of the patient has been found to affect the level of
adherence, with older patients using telehealth more regularly [130, 172]. Furthermore,
we see that patients taking higher number of medications to manage HF tend to interact
less with the conversational agents. The number of medications can be interpreted as a
proxy for the severity of the HF condition. Thus, from the model, it seems that sicker
patients interacted with the telehealth technology less frequently. This could be caused by
a number of reasons, including physiological and psychological factors, which may have
prevented the patient from using the corresponding technology. This finding highlights the
importance of encouraging patients to use the telehealth systems, by underlying their role
in helping them to manage their condition. Furthermore, it shows that it is important for
future research to identify factors associated with the patient’s health that are linked to low
levels of utilization.
Finally, the only variable that was statistically significant in all three regression mod-
els was the indicator variable for black race. When combining both populations, black
patients used the technology 25 fewer times on average during the study period. It is not
clear what is causing black patients to engage with the technology less often. Excluding
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other race variables, the variable for black race had a relatively strong correlation with the
variable showing that the patient was married (−0.52), and moderate correlation with an-
nual household income less than $50,000 (0.24) and years with heart failure (−0.22). With
the remaining variables there were weaker correlations. In order to investigate which so-
cioeconomic factors might be driving this result, we rerun the best subsets approach after
removing all race related variables from the data set. The model with the highest adjusted
R2 value (see Table F.1, Appendix F) was similar of that of Table 4.2. However, the vari-
able for black race was replaced by the variable showing that the patient is a high school
graduate or has some high school education, and the variable for high confidence in us-
ing technology was excluded from the model. The impact of education in this model was
statistically significant, with patients with high school education or less using the technol-
ogy about 18 fewer times compared to other patients with otherwise similar characteristics.
Nevertheless, the impact of education was not as large as it was for the black variable. Fur-
thermore, the adjusted R2 for this model was nearly half of that of the original model in
Table 4.2. Thus, this large difference in black patients may be an indication of other impor-
tant socioeconomic or medical factors that are beyond the scope of our data and deserves
further study.
4.5 Conclusions
In this chapter we studied the levels of telehealth engagement by HF patients, focusing
on the use of conversational agent technology. Using linear regression we found that the
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Alexa+ technology was used in higher rates than the Avatar technology. This difference in
the levels of engagement was most likely attributed to the option that the Alexa technology
offers to patients to set up daily reminder to answer the telehealth questionnaire. There was
no indication that the patient’s confidence in using technology affected the engagement
with technology, which shows that conversational agents are not difficult to use. Other
patient characteristics that were linked to the engagement levels included age, number of
medications they take to manage HF, and race.
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Chapter 5: An optimization model for multi-appointment scheduling in an
outpatient cardiology setting
5.1 Introduction
In this chapter, we tackle the problem of outpatient scheduling in the cardiology depart-
ment of a large medical center, in an effort to make access to care easy for patients, and
thus ensure that they will go through the necessary treatment. Thus, this is a problem that
focuses on facilitating tertiary prevention.
5.1.1 Motivation
Approximately 11% of the adult population in the U.S. is diagnosed with heart disease
[149], which is also ranked first as a cause of death [69]. Receiving treatment on time
is crucial in increasing the chances for survival [50]. It is critical to investigate ways of
making access to care as effortless as possible for patients with a heart condition. This is




We focus on appointment scheduling for outpatient interventional procedures (also
known as outpatient programs) and elective surgery in cardiology. The outpatient programs
that we study are the transcatheter aortic valve replacement (TAVR), the transcatheter mi-
tral valve repair (TMVR), the patent foramen ovale (PFO) closure, valvuloplasty, and the
Watchman. Examples of elective surgery that an outpatient could go through include the
coronary artery bypass grafting (CABG), the ventricular assist device (VAD) implanting,
heart valve surgery, heart transplant, and others.
Patients have to go through a number of steps including consultations, diagnostic tests,
and treatments before they are able to go through one of the outpatient programs or elective
surgeries described above. The steps that patients are required to go through depend on their
history and condition. Figure 5.1 includes the steps that TAVR patients have to complete.
More details about the steps included in each outpatient program or surgery can be found
in Appendix G. We generated the procedure diagrams based on discussions we had with
the scheduling staff and nurse practitioners in the University of Maryland Medical Center
(UMMC) in Baltimore. We were not able to find information about the exact sequence of
steps that outpatients have to follow in other hospitals. Nevertheless, the requirements in
other hospitals were similar to those of UMMC [76, 79, 100, 105, 109, 176]. Thus, the
model that we are studying is commonly used across different hospitals.
From Figure 5.1 we observe that not all TAVR patients will necessarily go through
all of the steps appearing in the diagram. The steps that the patients have to visit depend
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Figure 5.1: Procedure diagram for TAVR patients.
on their health and the procedures they have recently undergone. The dashed rectangles
in the figure indicate that the procedures contained in them can occur in any order. The
arrows indicate precedence between procedures or groups of procedures. Also note that
no more than 30 days should elapse from start to finish, i.e., from the day that the patient
gets referred to the hospital to the day that the patient goes through the TAVR procedure.
This is important both for the health of the patient and because some of the tests have to be
repeated if more than 30 days pass (e.g. history & physical, and blood tests [112]), which
leads to unnecessary use of resources. Each step depicted in Figure 5.1 requires numerous
resources to be available in order for the patient to pass through them.
Outpatients are patients who get treatment in the hospital without staying overnight or
getting admitted. The patients we are studying get admitted only after going through the
final procedure. This means that the patients have to travel to the hospital on multiple occa-
sions. The UMMC treats patients throughout Maryland and the surrounding region. Thus,
the patients may have to travel long distances to get to the hospital. Furthermore, they usu-
ally depend on someone else to drive them to and from the hospital. This complicates the
scheduling procedure, and in some cases the patients may not show up for their appoint-
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ments or they arrive late. Therefore, it is important to propose a scheduling approach that
makes the visits to the hospital as convenient as possible for the patients.
5.1.3 Problem statement
Currently, appointments are scheduled manually without the support of a decision
model. While the scheduling staff tries to generate schedules that will not cause unnec-
essary burdens on the patients, it can be time consuming to generate such a schedule, and
the outcome may not be optimal. The resources required for each appointment are in
many cases shared with other departments in the hospital, which means that the various de-
partments are competing for the same resources. Each outpatient is scheduled separately.
Different outpatient programs and surgeons have their own scheduling staff, who coordi-
nate with the outpatients to book the appointments. The scheduling staff first talks to the
patients to learn when they can come to the hospital. Then they call the corresponding labs
to find out the availability of appointments. After booking all the required appointments,
they inform the patient about the days and times of the appointments.
In this study, we propose an optimization model to help the staff decide how to schedule
the appointments. The objective is to generate schedules that are more convenient for
the outpatients. Furthermore, we investigate the effect that scheduling patients in groups
would have in the quality of the resulting appointments. This could help distribute the
available resources better since more information is available when additional patients are
included in the optimization. A number of hospital settings schedule patients in groups
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instead of one at a time. Examples include scheduling appointments for destination medical
centers [140], for radiotherapy pre-treatment [21], and for care of neuromuscular diseases
[80]. Scheduling patients in groups requires coordination between the scheduling staff
of the various outpatient programs and surgeons. There is a big overlap in the resources
required across the procedures that we study. If combining the scheduling of the outpatients
leads to better outcomes for the patients, the hospital wants to encourage this collaboration.
An additional advantage of grouping the patients is that the communication with the labs
will become easier. The scheduling staff will not have to book appointments as often,
since patients will be scheduled in batches. An additional derivative benefit, resulting from
this scheme, is cost savings on the side of the hospital treating the patients. It can be
time consuming every time that the scheduling staff has to find out the availability of each
resource, given that there is no centralized way of doing this. Each lab and personnel has to
be contacted separately. For the reasons discussed above, this is a direction that the hospital
is interested in exploring.
5.1.4 Constraints
Our objective is to generate schedules that are convenient for the patients. The patients
should not have to travel to the hospital more times than necessary. Furthermore, the pa-
tients should not have to spend too much time waiting in between appointments, because
this may tire or stress them. The scheduling process must satisfy the following constraints:
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• Once an appointment for a patient is set, it must not get canceled in order to accom-
modate another patient.
• The preference and the availability of the patient with respect to the different days of
the week should be taken into consideration when scheduling the appointments.
• The patients have to complete all the required steps within the allowed time limit.
• The patient should not go through more steps than those required.
• Enough time must be provided for the patient to prepare (or recover) before (or after)
a procedure.
• No more than the available resources can be used.
5.1.5 Contributions
The contribution of this research is threefold. First, to the best of our knowledge this
is the first study that looks into multi-appointment scheduling in outpatient cardiology. In
this work, we discuss the parameters and the constraints that need to be taken into account
in such a problem and develop an IP formulation. We also provide the procedure diagrams
including the steps that the outpatients have to go through. Second, we develop formulation
improvements which help solve the IP significantly faster. Those types of improvements
could be applied to other scheduling problems with a similar formulation approach. Third,
we examine whether outpatients should be scheduled in groups, which requires the collab-
oration of different scheduling staff in outpatient cardiology. We investigate what is the
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appropriate size of the group based on different levels of resource availability and external
demand. Taking external demand into account is important in a hospital setting, since the
various departments do not have complete control over all resources used by their patients.
The rest of the chapter is organized as follows. Section 5.2 provides a review of the
existing literature relevant to this problem. Section 5.3 includes a description of the multi-
appointment scheduling problem in outpatient cardiology. The formulation of the schedul-
ing problem is presented in Section 5.4, which also includes a number of formulation
improvements and discusses running times. Section 5.5 provides the computational ex-
periments and the discussion of the results. Section 5.6 discusses the managerial insights.
Finally, Section 5.7 states the main conclusions and provides directions for future research.
5.2 Literature review
This section discusses some of the relevant literature in outpatient scheduling. A thor-
ough review of the existing outpatient appointment scheduling literature and suggested
research opportunities can be found in [5, 23, 57]. We study scheduling outpatients to go
through multiple procedures, which, due to resource or recovery constraints, have to take
place on more than one days. While the majority of the outpatient scheduling research
examines single appointments, a number of studies have looked at scheduling multiple ap-
pointments for the same patient [5]. In particular, the existing literature can be classified
into one of the following groups: single appointments, combination appointments, or ap-
pointment series [5]. Combination appointments refer to multiple appointments booked for
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the same day, while appointment series refers to appointments booked on more than one
days for the same patient. However, appointment series usually refer to the same types
of appointments scheduled on multiple days, since as part of the treatment, the patients
have to make repeated visits. Examples include scheduling of chemotherapy [150, 163]
or radiotherapy patients [36, 37], where a similar type of treatment is repeated on many
days. Thus, our problem is better classified as a combination appointment even though
the appointments can be scheduled on different days. An extensive literature review of
multi-appointment scheduling for both inpatients and outpatients is provided in [98]. Our
research considers the multidisciplinary scheduling group of problems, since the appoint-
ments scheduled include staff and resources from various parts of the hospital. A literature
review on multidisciplinary planning can be found in [85], which discusses research on a
number of settings, including outpatient clinics, emergency care, blood collection sites, etc.
A mixed integer program (MIP) formulation is presented in [90] for scheduling a set
of patients to go through their path of required procedures in an ophthalmology clinic on a
given day, where the order of the procedures is predetermined. The objective is to minimize
the weighted sum of patient waiting time, resource use overtime, and congestion. Adaptive
scheduling heuristics are used to solve the problem, where patients are transferred from
more to less busy slots. Patients who have to go through radiotherapy pre-treatment are
scheduled in [21]. A MIP formulation with multiple hierarchical objectives is proposed,
in an effort to minimize the number of patients waiting longer than the waiting time tar-
gets. Each objective is added to the model separately, and its optimal value is passed as a
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constraint to the next phase which includes the subsequent objective. Due to complexity,
the problem is solved by passing initial solutions and not optimal solutions from one phase
to the next. It is assumed that the sequence of procedures that the patients go through is
known. Scheduling procedures in nuclear medicine is considered in [128], where there are
strict constraints on the time that each step of the medical procedure takes place. Four dif-
ferent scheduling algorithms are taken into consideration including scheduling the patients
as soon as possible, scheduling based on the day that the patient prefers to go to the clinic,
and two algorithms that take into account the preference of the patient up to a point and then
schedule them as soon as possible. A MIP formulation is developed in [9] for scheduling in
a pathology laboratory as an effort to maximize the patient satisfaction, which is achieved
by minimizing the completion time.
Scheduling procedures in nuclear medicine is also considered in [127], where an on-
line scheduling algorithm and a stochastic online scheduling algorithm are proposed. The
stochastic online scheduling algorithm consists of a two-stage stochastic program that also
takes into account future patient arrivals when scheduling each new request for appoint-
ment. The future arrivals include patients that might request an appointment on the same
day as the patient being scheduled requested. Scheduling chemotherapy appointments is
studied in [60], during which each patient goes through three stages. The uncertainty of the
type of appointments requested from new patients during a day and possible cancellations
are dealt with by developing a template schedule based on historical data and the deter-
ministic version of the problem. It is possible to update the template dynamically when
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a new patient arrives who does not fit in the existing template. The authors in [86] study
appointment scheduling in a cancer clinic, in an effort to minimize the weighted sum of the
waiting time of the patients, the time that the resources are being idle, and the overtime.
A stochastic IP is proposed, since the routes that each patient will follow are uncertain.
The sample average approximation method is used in order to obtain the upper and lower
bounds of the objective. The length of treatment and the course of the treatment of inpa-
tients is predicted through a discrete time Markov model in [78]. A two-stage stochastic
IP is proposed in [121] for scheduling patients in primary care. The patients go through a
sequence of predetermined steps with stochastic duration. In the first stage the appointment
times of all patients are scheduled, and in the second stage the service times in each stage
are realized. The objective is to minimize the idle time of the physician and the waiting
time of the patients. Scheduling outpatient surgeries is studied in [147], where the patients
go through the pre-operation, the surgery, and the recovery stage. Each stage has stochas-
tic duration. The authors propose simulation-based TABU search methods to solve the
scheduling problem.
The objective of our study has similarities with research on scheduling appointments
in rehabilitation and destination medical centers. Both types of problems aim to generate
schedules that are convenient for the patients. Scheduling patients in destination medical
centers means that the patients have to travel to the location of the hospital and stay in this
location for the duration of their treatment. Thus, in [140] patients are scheduled in an effort
to have them start their treatment as close to their start day as possible. Furthermore, the
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time that the patients wait until all steps of their treatment are completed is also minimized,
in order to avoid having patients spend too much time in a hotel. The problem is formulated
as a MIP, and is solved using a hybrid particle swarm optimization algorithm. An IP for
scheduling rehabilitation patients is proposed in [18]. Each appointment request is satisfied
as it arrives. The problem is formulated as a multi-objective minimization problem, where
the weight of each criterion is decided ahead of time. The eleven criteria taken into account
in the objective include the number of extra visits the patient has to make to the clinic (in
addition to the minimum number necessary), the time it takes until the first appointment
of the patient takes place, and the number of unscheduled appointments. The formulation
allows for a percentage of appointments in each discipline not to get scheduled. In the
majority of the cases, the optimal solution of the problem is obtained within a few seconds.
The number of visits that a child with a neuromuscular disease has to make to the hospital
for rehabilitation is limited to one per year in [80]. Based on this constraint, an IP is
proposed to schedule the appointments as well as decide on which children will visit the
hospital on each day. The formulation allows for patients to have only a subset of the
required appointments scheduled. The objective consists of five criteria, including the time
the patients spend being idle, and the number of patients with complete or partial visits.
The patients are scheduled in groups.
In this work, we aim to generate schedules that are convenient for the outpatients.
In particular, due to the specifics of the outpatient cardiology setting we do not want to
have patients travel to the hospital too many times or wait too long in between appoint-
110
ments. The majority of the research in outpatient multi-appointment literature has differ-
ent objectives, with most studies focusing on decreasing the waiting time for the patients
[21, 86, 90, 121, 127]. However, it is crucial to investigate this type of objective because it
is more suitable to the case of non-urgent outpatients. Generating convenient schedules for
those patients will help increase their willingness to go through the necessary treatment.
Research on rehabilitation outpatient scheduling [18, 80] has the most similarities to our
problem compared to other studies in the literature. Both of the cited studies formulate
the problem using a multi-objective function. It can be difficult to determine the necessary
weights of the objective function in a way that provides the hospital with the best schedule
in every case. In our study, we propose providing the hospital with Pareto optimal solu-
tions and allow them to decide which schedule is preferable. Thus, the weights do not have
to be determined ahead of time, which gives more flexibility to the hospital to decide on
the appropriate schedule. Furthermore, our method of finding the Pareto optimal solutions
is much more general and complete than the weighted sum approach, because the funda-
mental problem here is that of trade-off analysis between the various objectives, and our
solution provides precisely all the Pareto points corresponding to such trade-off analysis.
The weighted sum approach is the so-called “scalarization method” for trade-off analysis
that provides only one Pareto point, the one corresponding to the weights used [46]. De-
ciding on the weights ahead of time is not very easy or intuitive for the scheduling staff and
may not lead to the desirable balance between the two components of the objective. In addi-
tion, the constraints of our problem are different from [18, 80] due to the characteristics of
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our system. For example, we allow for recovery and preparation time when necessary, and
we have a strict target day for completion. Finally, we investigate whether patients should
be scheduled in groups by having different teams collaborate. This could help generate
appointments of better quality in a setting where there are other departments in the hospital
competing for the same resources. This is crucial, because in many hospital settings the
resources are shared across multiple departments. To the best of our knowledge this has
not been studied before in outpatient multi-appointment scheduling problems. In general,
we see that only a small portion of the outpatient literature focuses on multi-appointment
scheduling [5], which highlights the importance of investigating different aspects of this
problem.
5.3 Problem description
This section discusses the assumptions made for solving the problem of multi-appointment
scheduling and includes the description of the different elements of the formulation and the
corresponding notation.
5.3.1 Assumptions
In order to model the multi-appointment scheduling problem we make the following
assumptions.
1. The duration of each process is deterministic.
Some process steps may last for a longer or shorter time period than the duration
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for which they were booked. Nevertheless, in this work, we are assuming that the
duration of the appointments for each type of diagnostic test or treatment is fixed.
This is the approach currently followed in the hospital when scheduling, since ap-
pointments are booked based on slots of a predetermined length. Since we want to
provide a support tool for the scheduling staff in the hospital, we decided to solve the
problem following the same approach. A deterministic duration is also assumed in
[18, 80, 140]. The risk of assuming deterministic durations is that the patient may not
finish a step in the expected time, and therefore not have enough time to go through a
subsequent step. More complicated procedures (e.g. cardiac catheterization), which
can have higher variability in duration due to their complexity, also require a long
recovery time. This ensures that there will not be another procedure booked right
after. Therefore, we assume that the duration is deterministic. In the experiments
run, we use the maximum duration of a diagnostic test or procedure as the duration
of the appointment.
2. The steps that patients have to go through are determined as soon as they arrive.
In reality, some diagnostic test might be added later, after finding out more about the
patient’s health, or some future test might get canceled because it was deemed that
the particular procedure was not a good fit for the patient. Similarly, an entire series
of steps might have to get canceled if it is deemed that the patient is not a good match
for the final procedure at that point in time or in general. However, those cases are
less frequent, and the combinations of all possible paths that the patient might end
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up following in this case are many. Therefore, in order to get a simpler optimization
model which is easier to solve, we make this assumption.
3. The scheduling staff has enough time to book an appointment before the resource
availability changes.
In other words, when the scheduling staff obtains the available appointments they
will have enough time to solve the optimization problem and call back each resource
to book the appointments, without some other department being able to book these
resources for their own patients in the meantime. Depending on the number of pa-
tients that are getting scheduled at the same time, solving the problem could take
from a few seconds to a few minutes. We are assuming that the probability of an-
other department booking appointments that overlap with the ones proposed by our
model is very low, and thus there is no need to take this case into consideration.
5.3.2 Definitions
5.3.2.1 Time
Let D denote the set of days and H be the set of time slots or time units in the planning
horizon. For example, if each slot corresponds to one hour, we would have |H|= 24∗ |D|
because there are 24 hours in a day. The set of time slots Hd denotes the time slots h ∈H
included in a day d ∈D, so in our example we would have |Hd|= 24, ∀d ∈D. The length
of each slot is set to be equal to the greatest common divisor of the appointment durations of
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Figure 5.2: Example of patient arrivals during the time horizon.
all the procedures that patients could possibly go through in the system. Thus, the duration
of each procedure can be expressed as an integer multiple of the defined time unit. We
can schedule patients either one at a time, or in groups. Let T denote the set of decision
epochs in the planning horizon. In a decision epoch t, it is decided how to schedule any
patients that arrived between decision epoch t−1 and t, who have not been scheduled yet.
Decision epochs do not take place at predetermined or fixed intervals. They depend on the
arrival times of the last patient in the group. Function o : (T)→ (H) shows the time in
the planning horizon that a specific decision epoch corresponds to. Figure 5.2 includes an
example of the times that patients A through F were referred to the hospital. If patients
are scheduled one at a time, then o(1) = 1. The first decision epoch corresponds to the
arrival time of the first patient. On the other hand, if the patients are scheduled in groups
of two, we have o(1) = 2. In other words, the decision epoch equals to the arrival time of
the second patient. If patients are scheduled in groups of three, we get o(1) = 4, since the
decision epoch equals to the arrival time of the third patient.
115
5.3.2.2 Patients
Let I denote the set of patients that will be scheduled. There exists an amount of time
within which a patient i ∈ I has to complete the program, which is denoted by Li. In
other words, this is the maximum time that a patient is allowed to spend in the system.
It is assumed that as soon as a patient is referred to the hospital and the history of the
patient becomes available, the patient enters the system. The entry time is denoted by ai.
The planning horizon is set based on the latest it can take for a patient in the group being
scheduled to exit the system without violating the allowed period of completion. A patient
exits the system once the last procedure is completed, which is normally the main reason
that the patient was referred to the hospital. For example, in the TAVR program, the final
procedure is the TAVR being performed on the patient in a hybrid operating room.
5.3.2.3 Positions in system
Patients take various positions throughout their stay in the system. These positions can
be categorized into two different types: procedure and waiting positions. A patient that is
in a procedure position is a patient who is at a hospital going through a diagnostic test or a
treatment. Patients who are in a waiting position might be in the hospital or not. A patient,
who is in a waiting position, has already gone through a procedure and is expected to go
through another one on the same day, is assumed to be waiting in the hospital. These types
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Figure 5.3: Example of paths followed by a TAVR patient i.
procedure or are waiting to go through their next appointment which might not be available
right away due to capacity constraints. A patient who is in a waiting position is not using
any hospital resources. Let P̃ denote the set of procedure positions available in the hospital,
and Q̃ be the set of waiting positions. Note that for every element p̃ ∈ P̃ there exists an
element q̃ ∈ Q̃ which is the waiting position that the patients will take after they complete
procedure p̃. Also note that after the patients go through their last position in the system
they go to a waiting position where they stay for the entire horizon, which is the exit position
denoted by l. All patients that have reached this position are assumed to have exited the
system. Set Q̃ has one additional element (|Q̃|= |P̃|+1), which is the waiting position
entry which all patients take when they first enter the system before they go through any
procedures and is denoted by b.
A patient entering the system will only visit a subset of the procedures (and their cor-
responding waiting positions) offered in the hospital. Let P̃i and Q̃i denote the sets of
procedure positions and waiting positions, respectively, that a specific patient i has to visit,
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where P̃i ⊆ P̃ and Q̃i ⊆ Q̃. An example of the procedures that a specific TAVR patient i
may have to go through can be found in Figure 5.3a. In this case the elements appearing
in the rectangles will be included in set P̃i, since they refer to procedures that patient i will
go through, while those in the ovals will be part of the Q̃i set, since the patient is waiting at
those positions. For this example, the patient will follow one of the two paths presented in
Figure 5.3b. The patient arrives in the system at position entry. Then the patient will either
follow the first path in order to get a consultation and then do a CT scan or the second path
in which the patient will first do a CT scan and then get a consultation. Finally, the two
paths will merge into one and the patient will go through the TAVR procedure and then
exit the system. It is important to point out that a patient who followed the first path and
is going through a CT scan is in a different state in the system than a patient that followed
the second path and is going through the CT scan. Therefore, multiple types of the same
position are created, one for each path that a patient could follow. Let Pi denote the set of
all procedures in all possible paths that patient i could go through, and correspondingly let
Qi be the set of all waiting positions in all possible paths that patient i could go through.
Finally, let Si be the set of positions that a patient i may potentially visit, so Si = Pi∪Qi.
Let g : (Si)→ (P̃i ∪ Q̃i), denote a function that returns an element s̃ ∈ (P̃i ∪ Q̃i) for each
argument s ∈ Si. Table 5.1 includes the elements that each of the sets defined above con-
sists of, in the example presented in Figure 5.3. Finally, let Fi,s and Gi,s denote the set of
positions right before and right after a position s ∈ Si for patient i, respectively.
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Table 5.1: Elements included in each set in the example illustrated in Figure 5.3.
Set Elements
P̃i CT scan, Consultation, TAVR
Pi CT scan 1, CT scan 2, Consultation 1, Consultation 2, TAVR
Q̃i Entry, Wait after CT scan, Wait after Consultation, Exit
Qi Entry, Wait after CT scan 1, Wait after CT scan 2, Wait after Consultation 1, Wait
after Consultation 2, Exit
Si CT scan 1, CT scan 2, Consultation 1, Consultation 2, TAVR, Entry, Wait after
CT scan 1, Wait after CT scan 2, Wait after Consultation 1, Wait after Consulta-
tion 2, Exit
5.3.2.4 Availability, resources, and durations
For a patient to go through a procedure at a given time, the patient must be available
to come to the hospital on that day, and the necessary resources must be available for the
procedure to take place. Let Adi denote the availability of patient i to come to the hospital
on day d. In particular, Adi is a binary parameter taking the value 1 if the patient can come
to the hospital on day d, and 0 otherwise. Let R be the set of all resources in the hospital
that are required for the procedures to take place. These resources include equipment, labs,
and staff. Let Pp̃,r denote the number of each resource type r ∈ R required for a procedure
of type p̃ ∈ P̃ to take place. Let Rhr denote the number of resources of type r that are
available to be assigned to patients at time h. This number will change from one decision
epoch to the next, since it will be updated based on the patients that got scheduled in the
previous decision epoch and the demand from other departments in the hospital. Note that
on weekends or during time in a weekday outside the 8am-5pm range, the availability of
all resources is 0.
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Table 5.2: Scheduling problem sets, function, and parameters.
Sets
D Set of days in the planning horizon, indexed d
H Set of time slots in the planning horizon, indexed h
Hd Set of time slots belonging to the same day d, indexed h
T Set of decision epochs, indexed t
Edi Set of available appointment times for patient i on day d, indexed e
I Set of patients, indexed i
P̃ Set of procedures, indexed p̃
P̃i Set of procedures that patient i will visit, indexed p̃
Pi Set of procedure position states over all paths that patient i may visit, indexed p
Q̃ Set of waiting positions, indexed q̃
Q̃i Set of waiting positions that patient i will visit, indexed q̃
Qi Set of waiting position states over all paths that patient i may visit, indexed q
Si Set of position states over all paths that patient i may visit, indexed s, s′
Fi,s Set of positions preceding position s for patient i, indexed s, s′
Gi,s Set of positions subsequent to position s for patient i, indexed s, s′
C Set of steps required to reach the positions, indexed c
Ki,c Set of positions that can be reached by patient i after exactly c steps, indexed s, s′
P∗i Set of procedure position states that will solely take place on a day, indexed p
∗
R Set of resources, indexed r
Functions
o() Function mapping elements in T to elements in H
f () Function mapping elements in H to elements in Edi
g() Function mapping elements belonging in Si to elements in P̃∪ Q̃
Parameters
Rhr Number of resources of type r available at time h
Pp̃,r Number of resources of type r required for a process p̃ to take place
Adi Binary indicating availability of patient i to visit the hospital on day d
ai Arrival time of the patient to the system, ai ∈H
Li Number of time units within which patient i should complete the program
b First position that patients take in the system, b ∈ Si
l Last position that patients take in the system, l ∈ Si
dp̃ Duration in time units of procedure p̃
ωq̃ Time units of recovery needed after a procedure, spent in the subsequent waiting
position q̃
γp̃ Time units of rest required before procedure p̃
M Upper bound for the time in a day that a patient can be in the hospital
N ji Normalizing constant for patient i used in component j of the objective, j = 1,2
λ Trade-off parameter in the objective function, λ ∈ [0,1]
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Each procedure p̃ ∈ P̃ that a patient will go through has a duration dp̃. Any resources
that are allocated to the patient for a procedure p̃ will be allocated to the same patient for
the entire duration of the procedure. Every procedure position p̃ is followed by a waiting
position q̃, which is necessary to ensure that the patient has enough time to rest and recover
from the procedure. Let ωq̃ be the time that a patient needs to recover from a preceding
procedure p̃, or, in other words, the minimum time that the patient will spend in the waiting
position q̃. Depending on the procedure, the recovery time could last up to a few days.
Finally, let γp̃ denote the additional time required before a specific procedure p̃ takes place.
This is the case for procedures that require some preparation. For example, if the patient is
not supposed to eat or drink anything for a few hours before the procedure. In those cases,
in order to avoid stressing the patients further, we impose some additional rest time before
the procedure.
5.4 Scheduling problem
This section describes the formulation used to solve the problem of multi-appointment
outpatient scheduling. In Subsections 5.4.1 and 5.4.2, we present the decision variables, the
objective function, and the constraints of the scheduling problem. The problem is formu-
lated based on the notation discussed in Section 5.3 and included in Table 5.2. Subsection
5.4.3 describes the approach used to normalize the components of the objective function,
and Subsection 5.4.4 includes an example for obtaining the Pareto optimal solutions. In
















Figure 5.4: Difference between decision variables whi,s and y
h
i,s.
the time it takes to obtain an optimal solution.
5.4.1 Decision variables
The decision variables for the IP are presented below.
whi,s =













1, if patient i ∈ I went through procedure p ∈ Pi on day d ∈D
0, otherwise
udi ≡ time that patient i ∈ I arrived at the hospital on day d ∈D
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vdi ≡ time that patient i ∈ I left the hospital on day d ∈D
Note that the decision variable whi,s shows whether a patient has arrived at a position by
a specific time h. Once this variable takes the value 1 for a specific patient and position, it
will take the value 1 for all subsequent times, since the patient has reached this position by
all future times. This decision variable was first introduced in [14]. On the other hand, the
decision variable yhi,s only takes the value 1 if a patient is in position s at a specific point in
time h. Figure 5.4 shows the values for these two types of variables. A patient is scheduled
to go through a specific position from time h1 to time h2. We can see from the figure that
decision variable whi,s takes the value 1 for all times after h1. On the other hand, decision
variable yhi,s equals to 1 only for the times between h1 and h2. Appendix H includes an
example which illustrates the difference between the decision variables and the values they
take.
5.4.2 The Integer Program
Below is the mathematical formulation of the IP. The hospital would have to run the
following IP at every decision epoch t ∈ T, in order to schedule all patients that have arrived
since the last scheduling took place. The patients that have already been scheduled are not
taken into account again in the decision making since it is not allowed to reschedule already
scheduled patients. Nevertheless, the resources they occupy are updated to represent the
availability at time t. However, when previously scheduled patients do not show up for an
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appointment, they might be taken into account again in the decision making. In this case
their appointments have to get rescheduled. In particular, if the appointment that the patient
did not show up for can be rescheduled without affecting the timing of future appointments
it can be rescheduled manually, since it is considered as a single appointment. If the no-


















whi,s = 0,∀h ∈H : h≤ ai−1, i ∈ I,s ∈ Si (5.2)
whi,s = 1,∀h ∈H : h≥ ai, i ∈ I,s = b (5.3)
whi,s = 1,∀h ∈H : h≥ ai +Li, i ∈ I,s = l (5.4)
whi,s = 0,∀h ∈H : h≤ o(t), i ∈ I,s 6= b (5.5)
wh−1i,s ≤ w
h



















i,s,∀h ∈H, i ∈ I,s ∈ Si (5.9)
∑
s∈Si





yhi,sPg(s),r ≤ Rhr ,∀h ∈H,r ∈ R (5.11)
xdi ≤ Adi ,∀d ∈D, i ∈ I (5.12)





yhi,s,∀d ∈D, i ∈ I (5.14)




yhi,s,∀d ∈D, i ∈ I, p ∈ Pi,s = p (5.16)
udi ≤ (h−|Hd|∗(d−1))yhi,s +M(1− yhi,s)−M(1− xdi ),∀d ∈D,h ∈Hd,
i ∈ I,s ∈ Si∩Pi (5.17)







i,p ∈ {0,1},∀d ∈D,h ∈H, i ∈ I, p ∈ Pi,s ∈ Si (5.19)
udi ,v
d
i ∈ Z+,∀d ∈D, i ∈ I (5.20)
The objective function (5.1) minimizes the linear combination of the number of times
that the patients have to visit the hospital, and the time that the patients spend in the hospital
waiting for their next appointment. The first component of the objective has weight λ , and
is estimated based on the total number of visits to the hospital over all patients. For each
patient, the number of visits is normalized to take a value between 0 and 1. This is achieved
by dividing the number of visits of each patient by a constant N1i . More details about how
the value of the normalizing constant is chosen are included in Subsection 5.4.3. The
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second component of the objective has weight (1−λ ), and corresponds to the total time
that the patients spent in the hospital not going through a procedure, or in other words the
time spent in the hospital in-between procedures. Similarly to the first component, the total
idle time for each patient is normalized by dividing by a constant N2i . We plan to provide
the hospital with multiple schedules to choose from. Therefore, in each problem instance
we estimate the Pareto optimal solutions based on various values of λ . Varying λ in this
way allows us to obtain the convexification of the Pareto points boundary (see [46]), which
is much better than providing the solution for a single value of λ . Such an example is
discussed in Subsection 5.4.4.
Constraint (5.2) makes sure that the patients will not reach any position in the system
before they get referred to the hospital. Constraints (5.3), and (5.4) enforce that patients
will visit the first and the last positions in their path by their entry time and at most after
spending the maximum allowed time in the system respectively. Constraint (5.5) states
that patients who are referred to the hospital cannot go through any procedure before the
decision epoch following their arrival. Constraint (5.6) guarantees that once a patient has
reached a position, this position will have been reached in all future times by this patient.
Constraint (5.7) enforces a recovery and preparation time before the patient can move to
the next procedure. Similarly, constraint (5.8) imposes that a patient will move on from a
procedure to the subsequent waiting position exactly after time equal to the duration of the
procedure. Constraint (5.9) ensures that a patient is in a specific position, when the patient
has reached the current position but none of the subsequent positions. Constraint (5.10)
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makes sure that a patient is at most at one position in the system at all times. Constraint
(5.11) verifies that no more than the available resources are used at each point in time.
Constraint (5.12) enforces that all appointments are scheduled on days that the patient is
able to come to the hospital. Based on the discussions we had with the hospital, we decided
to consider availability based on the day and not the time. Since the hospital tries to fit as
many procedures as possible on a single day, we decided that patients are available if they
are available all day. However, if necessary, availability per time can be easily introduced to
the IP by changing constraint (5.12) to yhi,s ≤ Ahi , where Ahi is the availability of the patient
in each time slot h.
Constraints (5.13) and (5.14) capture whether a patient is scheduled to be in the hospital
on a specific day. Similarly, (5.15) and (5.16) capture whether a patient is scheduled to
go through a specific procedure on a specific day. Constraints (5.17) and (5.18) capture
the arrival and departure times of each patient on each day. Since this is a minimization
problem and variable udi has a negative sign, the variable will take the largest value possible.
Thus, udi ≤ (h−|Hd|∗(d−1))yhi,s ensures that variable udi will equal the time of day d that
the patient is scheduled for the first procedure of the day. If a patient is not scheduled for
procedure p on day d, but is scheduled for a different procedure, constraint (5.17) becomes
udi ≤ M for procedure p. This ensures that udi will equal to the start time of a procedure
that the patient is scheduled to go through on that day. This requires a large enough M.
On the other hand, if the patient is not scheduled for any procedure on day d, constraint
(5.17) becomes udi ≤M−M⇒ udi ≤ 0 for all procedures. Since vdi has a positive sign in
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the objective, it will take the smallest value possible. This corresponds to the time that the
patient finished with the last procedure for the day. Constraints (5.19) and (5.20) define the
binary and the nonnegative integer decision variables of the problem respectively.
Some of the constraints introduced above either come from, or are based on, constraints
from [13, 14]. Constraints (5.6) and (5.7) were used in [13, 14], and ensure connectivity
between the positions and connectivity in time. Constraint (5.8) is similar to (5.7) but
with an equal instead of a less than or equal sign. We adapted this type of constraint
to ensure that a patient will spend time in a procedure exactly equal to the duration of
the appointment. Constraint (5.11) has been extended to include the number of resources
required for a procedure to take place. The remaining constraints and objective functions
were created for the purpose of this problem.
5.4.3 Choice of normalizing constants
The two components of the objective are estimated based on different metric units. The
first component refers to the number of visits to the hospital, and the second to the total idle
time during a patient’s visits to the hospital. The idle time component tends to get larger
values, which effectively gives this component a larger weight in the objective. Therefore,
it is important to normalize the two components. For every patient getting scheduled, each
component of the objective will take values between 0 and 1 after the normalization. This
helps achieve a better balance between the two components, and avoids the well know
pitfall of different dynamic ranges (i.e. ranges of values) between two or more objectives
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Figure 5.5: Idle times observed per number of procedures required.
in trade-off analysis.
In the case of the number of visits to the hospital we achieve this by dividing the total
number of visits that a patient has to make to the hospital with the maximum number of vis-
its that the patient could make to the hospital (i.e., the number of procedures required). With
the second component of the objective we want to use a similar approach when normaliz-
ing. However, in the worst case scenario, where the patients have to wait in the hospital for
the longest time possible, the total wait time for each patient becomes a very large number.
If we divide the total idle time for each patient by the maximum possible wait time that this
type of patient could spend in the hospital, we obtain a very small number. The reason is
that the worst case scenario never occurs in reality. Therefore, the first component of the
objective would effectively have a larger weight. In an effort to decrease the value of the
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normalizing constant in the second component of the objective, we ran a number of exper-
iments where the objective only focused on minimizing the number of visits to the hospital
(i.e. λ = 1). For each patient, we estimated the total idle time in the hospital. The patients
were grouped based on the number of required procedures they have to go through. The
results are presented in Figure 5.5. The line at the top of the figure shows the maximum
idle time for each group in the worst case scenario. From the box plots we can see that the
actual idle times are considerably lower than the longest possible idle time. Therefore, the
normalizing constant for each type of patient is set equal to the longest idle time observed
in the experiments.
5.4.4 Pareto solutions
Our objective consists of two components, which are incompatible with each other. A
Pareto optimal solution ensures that in order to improve one of the components, the other
will have to become worse. The hospital should be the one to choose between schedules
that provide Pareto optimal solutions. Thus, the scheduling staff will select the schedule
that provides the desirable balance (or compromise) between the two components.
An example of the different solutions provided when solving a specific scheduling prob-
lem is presented in Figure 5.6. In this example, three patients are getting scheduled simul-
taneously. In order to obtain the different solutions, we solved the IP using different values
of λ (i.e., λ ∈ {0,0.1, ...,1}). Furthermore, we used different time limits, after which the
IP provided the best solution found up to that point. We also allowed enough time for the
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(a) Normalized values of the two objective func-
tion components.
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(b) Values of the two objective components.
Figure 5.6: Pareto optimal solutions (in red) in example of scheduling 3 patients simultaneously.
IP to reach optimality in some of the experiments. Note that in cases where the solver is not
allowed enough time to prove that a proposed solution is optimal (i.e., to reach optimality),
we subsequently cannot prove that a solution is Pareto optimal. Nevertheless, since enough
time was allowed in this particular example, we have generated Pareto optimal solutions.
The filled red points in Figure 5.6 are the Pareto optimal solutions. The gray areas in
both graphs indicate values that cannot be part of the solution, since there is a minimum
number of visits that a patient has to make to the hospital. Figure 5.6a shows the values
for each component of the objective. The y and the x axis of the graph range from 0 to
3, since for each of the 3 patients getting scheduled both components of the objective take
at most the value 1. Figure 5.6b includes the same solution without normalizing the two
components of the objective.
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It can be observed from Figure 5.6 that there exists a trade-off between the two compo-
nents of the objective. As it was expected, low values of idle time are achieved when the
patient makes many visits to the hospital. On the other hand, the time spent at the hospital
while waiting increases as the number of visits to the hospital decreases. If the hospital
is more interested in obtaining schedules where the patients visit the hospital few times,
they could choose a schedule that corresponds to 12 visits and 11 time units of wait in total
for the three patients being scheduled. Another option would be to choose a schedule that
corresponds to 13 visits and 7 time units waiting time in the hospital in total. The second
schedule proposed might be preferable, since the hospital would require one additional visit
from one of the three patients, but save four time units of wait, which corresponds to two
hours. Nevertheless, the hospital will have to decide whether this is indeed preferable.
5.4.5 Formulation improvements
We make improvements to the IP presented in Section 5.4.2 in order to help in solving it
faster. The improvements guarantee that the resulting IP will provide the same solutions as
the initial formulation. First, we ensure that the big M will take the smallest possible value,
which helps the IP to be solved faster. Second, we introduce valid inequalities. These
are constraints that eliminate some non-integer solutions, which are feasible in the initial
formulation. However, none of the integer solutions are eliminated. The improvements that
we introduce are based on the structure of this particular problem.
Valid inequalities have been used before in the outpatient scheduling literature [142].
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In [142], the valid inequalities have to do with the fact that the total resource demand on
a given day cannot be higher than the available capacity, and that a procedure cannot be
scheduled if none of the resources are used by this procedure on a specific day. The authors
use Bender’s decomposition, and their objective function only depends on the day that a
specific procedure is scheduled. The formulation approach and constraints are different to
the IP proposed here, which means that we use different valid inequalities.
As we described in Section 5.4.2, parameter M has to be large enough to ensure that it
will not be smaller than a potential appointment time. At the same time, for computational
efficiency M has to take the smallest possible value. One option is to set M equal to |Hd|,
since all appointments are completed by the end of the day, and there are |Hd| time units
in a day. Nevertheless, we achieve an even stricter bound by setting different M values for
different days and different patients. So in fact M becomes Mdi ,∀d ∈D, i ∈ I.
We know the available resources and the procedures that each patient is going to go
through. Thus, we can estimate the earliest and the latest time on each day that each patient
could potentially be scheduled to go through a procedure. We generate set Edi = {0,1, ...,E}
for each patient on each day. We define the earliest time that the patient could be in the
hospital as e= 1, and the latest time as e=E. For times in a day that a patient will definitely
not be in the hospital, we have e = 0. If the patient cannot be scheduled for any procedure
on a day, we get Edi = {0}. Let f : (H)→ (Edi ) denote a function that returns the order
in a day for each argument h ∈ H. If h corresponds to a time outside the appointment
range it returns 0. For example, consider the case where a patient could only be at the
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hospital for any appointment from 8am to 1pm on a specific day. This corresponds to
h = 8,9, ...,13, assuming that this is the first day in the planning horizon and the time unit
is in hours. The corresponding set E for the patient on this specific day, would include
elements {0,1,2, ...,6}, where e = 1 corresponds to h = 8, e = 2 corresponds to h = 9, etc.
In addition, e= 0 corresponds to all h on that day that the patient could not possibly be at the
hospital (e.g. 4am). Using this new information obtained from preprocessing, constraints
(5.17) and (5.18) can be replaced by constraints (5.21) and (5.22), where Mdi = |Edi |−1.
Through this change in the formulation, we obtain much smaller M values.
udi ≤ f (h)yhi,p +Mdi (1− yhi,p)−Mdi (1− xdi ),∀d ∈D,h ∈Hd, i ∈ I, p ∈ Pi (5.21)
vdi ≥ f (h)yhi,p,∀d ∈D,h ∈Hd, i ∈ I, p ∈ Pi (5.22)
∑
s∈Ki,c






yhi,s = dp̃,∀i ∈ I, p̃ ∈ P̃i (5.24)
(vdi −udi )≥ ∑
p∈Pi




i,p ≤ 1,∀d ∈D, i ∈ I, p∗ ∈ P∗i , p ∈ Pi : p 6= p∗ (5.26)
The time it takes to solve the IP can be decreased further by introducing valid inequali-
ties (5.23) through (5.26). Let C denote the set including the number of steps required for
patients to reach any position in their path. Let Ki,c denote the set including all positions
that could be possibly reached by patient i after exactly c steps. Valid inequality (5.23)
states that at most one position will be reached among those requiring exactly c steps to be
reached by patient i. This is similar to the antichain inequality used in [13]. Valid inequal-
ity (5.24) states that the time spent over all procedures of the same type will equal to the
duration of this specific procedure. Valid inequality (5.25) has to do with the fact that the
time that patients spend in the hospital on a given day is greater or equal to the duration
of the procedures that they go through. Let P∗i denote the set of procedure positions for
a patient i, where each procedure position included in the set will solely take place on a
day. In other words, the patient will not go through other procedures on the same day if he
goes through a procedure in P∗i . These are procedures that might require long preparation
and/or recovery times. Valid inequality (5.26) states that all patients can either go through
a procedure in P∗i or any other procedure on a given day, but not both.
5.4.5.1 Resulting running times
We ran experiments of scheduling 60 patients, where one patient was scheduled at a
time, in order to see how the proposed formulation improvements affected the running
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times. The maximum time that the solver was allowed to run was set to 1500 seconds.
If by that time no optimal solution was found the solver stops and returns the best solu-
tion obtained up to that point in time. This limit was selected due to our 3rd assumption,
which states that “The scheduling staff has enough time to book an appointment before the
resource availability changes". Therefore, we need to impose a limit to the time that we
allow the IP to run. We notice that the solver finds the optimal solution relatively fast, but it
takes a long time to prove optimality. In other words, by limiting the time to 1500 seconds
we might still get an optimal solution but it is not proven that it is optimal. In Section 5.5 we
ran the simulation experiments where we schedule patients in groups of 2 up to 5 patients.
This complicates the problem and it takes longer for the IP to run. Nevertheless, within
the 1500 second limit all IPs solved in the experiments had enough time to go through the
presolve section of Gurobi and generate a solution, even through it was not proven to be
optimal. Therefore, 1500 seconds seems to be reasonable time limit for our problem.
All experiments were coded in Java 8. We used the Gurobi 7.5 [58] optimization solver
through Java in order to solve the IP. Experiments were run on a computer with an 2.9 GHz
Intel Core i5 processor and 8 GB 1867 MHz memory.
Figure 5.7 includes the running times of the initial formulation (IF) and the final for-
mulation (FF), after introducing improvements (5.21) through (5.26). For all values of λ
the final formulation, including all of the proposed improvements, performed considerably
better than the initial formulation. We use the Wilcoxon rank sum test, which is a nonpara-
































































































































Figure 5.7: Running times of initial and final formulation.
Table 5.3: Results of the Wilcoxon rank sum test (comparing each model with the IF).
Model λ = 0 λ = 0.2 λ = 0.4 λ = 0.6 λ = 0.8 λ = 1
IF + (5.21, 5.22) 0.3853 0.0597 0.4917 0.4988 0.1975 0.4893
IF + (5.24) 0.2381 0.0241 0.2193 0.3127 0.0168 0.4768
IF + (5.25) 0.0000 0.0077 0.0208 0.0344 0.0110 0.2491
different running times. The null hypothesis states that they are samples from distributions
with equal medians. The resulting p-values reject the null hypothesis at the 5% level, with
the exception of λ = 1. The scheduling problem solved already fast for λ = 1, so adding
the valid inequalities did not significantly change the running time.
Figure 5.8 presents the results of experiments ran, where proposed improvements in
the formulation were added separately in the initial formulation (IF). While all formulation
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Figure 5.8: Running times after separately introducing improvements to the formulation.
improvements seem to provide faster running times in all cases, valid inequality (5.25) is
the one with the largest proportion of gains in running time. Table 5.3 includes the resulting
p-values of the Wilcoxon rank sum tests. Note that no multiple testing procedure has been
used. We see that valid inequalities (5.24) and (5.25) rejected the null hypothesis of equal
medians for at least some values of λ . However, introducing inequalities (5.21, 5.22) to
the initial formulation did not result in statistically different running times. Nevertheless,
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because we see an improvement in the running times even though is not significant at the
5% level, we decided to keep the aforementioned improvements in the formulation.
5.5 Numerical experiments
In this section, we include the results of the simulation experiments. First, we conduct
benchmark analysis. Second, we investigate under which circumstances it is better to group
outpatients together when scheduling, and the gains obtained in those cases.
5.5.1 Simulation
Due to the lack of historic data including the availability of resources over time and
information about the outpatients, we make a number of assumptions regarding the distri-
butions of the data.
5.5.1.1 Outpatients
The outpatients usually get referred to the hospital from different physicians, so the
referral times are independent from one another. Therefore, we assume that outpatients get
referred to the hospital following a Poisson distribution [56, 85]. In particular, outpatients
get referred to the hospital only on days Monday through Friday, and during the 8am-5pm
time range. Based on discussions we had with the hospital personnel we know that on av-
erage 60 outpatients per month go through cardiology programs or elective surgery. About
10 patients per month go through the TAVR program, 4 through the TMVR, 4 through
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the Watchman, 1 through the PFO closure, 1 through the Valvuloplasty, and 40 through
elective surgery. Each new outpatient that arrives gets assigned to one of the aforemen-
tioned outpatient programs or to elective surgery based on the probabilities generated from
the corresponding average numbers discussed above. Then, the combination of required
steps is determined. Each combination is equally likely to be required for an outpatient
of a specific condition. Finally, the outpatients are assigned the days that they are able to
come for an appointment to the hospital within the planning horizon. We are assuming that
with probability 0.1 a patient will not be able to come to the hospital on a given day. We
were not able to find information about the real availability of the patients. We chose a
non-zero probability to illustrate that our formulation takes into account the availability of
the patient. However, the number is low enough to avoid infeasible solutions. We assume
that the outpatients will make the effort to come to the hospital unless there are excep-
tional circumstances that makes them unavailable. This rare case is captured by this low
probability.
5.5.1.2 Durations
Table 5.4 includes the duration of each procedure and the minimum required recovery
time after a procedure. Those times are maximum estimations of the durations, and are
based on information found online and discussions we had with the staff in the hospital.
These durations are used to illustrate the performance of the system. However, they can be
easily adjusted if the real numbers from the hospital are different. Based on these durations
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Table 5.4: Procedure durations and recovery times.
Type Procedure Duration Recovery Time
Common
TTE [67] 30 mins 0 mins
CT scan [102] 30 mins 0 mins
Carotid Ultrasound [101] 30 mins 0 mins
PFT [93] 30 mins 30 mins
PREP [164] 2 hours 1 hour
TEE [160] 1.5 hours 24 hours
Cath [66] 1.5 hours 72 hours
TAVR
Consultation 1.5 hours 30 mins
Procedure [162] 2.5 hours (admitted)
TMVR
Consultation I 1 hour 30 mins
Consultation II 30 mins 0 mins
Procedure [165] 2.5 hours (admitted)
PFO closure
Consultation 1 hour 30 mins
Procedure [24] 2 hours (admitted)
Valvuloplasty
Consultation 1 hour 30 mins
Procedure [82] 1.5 hours (admitted)
Watchman
Consultation 1 hour 30 mins
Procedure [49] 1.5 hours (admitted)
Surgery
Consultation 1 hour 30 mins
Procedure [65] 4 hours (admitted)
we determine the length of the time unit in the scheduling problem. A time unit is equal to
30 minutes, since all durations and recovery times are multiples of 30 minutes. We choose
30-minute slots for this simulation, because we have no data available showing the length
of the slots used in the hospital. The parameters of the IP can be easily adjusted to include
slots of different length, as for example 15 minute slots. Thus, the scheduling staff can
change the slot length if necessary in the future. In addition to the times presented in Table
5.4, we assume that the patients will spend some time after they enter the system but before
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they go through any procedures. This time is set equal to 48 hours and it represents the time
it takes for the hospital to learn about the patients and decide on the procedures that they
will follow. Some procedures require some preparation time, where the patient usually is
not allowed to eat or drink for some time. Those procedures are the TEE, the Cath, and all
the procedures where the patient gets admitted afterwards.
5.5.1.3 Scenarios
In the beginning of each simulation we generate the initial resources available. We
consider scenarios of different initial availability. In particular, low initial availability cor-
responds to 30% of the appointments of each resource being free. High availability cor-
responds to 50% of the appointments being free. The slots of each physical resource are
grouped in blocks that equal to the maximum duration of all the procedures that this re-
source may participate in. In the case of personnel, the slots are grouped in blocks equal to
half-days. This way we avoid having fragmented availability of resources. Each block is
free with probability 0.5 or 0.3, depending on the scenario. The total number of each type
of resource present in the hospital can be found in Appendix I. The available resources are
updated during the simulation, as external demand and new cardiology outpatients arrive.
The external demand arrives following a Poisson distribution during working hours on
weekdays. We consider different arrival rates (low and high) of external demand. The ar-
rival rates depend on the number of blocks of slots present in the hospital for each resource.
In the case of high levels of external demand about 14% of the blocks will be occupied in
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the entire planning horizon. When there are low levels of external demand 7% of the blocks
present in the hospital will be occupied. Based on these numbers we produce the interar-
rival times of external demand for each type of resource. Thus, resources that can treat
higher number of patients during a fixed time also have higher rates of external demand. In
other words, we assume that a resource is present in higher numbers in the hospital because
there is also higher demand for this resource.
We investigate four different scenarios based on the initial resource availability and ex-
ternal demand. Scenario 1 considers an environment with low availability of resources
and high external demand. Scenarios 2 and 3 consider the cases of low resource avail-
ability and low external demand, and high resource availability and high external demand
respectively. Scenario 4 corresponds to a setting with high availability of resources and low
external demand.
5.5.1.4 Simulation components
The parameters described in Subsections 5.5.1.1 through 5.5.1.3 are used as an input in
the simulation. Figure 5.9 shows the steps followed in our simulation.
1. Based on the scenario we are in, we generate the availability of each type of resource
during the planning horizon. Furthermore, we generate the list of cardiology outpa-
tients that are going to get referred to the hospital, which includes the referral time,
the steps that they have to complete, and their availability (as discussed in Subsec-
tion 5.5.1.1). Similarly, depending on the scenario, we generate the external demand,
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which is a list of resource types and the times that they are requested. Finally, we
set the group size (i.e. how many outpatients are scheduled together in each decision
epoch).
2. Next we run the simulation, where we schedule appointments for cardiology out-
patients and external demand. Based on the referral times of the last outpatient in
each group (i.e., if the group size is four, the referral times of the 4th, 8th, 12th
outpatient, etc.), and the arriving times of external demand we generate events. Dur-
ing an event we either solve the IP, if the last outpatient in a group has arrived, or
an abbreviated version of the IP, which simply schedules the external demand, if
an external demand has arrived. Thus, the IP presented in Section 5.4.2 is solved
d # of outpatients# of outpatients in each groupe times in each simulation. After each event we up-
date the available resources based on the schedule resulting from the corresponding
IP. Once the last event is executed, the simulation terminates.
As we see from the above, all of the random factors in the system are generated in the
first step. This allows us to rerun the second step multiple times using the same input, but
with a different group size or λ value each time. Thus, we are able to compare the change in
the objective value and the resulting schedules in the same setting. To get different input we
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* Event types:  (1) decision epoch: takes place at the referral time of the last oupatient in the group 
 (2) external demand: takes place at the arrival time of an external demand
Figure 5.9: Simulation diagram and corresponding input.
5.5.2 Numerical results
This section presents the numerical results. We use five different seeds in the simu-
lations. For each seed, we run the simulation once for each combination of: scenario,
λ = {0,0.2, ...,1}, and group size (we consider sizes 1 through 5).
5.5.2.1 Benchmark analysis
Based on the results from the simulations we conduct a benchmark analysis. First,
we estimate the number of visits and the time spent waiting in between appointments for
different types of patients in the ideal case, where there are no resource restrictions. In total,
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Table 5.5: Average visits and time spent waiting when there are no resource restrictions.
Number of steps required: 3 4 5 6 7 8 9 10
Average Visits 2 2.34 3.01 3.56 4.25 5 5 5
Average Idle Time 0.67 2.5 2.67 3.56 3.5 4.5 4.5 6
we have 88 types of patients in our setting. Each type has a unique set of steps they have to
complete. For example, TAVR patients can be classified into 16 different types. However,
a TAVR patient that has to go through 3 procedures is expected to behave differently from
a TAVR patient that has to go though 7 procedures. For that reason we categorize patients
based on the number of steps they are required to go through and not the condition they
have. Table 5.5 includes the average number of visits and the units of time spent waiting
when there are no resource restrictions. We use λ = 0.8 to estimate the results. We can see
that patients with more requirements make more visits to the hospital and spend more time
waiting in between appointments, even when there are no resource restrictions.
Next, for each scenario, we estimate the average number of visits and the idle time
based on the optimal schedules generated from the IP. We assume that λ = 0.8 in order to
compare the results with the best case scenario presented in Table 5.5. Figure 5.10 includes
the average change in the values included in Table 5.5. Note that the values presented
the figure are not integer because they correspond to the average over many patients of
each type. We see that in most cases Scenario 1 has the largest increase in the number
of visits and the idle time. This was expected, since Scenario 1 has the fewest available
resources. The opposite effect is observed for Scenario 4. We also see that as the number of
requirements increases the patients are more likely to visit the hospital more times than the
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minimum required. The same is true for the time they spend waiting. This was expected,
because when there are limited resources it is harder to create convenient schedules for
patients that have more requirements. Nevertheless, there is no indication that the proposed
IP benefits some patients more than others. On average, the extra visits that patients have
to make are less than 1 for all types of patients. The additional waiting time is less than 2
hours on average. Thus, we do not observe a large variation between the different types of
patients.
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Figure 5.10: Additional visits and additional idle time spent in the hospital on average, compared
to the no resource restrictions setting.
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5.5.2.2 Scheduling in groups
Initially we schedule one patient at a time and then we schedule patients in groups
of two to five patients. Patients are grouped together based on the order that they were
referred to the hospital. Thus, we are able to compare the total objective value at the end of
the month for each case.
Table 5.6 includes the percentage of group scheduling cases where the objective value
increased, decreased, or there was no change observed compared to the baseline case of
scheduling one patient at a time. It also includes the percentage of cases where an infeasible
solution was obtained. Each column is based on the experiments of a particular group size,
which includes the 6 λ values taken into account, and the 4 Scenarios, using 5 different
seeds. In other words, in each column we have 120 objective values to compare with the
case of grouping 1 patient at a time. Each objective value is compared to the corresponding
objective value (same λ , Scenario, and seed) in the setting of scheduling one patient at a
time. Thus, the percentages of each column show in which portion of the 120 objective
values there was an increase, decrease, no change, or we got an infeasible solution. We
see that over 60% of the cases performed better when scheduling patients in groups of
two instead of one at a time. However, in about 8% of the cases there was an increase in
the objective value. The increase in the objective value when scheduling in groups can be
the result of missed opportunities, since we have to wait before scheduling a patient. One
situation is that the day that a convenient combination of resources was available for the
patient has passed when we finally scheduled the patient. Another case is that the external
149
Table 5.6: Type of change observed in the objective value after scheduling patients in groups.
Outcome 2 per group 3 per group 4 per group 5 per group
No Change 28.33% 29.17% 21.67% 27.5%
Increase 8.33% 15.83% 25% 34.17%
Decrease 63.33% 51.67% 45.83% 35%
Infeasible 0% 3.33% 7.5% 3.33%
demand occupied the resources that would have otherwise been occupied by the patient. We
observe that as the number of patients getting scheduled simultaneously increases, there is
a smaller percentage of cases where a decrease in the objective value was observed. On
the other hand, there were more cases of increase in the objective value. The cause of this
is that patients getting scheduled in groups of a larger size, usually have to wait longer to
get scheduled and therefore have a higher chance of missing a good opportunity. Thus,
while scheduling patients in groups provides us more information about patients, waiting
too long can have a negative effect. Finally, in the cases of groups of three patients or more,
we can observe that there is a chance of getting an infeasible solution. This means that of
all the patients scheduled during the month we are taking into consideration, at least one
patient was not able to complete all steps in the required time. For those patients it would
take more than 30 days to go through all the required steps.
Table 5.7 presents the results included in Table 5.6 separately for each value of λ . The
chance of getting an infeasible solution does not seem to depend on the value of λ , based
on the results included in Table 5.7. Nevertheless, we can observe that the chance of in-
crease or decrease in the objective value can differ considerably for different values of λ .
For example, for λ = 0 we can see that for all group sizes in the majority of the cases the
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Table 5.7: Type of change observed in the objective value for different values of λ when scheduling
in groups.
λ Outcome 2 per group 3 per group 4 per group 5 per group
0
No Change 100% 95% 90% 95%
Increase 0% 0% 0% 0%
Decrease 0% 0% 0% 0%
Infeasible 0% 5% 10% 5%
0.2
No Change 65% 65% 35% 35%
Increase 0% 0% 20% 25%
Decrease 35% 35% 40% 35%
Infeasible 0% 0% 5% 5%
0.4
No Change 5% 0% 0% 0%
Increase 10% 20% 50% 50%
Decrease 85% 80% 45% 45%
Infeasible 0% 0% 5% 5%
0.6
No Change 0% 0% 0% 0%
Increase 5% 35% 40% 75%
Decrease 95% 60% 55% 25%
Infeasible 0% 5% 5% 0%
0.8
No Change 0% 0% 0% 20%
Increase 10% 20% 20% 10%
Decrease 90% 75% 70% 65%
Infeasible 0% 5% 10% 5%
1
No Change 0% 15% 5% 15%
Increase 25% 20% 20% 45%
Decrease 75% 60% 65% 40%
Infeasible 0% 5% 10% 0%
objective value does not change, excluding the few cases with infeasible solutions. How-
ever, for λ = 0.2 or λ = 0.4 it seems to make sense to schedule patients in groups of two
or three patients, since in most cases the objective value decreases. For λ = 0.8 the results
suggest that we could use even larger groups of patients when scheduling. Nevertheless,
as we discussed in Subsection 5.4.4, the hospital will be provided with Pareto optimal so-
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lutions to choose from. This requires using multiple values for λ , when scheduling the
same group of patients, in order to obtain multiple solutions. Therefore, since we have to
decide on the size of the group ahead of time, we should select a size that provides good
enough results for all values of λ . Therefore, based on Table 5.7 a good choice seems to be
scheduling patients in groups of two or three in order to avoid the increases in the objective
value cancel out any potential decreases.
When scheduling one patient at a time, the patients get informed quickly about their
appointments. However, when grouping the patients together, the patients have to wait
until the arrival of the last patient in the group in order to get scheduled. This means that
patients may have to wait up to a few days in order to find out about their appointments.
The patients prefer to learn their schedule as early as possible, in order to be able to plan
ahead. Figure 5.11 presents an example of the hours that patients arriving over a month
had to wait for each group size. As expected, for smaller group sizes the patients are more
likely to wait for a shorter period of time. Also it appears that when scheduling patients in
groups of two or in groups of three patients, the wait time is approximately the same. On
the other hand, for groups with size four and five we can observe a considerable increase
in the wait time.
The level of change in the objective value for each Scenario is presented in Table 5.8.
The results were estimated after excluding the cases where an infeasible solution was ob-
tained. In particular, all of the infeasible cases occurred under Scenario 1, where there
is low availability of resources and high external demand. Infeasible solutions appeared in
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Figure 5.11: Wait time in hours from the time the patients got referred to the time that the appoint-
ments were scheduled.
Table 5.8: Amount of change observed in the objective value for each Scenario.
Scenario Measure 2 per group 3 per group 4 per group 5 per group
1
Mean Change -0.43 -0.21 -0.1 -0.07
Mean Pct. Change -2.33% -1.57% -0.93% -0.93%
2
Mean Change -0.14 -0.13 -0.03 -0.03
Mean Pct. Change -0.44% -0.45% -0.05% -0.15%
3
Mean Change -0.12 -0.13 -0.04 -0.04
Mean Pct. Change -0.73% -0.74% -0.32% 1.44%
4
Mean Change -0.05 -0.12 -0.16 -0.10
Mean Pct. Change -0.15% -0.39% -0.59% -0.24%
two out of the five seeds used in the simulation. In each case there was one infeasible group
across all the groups getting scheduled. The bold entries in Table 5.8 indicate the largest
percentage improvements across all group sizes for each scenario. In Scenario 1 the high-
est percentage of decrease was observed when scheduling in groups of two patients. Since
Scenario 1 also included infeasible solutions, it seems that having groups of two patients is
a reasonable choice in a setting with low initial availability and high external demand. In
an environment with big competition for resources, it is best not to risk waiting too long to
schedule the appointments of the patients. Scenarios 2 and 3 seem to behave in a similar
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Table 5.9: Change in the objective value and the wait time to find out about the appointments.
From To Wait Increase Pct. Change in Objective value
size size (in hours) Scenario 1 Scenario 2 Scenario 3 Scenario 4
1 2 4.77 -2.33% -0.44% -0.73% -0.15%
2 3 6.19 0.78% -0.01% -0.01% -0.24%
3 4 8.5 0.65% 0.40% 0.42% -0.20%
4 5 4.45 0.00% -0.10% 1.77% 0.35%
manner with each other. They both appear to have the highest percentage of decrease when
the patients are scheduled in groups of three, but they only perform slightly better com-
pared to scheduling patients in groups of two. Finally, Scenario 4 gives better results when
scheduling in groups of four patients. As was expected, when there are many resources
available, and not a lot competition caused by the external demand, it is possible to wait for
more patients to arrive before scheduling without worrying that the appointments are going
to get booked. The results in Table 5.8 show that the scheduling staff could adjust the size
of the groups if they have information about the availability of resources and the expected
rate of external demand in the next few weeks. Nevertheless, if is not possible to get an
estimate of the state of the system regarding the resources and the demand, the hospital
could schedule the patients in groups of two or three based on the results obtained from the
simulations. The exact group size should be determined by the hospital depending on the
likelihood of getting each Scenario and on their willingness to risk.
Table 5.9 shows the increase observed in the average time it takes for the outpatients to
find out about their appointments, and the percentage of change observed in the objective.
We consider the different group sizes separately, but in each case the size of the group
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increases by 1 patient. We see that the smaller increase in the time it takes to find out the
appointments is observed when going from a group size of 1 to a size of 2, and from a group
size of 4 to a size of 5. Furthermore, the only transition to a larger group size that leads to
a decrease to the objective value in all of the scenarios studied is increasing the group size
from 1 patient to 2. Thus, from the above we see that having a group of two patients seems
to improve the objective value, while at the same time not considerably increasing the time
it takes for outpatients to get informed about their appointments.
While the results show that there are gains in grouping patients when scheduling, the
percentages of decrease in the objective value are small. We use an example from the
simulations to illustrate. The example is in a Scenario 2 setting, where λ = 0.8. During
the month of the simulation 54 patients were scheduled. When scheduling each patient
separately, there were 196 visits to the hospital with a total wait time of 248 time units (124
hours). If we scheduled in groups of two patients, the total objective value in this example
decreased by 0.29%. The resulting schedule corresponded to 195 visits to the hospital and
and a wait of 248 time units. In other words, a decrease of 0.29% corresponded to one less
visit to the hospital across all patients. On the other hand, if we scheduled in groups of
three patients there was a decrease of 1.45% in the objective value, which corresponded to
a schedule of 193 visits and 251 time units of waiting. Thus, compared to scheduling one
patient at a time, there were three fewer visits to the hospital but the wait time increased
by one and a half hours. We can see from the examples above that the improvements to
the final schedule are relatively small, and are expected to affect only a few patients among
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Table 5.10: Amount of change observed in the objective value.
Measure 2 per group 3 per group 4 per group 5 per group
Mean Percentage Change −1.11% −4.01% −1.85% −1.37%
those getting scheduled.
5.5.2.3 Scheduling in a larger department
Based on the results presented in Subsection 5.5.2.2, we see that only a small number
of patients will get an improved schedule when scheduling in groups in our outpatient
cardiology setting. In this section, we investigate the effect of scheduling in groups in a
department treating a larger number of outpatients each month. In order to study this, we
increased the average number of outpatients referred to the cardiology department by 50%.
All other input parameters remain the same based on the description of Subsection 5.5.1.
This allows us to investigate the effect of scheduling in groups in a larger department.
We ran experiments for λ = 0.8. The change observed in the objective value compared
to scheduling one patient at a time is included in Table 5.10. The results show that the
largest decrease is observed when scheduling in groups of 3 patients. Furthermore, the
patients had to wait for a shorter time period in order to find out about their scheduled
appointments. For example, the average time was around 10 hours in the original setting
(smaller department) when scheduling in groups of 3 patients. In this setting, where we
consider a larger department, the average time decreased to about 6 hours. This was ex-
pected, because patients arrive more often, and therefore the groups are completed in higher
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rates.
Let us consider a specific example in this setting. In total, 88 cardiology outpatients
were referred to the hospital during the course of one month. In this case, scheduling one
patient at a time leads to 316 total visits and 165 hours of waiting in the hospital between
appointments. Scheduling in groups of three patients at a time leads to 303 visits to the
hospital and 164 hours of waiting in the hospital. In other words, there were 13 fewer visits
in the hospital in this case. Thus, the experiments show us that in larger departments there
are greater gains obtained when scheduling in groups, since more patients are affected by
the improved schedules. Furthermore, in a larger department the patients do not have to
wait as long on average to find out about their schedule.
5.6 Implementation and managerial insights
This study resulted from discussions we had with the procedural director of the heart
and vascular center, who identified the outpatient procedures as an area of interest. How-
ever, the proposed IP was not used in the hospital. Nevertheless, in this work we provide
the decision tool and an initial analysis of the expected outcomes. This information can be
used in the future if the hospital decides to go forward with this scheduling approach. In
this section we discuss the implementation requirements for using such a tool and provide
some managerial insights.
The implementation requirements refer to a) the deployment environment, and b) infor-
mation exchange.
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With regards to a), the hospital must have access to a solver (e.g. Gurobi, CPLEX,
etc.) coupled with a suitable platform to allow the scheduling staff to provide information
about outpatient availability, required steps, and resource availability. With regards to b),
information sharing between different members of scheduling staff will facilitate schedul-
ing patients in groups by gradually inputting information about patients, until the group is
complete. In addition, shared information between scheduling and lab staff facilitates the
procedure of determining the availability of resources in advance of each appointment and
scheduling accordingly while at the same time considering patient convenience.
The proposed IP can help generate schedules that are convenient for the patients. Espe-
cially as the number of procedures that the patient has to go through increases it becomes
very complicated to schedule the appointments manually. By providing multiple schedules
to choose from, the scheduling staff will be able to choose the one that best fits the needs of
each specific patient. Finally, we see that grouping patients when scheduling provides bet-
ter schedules. The improvements only affect a small number of patients in the case of our
outpatient cardiology setting. However, in the case of a slightly larger department, which
treats more outpatients each month, the results showed that an increased number of outpa-
tients gets positively affected by scheduling in groups. Furthermore, in a larger department
the outpatients would not have to wait as long to find out about their appointments. Thus,
having groups within the same department collaborate when scheduling can lead to im-
provements that benefit the outpatients. Additionally, scheduling in groups means that the
staff responsible for scheduling the appointments will not have to contact the various re-
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sources as often to find out about the availability, since there are fewer decision epochs in
each month. Considering that this will also be done collaboratively with other members
of the scheduling staff means that this option will safe them time during the course of the
month.
5.7 Conclusions
In this chapter we discussed the problem of multi- appointment scheduling in outpatient
cardiology. We generated the procedure diagrams including the steps that the patients have
to go through in order to be able to complete the procedure they were referred to the hospital
to have. Each step was linked to the corresponding resources that need to be available for
the patient to be able to go through the step. We proposed an IP formulation, in order to
support the staff in making appointment scheduling decisions, which are currently done
manually. We identified the objective of the problem as minimizing the combination of the
number of visits that the patients make to the hospital and the time the patients spend in
the hospital in-between appointments. The formulation allows for patients to be scheduled
either one at a time or in groups. The scheduling staff will be provided with Pareto optimal
solutions to choose from when deciding on which appointment to book for the patients. We
discussed improvements to the initial formulation and added valid inequalities to the IP in
order to decrease the time it takes for the solver to find an optimal solution and prove that
it is optimal. Through the suggested improvements the running time of the IP decreased
significantly. Finally, we investigated the advantages of scheduling patients in groups. We
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considered various hospital settings based on the initial availability of resources and the
rate of external demand. Since many of the resources used by the cardiology outpatients
are shared across many departments in the hospital, it is crucial to take into account the
external demand generated by the patients in those departments. The results varied for
different levels of initial resources and external demand. In particular, when more resources
were available there were better results obtained for larger sizes of groups. On the other
hand, when fewer resources were available there was a risk of obtaining infeasible solutions
when scheduling in large group sizes. Also, there was a larger decrease in the number of
visits and the wait time for smaller group sizes. Nevertheless, the improvements observed
across the various settings were on the level of few visits or time units. Thus, while on
average there are improvements in scheduling in groups, those improvements were not
major and expected to affect only a small portion of the patients getting scheduled in our
cardiology outpatient setting. Additional experiments showed that in departments that treat
an increased number of outpatients, scheduling in groups positively affects a larger portion
of patients.
5.7.1 Limitations and future research
One limitation of this work is that we do not have access to data from the hospital. For
that reason we were not able to generate a simulation model that can be validated to match
the current system. This did not allow us to make comparisons between the schedules
that the scheduling staff currently generates and the schedules resulting from the proposed
160
IP. Furthermore, while we were able to conduct some initial analysis about scheduling
patients in groups, this could be examined further. Future directions of this research could
investigate ways of getting a good estimate of the state of the system. This refers to the
levels of available resources and the rate of external demand. Based on historical data, it
could be possible to make predictions about how the availability of resources will change
within the scheduling horizon. Thus, the scheduling staff would be able to decide on the
size of the groups and adjust them if necessary.
The second limitation of this work is that we assume a number of parameters to be
deterministic. We assume that each appointment that the outpatient goes through will start
on time, and will not take longer than the duration that it was booked for. However, in
reality this might not be the case. Having considerable delays in the system may not allow
the patient to go through all necessary steps booked for a specific day. Therefore, future
research could investigate how to schedule the outpatients after taking into account this
variability in the system. A robust schedule to uncertainty can be achieved by simulating
multiple scenarios of the duration of the individual procedures and formulating a stochas-
tic programming model. In this case, the objective of the problem is to minimize not a
deterministic value of the number of visits or idle time, rather than a stochastic measure




The U.S. is leading in healthcare expenditures worldwide, both based on per capita
expenses [73], and based on the percentage of the country’s GDP corresponding to health-
care related expenses [72]. However, increased expenditures do not seem to translate to a
healthier population in the U.S. [39]. Prevention, which includes actions that prevent dis-
eases from occurring, detect diseases at an early stage, and manage diseases that have been
diagnosed, plays a crucial role in improving the health of people. In this dissertation, we
study four problems that facilitate disease prevention in the U.S., with two problems at the
public health level followed by two at the healthcare provider level. A summary of each
study, including contributions and future directions, is presented below.
In Chapter 2, we use U.S. state level data to identify factors that impact MMR vacci-
nation rates. The MMR is the most commonly used vaccine for measles prevention. With
some parents choosing not to vaccinate their children, there have been a number of measles
outbreaks in the U.S. in recent years. In the U.S., students are required to get vaccinated in
order to be able to attend school. However, a number of exemptions are allowed. Medical
exemptions are allowed in all 50 states and the District of Columbia. Nevertheless, some
states also allow for religious as well as personal belief exemptions. Our data cover a period
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of seven years, during which, the measles outbreak in Disneyland took place. This specific
outbreak was covered extensively in the news at the time. In this study, we investigate the
impact of state level vaccination exemption policy, and of the highly publicized Disneyland
measles outbreak on MMR vaccination rates of young children (19-35 months old).
We try a number of approaches to select the socioeconomic controls for our linear re-
gression model, in order to demonstrate the influence that different socioeconomic factors
can have on the outcomes of interest (i.e., the impact of exemption policy, and the Disney-
land outbreak). First, we use an econometric approach, where the socioeconomic controls
are selected based on past research findings. Second, as sensitivity analysis on the coef-
ficients of interest, we use a number of approaches including variable selection methods,
principal component analysis, and indices summarizing socioeconomic controls of each di-
mension (i.e., education, economy, and community). The results show a consensus across
all modelling approaches that allowing personal belief exemptions in a state is linked to
lower vaccination rates. However, depending on the modelling approach followed, the im-
pact ranges from −0.74 to −0.99 percentage points. On the other hand, the results on the
impact of the Disneyland outbreak on the vaccination rates during the subsequent year are
not conclusive, since different modelling approaches yield different results.
Previous studies have linked personal belief exemptions to lower vaccination rates in
children attending kindergarten [122, 151]. Through this study, we show that the impact
of personal belief exemption is similar for children younger than 3 years old, who do not
necessarily attend school. This underlines the significance of vaccination exemption poli-
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cies, since young children have a higher risk of serious complications from measles [175].
Furthermore, to the best of our knowledge, this is the first study that looks into the impact
of the Disneyland outbreak on vaccination rates at a national level. The fact that there is no
clear impact, shows that even though most parents found out about the dangers of the dis-
ease during that time, this did not necessarily change their decision about vaccination. Fi-
nally, through this study we highlight the importance of carefully selecting socioeconomic
controls, and reporting the resulting models in detail, since including a single control can
change the outcome considerably. Future research could focus on identifying additional
factors that impact vaccination rates, including, for example, vaccination campaigns, and
the level of anti-vaccination activity in an area. Our models only explain up to 31% of the
variation in state level vaccination rates, which shows that there are other factors that we
could not control for. Furthermore, other sources of data could provide better estimates
of the actual MMR vaccination rates in an area. In our study, MMR vaccination rates are
based on survey data. However, relatively large fluctuations in the same state from one
year to the next indicate that the rates may not be as accurate. A different approach for esti-
mating vaccination rates of various geographical areas could be based on insurance claims
data.
In Chapter 3, we study the cost behavior of various types of chronic conditions. Chronic
conditions are common in the U.S., with about half of the adult population having at least
one chronic condition, and one in four adults having multiple (two or more) chronic condi-
tions [171]. Annual expenditures as well as different cost components (outpatient, inpatient
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and other services) are known to be higher for those with chronic diseases [10, 30, 51, 153].
Furthermore, individuals with chronic conditions make more frequent outpatient [139], and
emergency department visits [133]. The cost of each type of condition can be used as an
indication of how difficult it is to treat, and by extension its severity. With many people
suffering from multiple chronic conditions, it is crucial to understand how each type of
condition interacts with other chronic conditions that are present in the same individual.
Thus, in this study, we estimate the additive cost of chronic diseases and study their cost
patterns.
We use gamma regression with a log link to model the relationship between healthcare
costs and the chronic conditions that are present in the same person. In particular, we use
a cost hierarchy, where the cost of each condition is modeled as a function of the number
of other more expensive chronic conditions that the individual has. The analysis is based
on insurance claims data, from which we obtain annual healthcare costs and diagnoses
of individuals. Based on the results of the regression, we estimate the cost contribution
of each type of chronic condition dependent on the number of more expensive conditions
that are present. We characterize the resulting cost patterns based on the average value
(and corresponding variance), and the slope of the cost contributions. We use clustering
techniques to group together conditions that behave in a similar manner. The results show
that for the majority of the chronic conditions, their cost contribution increases with the
number of other more expensive conditions that are present. This illustrates that these
conditions impose an additional burden to the treatment of other conditions when they are
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present in a patient. Examples in this category include obesity, asthma, congestive heart
failure, hypertension, and bipolar disorder. On the other hand, for some chronic conditions,
the cost contribution does not increase or sometimes decreases as the number of more
expensive conditions that the patient has increases. This means that those conditions either
do not add more complexity to the treatment of other conditions, or the individual does not
get the necessary treatment for other conditions when they are present. Examples include
back problems, allergies, Parkinson’s disease, dementia, and malignant neoplasm.
The majority of previous studies analyzing the cost of combinations of chronic condi-
tions has focused on a small number of conditions [45, 104]. In [38], the authors expand
their analysis to 10 conditions, but limit the number of possible combinations to two at a
time. Through our proposed methodology, we increase the number of chronic conditions
taken into account to 69, and manage to study the cost contribution of conditions when an
increased number of other conditions are present. This allows us to build a comprehensive
picture of the chronic cost burden. The proposed methodology and the resulting estimates
of chronic cost burden can be used for policy and program designs, since they can help
estimate the effect of interventions on the healthcare cost of patients with specific chronic
conditions, and make better healthcare cost predictions for people with chronic conditions.
Future research could focus more on the cost contribution of chronic conditions in indi-
viduals with multiple chronic conditions, after taking into account socioeconomic factors
linked to the individual. Those could include factors like gender, income, education level,
and others. It would be interesting to see to what extent the cost behavior of each condition
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changes based on these socioeconomic factors.
In Chapter 4, we study the use of conversational agents in patients with heart failure.
The management of heart failure relies a lot on self-care, which includes taking medica-
tions, controlling salt and fluid intake, and checking for symptoms such as weight increase
or swelling in ankles. A number of telehealth technologies have been developed in the past,
in order to help patients with heart failure to manage their condition [7, 48, 81, 87, 97].
Telehealth technologies provide frequent updates to the patients’ physicians, which allows
them to intervene when necessary. Some factors that have been found to negatively in-
fluence telehealth adoption include difficulties with using the technology, or not remem-
bering to use it every day [54]. Conversational agents that use speech, can make the use
of the telehealth technology easier, since they allow patients to answer questions about
their symptoms using their voice. In this study, we compare two types of conversational
agent technologies, and investigate which patient’s characteristics are important factors in
determining the patient engagement.
Over a period of 90 days, thirty patients with heart failure used the conversational agent
that was based on Amazon’s Alexa technology, and thirty different patients used the con-
versational agent that utilized an avatar to ask the questions, thus, combining sound and
image. We obtained demographic information about the patients through a survey, and
from electronic health records. We use multiple linear regression, in order to model the re-
lationship between the number of times that a patient used the conversational agent during
the 90 days, and the patient’s characteristics. The results show that patients participating
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in the Alexa survey completed the questionnaire more often than in the Avatar study. This
could be explained by the fact that the Alexa technology allows patients to set-up daily
remainders. Furthermore, older patients, and non-black patients engaged with the con-
versational agent technology more often, while patients that are prescribed an increased
number of medications to manage heart failure were linked to lower levels of engagement.
On the other hand, confidence in using technology did not have a statistically significant
effect on patient engagement.
In this work, we compare two types of conversational agent technologies, that follow
identical questionnaire scripts, and are used by two similar groups of heart failure patients.
The difference in patient engagement highlights that even small changes in the design or
capabilities of the technology can considerably influence the adoption levels. Furthermore,
to the best of our knowledge, this is the first study that examines factors that influence
conversational agent technology uptake in patients with heart failure. Future research could
investigate to what extent engagement and compliance influence health results, through
the use of electronic health data. This would provide information on hospitalizations and
health complications, which would provide an insight on the value obtained from the use
of conversational agent technology.
In Chapter 5, we study the problem of appointment scheduling for patients who are
referred to the cardiology department of a large medical center in order to go through an
elective procedure. Those patients have to go through a number of diagnostic tests and/or
treatments before they are ready to complete the elective procedure. Because those patients
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are not admitted to the hospital until after they complete the elective procedure, they have
to visit the hospital every time they have an appointment. This can be complicated for the
patients, since they could live a long distance from the hospital and they usually depend on
someone else to drive them to the hospital. In an effort to make the visits to the hospital
as effortless as possible for the patient, we develop an IP to help the scheduling staff in
deciding on the day and time of each patient’s appointments.
Our objective is to book appointments that minimize the number of visits that the pa-
tients have to make to the hospital as well as the time that the patients have to spend in the
hospital waiting in between appointments. The goal is to provide the scheduling staff with
all Pareto optimal solutions to choose from. We develop an IP formulation that takes into
account the available resources and the availability of the patients on each day, and provides
the optimal solution. At the same time, it is ensured the patients will be able to complete
all of the required steps on time. In addition to the IP formulation, we propose a number of
improvements to the formulation in order to obtain an optimal solution faster. The improve-
ments include formulation changes based on information obtained through preprocessing
as well as inclusion of valid inequalities to the formulation. Through these improvements,
we manage to decrease the running times considerably. Finally, we investigate the value
of scheduling patients in groups under various scenarios, which vary based on the avail-
ability of resources and the demand. We conclude that in scenarios where more resources
are available there are better results obtained for larger sizes of groups. On the other hand,
when fewer resources are available there was a risk of obtaining infeasible solutions when
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scheduling in large group sizes. However, the improvements only affect a few patients. The
results show improvements in the total objective value over a period of one month, ranging
from 0.45% to 2.33% on average, depending on the scenario taken into account.
To the best of our knowledge, this is the first study that looks into multi-appointment
scheduling in outpatient cardiology. Through this work, we provide the procedure dia-
grams, parameters, and constraints that need to be taken into account in such a problem
and develop an IP formulation. Furthermore, we propose formulation improvements, which
could potentially be applied to other scheduling problems with a similar formulation ap-
proach. Finally, we examine whether outpatients should be scheduled in groups, which
looks at the problem of different departments in the hospital competing for the same re-
sources. In future research, if hospital data become available, it would be possible to esti-
mate the gains from moving from manually scheduling appointments, to using the proposed
optimization model. Furthermore, it could be possible get estimates of the state of the sys-
tem (i.e., availability of resources, and levels of external demand), and based on historical
data, make predictions about how the availability of resources will change within the hori-
zon. Thus, the scheduling staff would be able to decide on the size of the groups and adjust
them accordingly.
The studies included in this dissertation show the range of problems associated with
disease prevention in the U.S. Those span from understanding the impact of health policies,
and identifying areas that require prevention interventions at the public health level, to
helping patients manage their health, and making treatments as effortless as possible at the
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provider level. Data analytics, and mathematical modelling techniques can play a crucial
role in better understanding the underlying issues, and providing efficient solutions.
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Appendix A: Summary statistics for variables used in the MMR study
Table A.1: Summary statistics for all non-binary variables in dataset.
Variable Min. 1st Qu. Median Mean 3rd Qu. Max.
MMR rates 83.40 89.80 91.70 91.59 93.50 98.60
American Indian/Alaska Native 0.00 0.20 0.40 1.46 0.90 14.20
Asian 0.50 1.40 2.50 3.92 4.20 38.80
Black 0.00 3.00 7.00 10.84 15.10 50.20
Hispanic 1.00 4.60 9.00 11.22 13.20 48.20
Native Hawaiian/Pacific Islander 0.00 0.00 0.00 0.27 0.10 9.70
White 21.70 58.10 73.10 69.55 81.50 94.50
Multiracial 0.90 1.80 2.10 2.69 2.50 21.20
Economy Dimension 34.21 48.27 53.20 53.19 58.30 69.54
Jobs 2.200 4.300 5.500 5.848 7.200 13.700
Wages 35225 43966 48485 50334 55847 70538
Poverty 8.20 12.10 14.60 14.76 17.20 24.20
Income Inequality 3.71 4.32 4.63 4.70 4.96 7.40
Access To Banking Services 2.400 3.810 4.370 4.449 4.800 8.110
Affordable Housing 51.20 62.40 67.10 66.39 70.34 79.55
Education Dimension 23.79 45.32 50.70 50.23 54.93 66.50
Preschool Enrollment 29.30 41.40 45.80 46.53 50.10 86.36
High School Graduation 56.00 75.50 80.40 79.65 85.30 93.00
Postsecondary Education 23.29 33.30 36.95 37.05 40.80 59.70
Health Insurance Coverage 3.457 11.004 13.829 14.134 17.072 25.483
Access To Medical Care 157.4 216.2 251.9 270.6 285.1 1025.4
Community Dimension 37.61 48.85 53.84 54.00 59.24 76.93
Volunteering 16.68 23.93 27.13 27.86 31.70 45.58
Youth Disconnection 7.20 11.48 13.43 13.46 15.60 20.74
Violent Crime 99.3 255.0 336.3 376.1 454.8 1348.9
Access To Healthy Food 1.200 1.740 1.990 2.104 2.270 5.600
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Appendix B: Extended diagnosis codes used in the chronic conditions study
In this appendix, we describe the process of including additional ICD-9 diagnosis codes
to the existing hipxchange algorithm.
We selected the first 3 digits of the ICD-9 (International classification of diseases, Ninth
revision) diagnosis codes included in the hipxchange list [94]. This resulted to 396 unique
numbers. We went through each of the 396 codes in [74] and added necessary codes that
were not included in the initial list.
In particular, a shorter code was added only if all extensions of that code were included
in the hipxchange list and classified as the same condition. On the other hand, a longer
code was included only if its first set of digits (non-billable code) was included in the hipx-
change list. Note that code 3020 (Ego-dystonic sexual orientation) was changed from sleep
disorders to sexual and gender identity disorders, which is a subsection of the personality
disorder.
In total 640 additional codes were added to the initial hipxchange list. In particular, the
codes added for each condition are included in Table B.1.
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Table B.1: Additional ICD-9 codes.
Chronic Condition Category Codes
Allergy, ENT and other upper respiratory
disorders
4783, 477, 476, 474, 4741, 473, 472, 3890,
3860, 3811, 3812
Anemia and other non-cancer heme dis-
orders
2898, 28741, 28749, 286, 2852, 284, 283
Aneurysm 4477, 4432, 441, 442, 4428
Anxiety disorders 3075, 3000, 3002, 308
Asthma, COPD, other chronic lung dis-
ease
516, 5166, 495, 493, 4930, 4931, 4932, 4938,
4939, 492, 491
Coronary atherosclerosis 413, 411, 41402, 41403, 41404, 41405, 41407
Back problems 722, 7221, 7223, 7225, 7227, 7228, 7229, 721,
7214, 7219, 7208
Behavior disorders 318, 314, 315, 3150, 3153, 3140, 312, 3120,
3121, 3122, 3123, 3072, 299, 2990, 2991, 2998,
2999
Bipolar disorder 2960, 2961, 2964, 2965, 2966, 2968, 2969
Cerebrovascular Disease 3466, 4381, 4382, 4383, 4384, 4385, 4388, 435,
434, 433, 432
Congestive heart failure 428, 4282, 4283, 4284
Other central and peripheral nervous sys-
tem disorders
3382, 337, 3372, 336, 335, 3351, 3352, 334,
330, 046, 0467, 952, 9520, 9521, 3597, 3583,
356, 355, 354, 353, 348, 3470, 3471
Congenital Heart Disease 747, 7471, 7472, 7474, 7478, 7468, 745, 7451,
7456
Non-cardiac congenital disorder 754, 759, 758, 757, 7573, 756, 7561, 7565,
7568, 755, 7550, 7551, 7552, 7553, 7555, 7556,
7543, 7544, 7545, 7546, 7547, 7548, 753, 752,
7521, 7524, 751, 7516, 750, 7501, 7502, 749,
7490, 7491, 7492, 748, 7486, 744, 7440, 7442,
7444, 7448, 743, 7430, 7431, 7432, 7433, 7434,
7435, 7436, 740, 742, 7425, 741, 7410, 7419
Cystic fibrosis 2770
Organic brain problem (dementia) 290, 2901, 2902, 2904, 294, 2942
Dental and mouth disorders 5231, 5254, 5234
Depression and depressive disorders 2962, 2963
Diabetes mellitus 249, 2490, 2491, 2492, 2493, 2494, 2495, 2496,
2497, 2498, 2499, 250, 2500, 2501, 2502, 2503,
2504, 2505, 2506, 2507, 2508, 2509
continued . . .
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. . . Table B.1 continued
Chronic Condition Category Codes
Conduction disorder or cardiac dysrhyth-
mia
426, 427, 4273, 4274, 4276, 4278, 4261, 4265,
4268
Epilepsy 345
Esophageal disorder and GI ulcers 4562, 5357, 5344, 5346, 5345, 5347, 5349,
5334, 5336, 5335, 5337, 5339, 5326, 5325,
5327, 5329, 5316, 5315, 5317, 5319
Degenerative eye problem (glauc/eye) 3792, 3793, 3794, 3795, 377, 3770, 3771, 3772,
3773, 3774, 3775, 3776, 3777, 3761, 3762,
3763, 3764, 3765, 3768, 3721, 3705, 3706, 369,
3690, 3691, 3692, 3696, 3697, 365, 366, 3660,
3661, 3662, 3663, 3664, 3665, 3650, 3651,
3652, 3653, 3654, 3655, 3656, 3657, 3658, 362,
363, 3630, 3631, 3632, 3633, 3634, 3635, 3641,
3636, 3637, 3620, 3621, 3622, 3623, 3624,
3625, 3626, 3627, 3628, 3611, 360, 3600, 3601,
3602, 3603, 3604, 3605, 3606, 3608, 076
Female infertility and GU anatomic dis-
orders (e.g. prolapse, endometriosis)
6491, 6480, 6482, 6420, 6421, 6422, 6427,
6429, 6292, 626, 6257, 619, 618, 617
Diverticulosis, diverticulitis, enterocoli-
tis, intestinal malabsorption
562, 5620, 5621, 5584, 555
Gout or other crystal arthropathy 712, 7121, 7122, 7123, 7128, 7129, 274, 2741,
2748
Chronic Hepatitis 5714
Hypertension 405, 4050, 4051, 4059, 404, 403, 402, 4020,
4021, 4029, 401
Immunity disorder 288, 2885, 2886, 2790
Kidney and Vesicoureteral Disorders
(excl. renal failure)
596, 59681, 59682, 59683, 59689, 5900, 588,
583, 5838, 582, 5828, 581, 5818
Male GU excluding BPH 607, 6078
continued . . .
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. . . Table B.1 continued
Chronic Condition Category Codes
Malignant neoplasm 141, 143, 145, 146, 147, 148, 149, 150, 154,
159, 151, 153, 160, 158, 161, 162, 157, 163,
164, 144, 170, 171, 174, 172, 175, 155, 195,
198, 200, 2000, 2001, 2002, 2003, 2004, 2005,
2006, 2007, 201, 2010, 2011, 2012, 2014, 2015,
2016, 2017, 202, 2020, 2021, 2022, 2023, 2024,
2025, 2026, 2027, 2029, 2028, 2019, 2008, 208,
2090, 2091, 2092, 2093, 230, 231, 233, 234,
2333, 2097, 207, 206, 205, 204, 203, 199, 1988,
197, 196, 194, 192, 191, 176, 190, 187, 188,
189, 186, 180, 183, 184, 182, 165, 156, 152,
142, 140
Malnutrition and F/E cond (not
obesity/overweight)-includes disorders of
metabolism
275, 273, 272, 271, 270, 268, 263
Menopause and perimenopause 627
Acute myocardial infarction 410
Migraines 3463, 3464, 3465, 3467
Misc mental health 3078
Osteoarthritis 7193, 7160, 7162, 7163, 7164, 7165, 7166,
7168, 7169, 713, 715, 7150, 7151, 7152, 7153,
7158, 7159, 7181, 7185, 7187
Other endocrine 628, 258, 257, 256, 255, 253, 252, 251, 242,
2420, 2421, 2422, 2423, 2424, 2428, 2429, 244,
245, 241, 240
Other MSK including osteoporosis 7161, 717, 7174, 7178, 7180, 7184, 7371, 7372,
7373, 7374, 7330, 7334, 732, 730, 7300, 7301,
7302, 7303, 7307, 7308, 7309, 897, 887
Paralysis 343, 342, 3428
Personality disorder 301, 3011, 3012, 3015, 3018, 302, 3025, 3027,
3028
Pulmonary heart disease 416
Rheumatoid arthritis 714, 7143, 7148
Schizophrenia and Psychotic Disorders 295, 2950, 2951, 2952, 2953, 2954, 2955, 2956,
2957, 2958, 2959, 297
Sickle cell anemia 2826
Chronic skin ulcer 696, 707, 7072, 694, 6946
Sleep disorders 3274
STI 0932, 0541
continued . . .
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. . . Table B.1 continued
Chronic Condition Category Codes
Cardiomyopathy and Structural Heart
Disease
4297, 4298, 4141
Substance-use Disorders 291, 305, 3050, 3052, 3053, 3054, 3055, 3056,
3057, 3058, 3059, 303, 3030, 3039, 304, 3040,
3041, 3042, 3043, 3044, 3045, 3046, 3047,
3048, 6483, 3049
Tuberculosis 137
Thrombosis and Embolism 445, 4450, 4458, 444, 4442, 4535, 4537, 4448
Heart valve disorder 397, 396, 395, 394, 424, 4249
Non-thrombotic, non-athlerosclerotic
vascular disease
4438, 4593, 446, 457
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Appendix C: Extended output from the chronic conditions study
In this appendix, we include the complete version of Table 3.4 appearing in the main
text. The information is presented in Table C.1, which includes the average costs (and
standard deviations) for all 69 conditions taken into account in the study. The costs are
estimated based on individuals with each specific chronic condition but no other chronic
condition (columns 3 and 4), and all individuals that have been diagnosed with each condi-
tion (columns 5 and 6). Furthermore, in this appendix we include Table C.2, which includes
the complete regression output for the model used in the main text. The table also includes
additional information about the number of observations with each specific variable equal
to 1, and the average cost of patients with this variable equal to 1.
Table C.1: Ordering of conditions and corresponding costs.
Chronic Order Average Cost (and Std Dev) Average Cost (and Std Dev)
Condition members with only this cond. all members with this cond.
allergy 55 2,068 (2,914) 7,962 (12,341)
anemia 16 4,112 (7,654) 25,353 (34,793)
aneurysm 62 1,948 (2,093) 15,961 (21,645)
anxiety 53 2,157 (2,897) 8,921 (14,358)
asthma 42 2,742 (3,930) 12,526 (18,963)
athero 40 2,763 (4,674) 15,081 (21,050)
back 25 3,572 (5,998) 13,379 (17,333)
behavio 50 2,240 (2,803) 5,589 (9,435)
benign 7 8,473 (16,587) 12,453 (14,776)
continued . . .
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. . . Table C.1 continued
Chronic Order Average Cost (and Std Dev) Average Cost (and Std Dev)
Condition members with only this cond. all members with this cond.
bipol 32 3,206 (4,180) 10,104 (13,316)
bph 65 1,892 (2,891) 10,001 (15,045)
breast 48 2,333 (2,541) 6,451 (9,410)
cerebro 17 3,978 (6,321) 17,505 (22,390)
chf 60 1,958 (2,544) 25,987 (29,871)
chroninf 15 4,309 (13,239) 11,264 (15,657)
cnspns 28 3,508 (4,908) 16,404 (21,894)
concard 52 2,204 (3,673) 14,463 (21,893)
congen 36 2,991 (4,392) 12,795 (17,821)
cystic 1 18,245 (15,919) 32,056 (24,196)
dem 49 2,279 (2,803) 15,186 (20,356)
dental 69 706 (479) 14,033 (16,699)
depress 46 2,420 (3,056) 9,570 (15,115)
dm 33 3,180 (4,426) 11,252 (17,601)
dysrhy 30 3,401 (6,327) 17,082 (22,790)
epilepsy 29 3,446 (4,766) 12,513 (19,351)
esoph 43 2,738 (3,491) 10,660 (15,808)
eye 57 2,011 (3,316) 9,602 (14,456)
femalegu 26 3,554 (4,225) 7,154 (9,750)
gi 13 5,441 (8,697) 12,781 (17,469)
gout 67 1,387 (2,116) 13,641 (21,916)
hep 5 12,423 (29,036) 21,076 (36,295)
hiv 2 17,094 (10,167) 24,392 (17,381)
htn 63 1,925 (3,774) 9,070 (14,753)
hyprlip 66 1,669 (2,605) 8,351 (13,736)
immun 38 2,853 (4,019) 22,767 (32,132)
kidney 24 3,606 (4,312) 18,171 (25,258)
liver 27 3,530 (4,648) 15,559 (22,019)
lupus 44 2,553 (3,264) 11,831 (18,461)
malegu 54 2,079 (3,065) 8,548 (12,778)
malig 11 6,950 (13,331) 14,843 (20,473)
malnutr 56 2,044 (3,660) 9,867 (17,186)
menop 61 1,952 (2,132) 7,379 (10,708)
mi 6 12,136 (16,907) 30,792 (33,213)
migrain 22 3,691 (4,065) 8,399 (11,608)
miscmh 59 1,978 (3,820) 11,486 (15,093)
ms 4 15,599 (15,205) 23,994 (21,190)
obesity 47 2,352 (3,891) 10,128 (16,202)
continued . . .
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Chronic Order Average Cost (and Std Dev) Average Cost (and Std Dev)
Condition members with only this cond. all members with this cond.
osteo 23 3,626 (5,881) 12,327 (16,707)
othendo 39 2,822 (5,139) 9,320 (15,281)
othmsk 21 3,716 (4,727) 11,693 (17,301)
panc 9 7,323 (6,346) 19,722 (21,869)
para 20 3,741 (6,344) 20,970 (32,339)
parkin 14 4,453 (7,644) 15,202 (17,848)
periph 64 1,900 (2,646) 20,442 (26,943)
persnal 45 2,423 (3,708) 9,360 (14,110)
pulmhrt 34 3,086 (5,276) 28,448 (33,038)
renal 8 7,481 (17,098) 23,470 (31,909)
rheum 10 7,309 (9,896) 13,766 (17,321)
schiz 19 3,835 (5,730) 16,199 (21,398)
sickle 12 6,780 (7,344) 19,049 (21,786)
skin 18 3,923 (6,950) 14,029 (22,270)
sleep 51 2,237 (2,661) 11,644 (17,101)
sti 41 2,757 (3,330) 10,747 (21,627)
strctht 58 2,007 (4,110) 21,593 (27,815)
subst 35 2,994 (4,330) 8,951 (14,561)
tb 68 1,058 (0) 1,058 (0)
thrombemb 3 16,177 (24,393) 27,853 (34,436)
valve 37 2,982 (6,456) 15,361 (22,286)
vasc 31 3,316 (4,732) 17,812 (24,675)
Table C.2: Regression output, sample sizes, and average costs for each condition order.
Variable Coefficient Std Error p-value sample size average cost
(Intercept) 7.7921 0.0511 0.000 (-) (-)
allergy1 -0.1012 0.0528 0.055 9,837 2,326
allergy2 0.2488 0.0138 0.000 11,115 4,092
allergy3 0.0448 0.0085 0.000 29,788 11,268
anemia1 0.4910 0.0548 0.000 4,400 11,869
anemia2 0.8514 0.0250 0.000 3,898 32,959
anemia3 0.6357 0.0446 0.000 1,208 44,318
anemia4 0.4193 0.1119 0.000 203 58,741
aneurysm1 0.2142 0.1356 0.114 109 3,569
aneurysm2 0.3586 0.0795 0.000 276 4,644
aneurysm3 0.1863 0.0631 0.003 440 6,953
aneurysm4 0.2294 0.0561 0.000 556 9,350
aneurysm5 0.1172 0.0264 0.000 2,612 20,598
continued . . .
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Variable Coefficient Std Error p-value sample size average cost
anxiety1 -0.0853 0.0532 0.109 7,672 2,376
anxiety2 0.2866 0.0138 0.000 11,169 4,037
anxiety3 0.1554 0.0152 0.000 9,320 6,163
anxiety4 0.1963 0.0185 0.000 6,263 9,204
anxiety5 0.1718 0.0142 0.000 11,490 20,121
asthma1 0.1866 0.0525 0.000 12,167 3,831
asthma2 0.4741 0.0148 0.000 10,763 7,106
asthma3 0.2965 0.0169 0.000 8,107 10,817
asthma4 0.2775 0.0203 0.000 5,457 14,849
asthma5 0.2067 0.0157 0.000 9,870 29,272
athero1 0.3240 0.0545 0.000 4,928 4,747
athero2 0.4888 0.0171 0.000 8,214 7,818
athero3 0.2437 0.0178 0.000 7,902 11,090
athero4 0.2136 0.0196 0.000 6,303 14,815
athero5 0.0961 0.0164 0.000 10,977 28,182
back1 0.4839 0.0526 0.000 11,272 7,547
back2 0.5116 0.0181 0.000 8,026 13,013
back3 0.2830 0.0246 0.000 4,489 17,539
back4 0.2494 0.0351 0.000 2,075 23,952
back5 0.1109 0.0433 0.010 1,213 36,514
behavio1 -0.0579 0.0556 0.298 3,567 2,485
behavio2 0.2548 0.0257 0.000 2,829 4,043
behavio3 0.1624 0.0354 0.000 1,480 6,510
behavio4 0.1424 0.0329 0.000 1,679 13,979
benign1 0.5307 0.0761 0.000 537 12,453
bipol1 0.3362 0.0552 0.000 4,033 5,754
bipol2 0.4406 0.0324 0.000 1,866 10,326
bipol3 0.2617 0.0484 0.000 808 15,574
bipol4 0.1935 0.0491 0.000 787 26,259
bph1 -0.2036 0.0667 0.002 939 1,962
bph2 0.2405 0.0314 0.000 1,859 3,225
bph3 0.1356 0.0265 0.000 2,668 4,670
bph4 0.1314 0.0251 0.000 2,881 5,958
bph5 0.0436 0.0133 0.001 11,239 14,095
breast1 0.0272 0.0805 0.735 443 2,672
breast2 0.2932 0.0703 0.000 350 4,851
breast3 0.1509 0.0894 0.092 216 6,883
breast4 0.2073 0.0792 0.009 275 14,238
cerebro1 0.4740 0.0533 0.000 8,876 12,709
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Variable Coefficient Std Error p-value sample size average cost
cerebro2 0.2700 0.0217 0.000 5,288 25,556
ch f1 0.0254 0.1923 0.895 50 2,836
ch f2 0.4672 0.0900 0.000 217 5,021
ch f3 0.3610 0.0597 0.000 519 8,079
ch f4 0.3398 0.0469 0.000 849 10,390
ch f5 0.2641 0.0164 0.000 9,800 28,869
chronin f1 0.3632 0.0680 0.000 856 8,904
chronin f2 0.2150 0.0814 0.008 264 18,916
cnspns1 0.4044 0.0531 0.000 8,335 7,293
cnspns2 0.4965 0.0173 0.000 8,753 12,802
cnspns3 0.3103 0.0217 0.000 6,009 18,434
cnspns4 0.3239 0.0286 0.000 3,536 24,523
cnspns5 0.2248 0.0303 0.000 3,018 38,454
concard1 -0.0473 0.1060 0.656 199 2,584
concard2 0.4256 0.0685 0.000 375 5,553
concard3 0.2000 0.0663 0.003 399 7,389
concard4 0.2330 0.0709 0.001 347 10,874
concard5 0.2061 0.0444 0.000 893 25,407
congen1 0.2620 0.0615 0.000 1,462 4,578
congen2 0.4739 0.0335 0.000 1,631 8,430
congen3 0.2278 0.0363 0.000 1,398 11,777
congen4 0.2619 0.0447 0.000 923 16,137
congen5 0.1160 0.0382 0.002 1,254 26,727
cystic1 1.8343 0.1899 0.000 51 32,056
dem1 0.1560 0.0844 0.065 381 3,440
dem2 0.4230 0.0456 0.000 850 5,665
dem3 0.1934 0.0388 0.000 1,186 8,128
dem4 0.0701 0.0193 0.000 5,423 19,047
dental1 0.5280 0.3505 0.132 14 14,033
depress1 0.0495 0.0520 0.342 18,674 3,024
depress2 0.3927 0.0127 0.000 16,646 5,661
depress3 0.2277 0.0149 0.000 11,368 8,619
depress4 0.2453 0.0181 0.000 7,016 12,339
depress5 0.1903 0.0143 0.000 12,271 24,133
dm1 0.2698 0.0518 0.000 28,222 5,018
dm2 0.3956 0.0138 0.000 18,210 9,259
dm3 0.1950 0.0170 0.000 10,510 13,830
dm4 0.2207 0.0225 0.000 5,729 19,636
dm5 0.1158 0.0216 0.000 5,970 34,211
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Variable Coefficient Std Error p-value sample size average cost
dysrhy1 0.4445 0.0528 0.000 11,196 8,042
dysrhy2 0.5525 0.0172 0.000 9,562 13,560
dysrhy3 0.3299 0.0207 0.000 6,604 18,937
dysrhy4 0.3440 0.0270 0.000 3,905 25,779
dysrhy5 0.1731 0.0263 0.000 3,941 39,585
epilepsy1 0.3540 0.0630 0.000 1,261 5,540
epilepsy2 0.4303 0.0504 0.000 702 9,597
epilepsy3 0.3479 0.0663 0.000 408 16,216
epilepsy4 0.2273 0.0590 0.000 520 30,454
esoph1 0.1201 0.0527 0.023 10,354 3,465
esoph2 0.3528 0.0139 0.000 12,445 5,935
esoph3 0.1932 0.0155 0.000 9,632 9,101
esoph4 0.1998 0.0184 0.000 6,724 12,498
esoph5 0.1144 0.0144 0.000 11,198 22,801
eye1 -0.0491 0.0527 0.351 10,688 2,458
eye2 0.2701 0.0134 0.000 13,758 4,339
eye3 0.0305 0.0069 0.000 63,387 11,948
f emalegu1 0.4102 0.0521 0.000 15,173 5,251
f emalegu2 0.3935 0.0233 0.000 3,822 9,373
f emalegu3 0.1548 0.0382 0.000 1,350 13,133
f emalegu4 0.1525 0.0469 0.001 866 21,387
gi1 0.5305 0.0522 0.000 16,630 10,121
gi2 0.3941 0.0252 0.000 3,745 21,649
gi3 0.2692 0.0734 0.000 463 36,597
gout2 0.0200 0.0637 0.754 427 2,479
gout3 0.1155 0.0501 0.021 696 3,441
gout4 0.1266 0.0424 0.003 975 4,753
gout5 0.0974 0.0176 0.000 5,914 17,601
hep1 1.0308 0.0586 0.000 1,749 21,076
hiv1 1.7206 0.0649 0.000 913 24,392
htn1 -0.2024 0.0523 0.000 17,507 1,987
htn2 0.1715 0.0108 0.000 30,227 3,423
htn3 0.0480 0.0101 0.000 33,998 4,963
htn4 0.1334 0.0097 0.000 29,656 6,904
htn5 0.1331 0.0088 0.000 77,225 15,527
hyprlip1 -0.3742 0.0533 0.000 7,600 1,666
hyprlip2 -0.0228 0.0110 0.039 19,477 2,463
hyprlip3 -0.0834 0.0103 0.000 28,801 3,561
hyprlip4 -0.0137 0.0065 0.034 123,944 10,799
continued . . .
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. . . Table C.2 continued
Variable Coefficient Std Error p-value sample size average cost
immun1 0.1473 0.0775 0.057 504 4,109
immun2 0.5386 0.0531 0.000 626 10,034
immun3 0.4991 0.0546 0.000 595 18,180
immun4 0.4393 0.0622 0.000 459 23,492
immun5 0.3739 0.0465 0.000 835 46,447
kidney1 0.3423 0.0568 0.000 2,887 7,679
kidney2 0.3431 0.0241 0.000 3,801 12,716
kidney3 0.2387 0.0289 0.000 2,819 21,261
kidney4 0.2315 0.0402 0.000 1,470 29,884
kidney5 0.1157 0.0499 0.021 893 46,269
liver1 0.2540 0.0598 0.000 1,795 6,097
liver2 0.5557 0.0340 0.000 1,640 14,474
liver3 0.3096 0.0449 0.000 949 21,396
liver4 0.1505 0.0500 0.003 771 32,712
lupus1 0.0475 0.0238 0.046 3,416 11,831
malegu1 -0.0286 0.0666 0.668 948 2,764
malegu2 0.0608 0.0180 0.001 5,718 9,507
malig1 0.8265 0.0518 0.000 27,394 13,472
malig2 0.5110 0.0307 0.000 2,787 26,871
malig3 0.2413 0.1234 0.051 142 43,331
malnutr1 -0.2338 0.0544 0.000 5,070 2,121
malnutr2 0.0939 0.0152 0.000 9,444 3,614
malnutr3 -0.0219 0.0147 0.136 9,615 5,570
malnutr4 0.0335 0.0160 0.037 7,862 7,920
malnutr5 0.0765 0.0114 0.000 16,810 19,084
menop1 -0.1540 0.0637 0.016 1,185 2,132
menop2 0.1782 0.0322 0.000 1,709 3,513
menop3 0.0413 0.0166 0.013 6,562 9,333
mi1 0.7898 0.0634 0.000 1,313 30,792
migrain1 0.3656 0.0529 0.000 9,330 6,444
migrain2 0.4167 0.0309 0.000 2,079 12,861
migrain3 0.1674 0.0545 0.002 631 22,601
miscmh1 -0.2627 0.1459 0.072 92 1,909
miscmh2 0.1560 0.1097 0.155 143 3,405
miscmh3 0.0233 0.1054 0.825 155 4,996
miscmh4 0.1125 0.0508 0.027 674 16,000
ms1 1.6102 0.0579 0.000 2,208 23,994
obesity1 -0.1056 0.0543 0.052 5,086 2,598
obesity2 0.2701 0.0168 0.000 7,646 4,755
continued . . .
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. . . Table C.2 continued
Variable Coefficient Std Error p-value sample size average cost
obesity3 0.1779 0.0183 0.000 6,354 7,680
obesity4 0.2364 0.0217 0.000 4,366 11,216
obesity5 0.2045 0.0174 0.000 6,777 23,436
osteo1 0.4383 0.0517 0.000 29,081 8,241
osteo2 0.3949 0.0148 0.000 18,938 12,615
osteo3 0.2169 0.0226 0.000 7,465 18,979
osteo4 0.1067 0.0346 0.002 3,142 32,600
othendo1 0.0582 0.0518 0.261 23,329 3,443
othendo2 0.2619 0.0122 0.000 20,236 6,418
othendo3 0.0849 0.0150 0.000 12,388 9,851
othendo4 0.1066 0.0184 0.000 7,546 13,893
othendo5 0.0555 0.0167 0.001 8,966 26,579
othmsk1 0.3514 0.0520 0.000 19,666 7,775
othmsk2 0.2894 0.0196 0.000 8,528 13,860
othmsk3 0.1542 0.0288 0.000 3,580 28,050
panc1 0.7735 0.0896 0.000 295 19,722
para1 0.5363 0.0841 0.000 391 9,274
para2 0.6710 0.0732 0.000 336 21,053
para3 0.5027 0.0921 0.000 214 42,209
parkin1 0.5420 0.0621 0.000 1,419 13,185
parkin2 0.1908 0.0619 0.002 472 21,265
periph1 -0.1031 0.1767 0.560 60 2,178
periph2 0.7286 0.0951 0.000 191 5,179
periph3 0.3841 0.0692 0.000 364 5,950
periph4 0.3566 0.0541 0.000 597 7,870
periph5 0.1572 0.0164 0.000 7,516 22,676
persnal1 -0.0564 0.0724 0.436 654 3,043
persnal2 0.2485 0.0501 0.000 704 5,471
persnal3 0.1209 0.0387 0.002 1,188 15,143
pulmhrt1 0.9215 0.1259 0.000 130 14,719
pulmhrt2 0.8678 0.0834 0.000 253 19,857
pulmhrt3 0.3522 0.0813 0.000 267 19,930
pulmhrt4 0.1389 0.0522 0.008 672 37,722
renal1 0.6163 0.0532 0.000 11,244 22,126
renal2 0.4216 0.0676 0.000 512 52,826
rheum1 0.6939 0.0533 0.000 6,855 12,834
rheum2 0.2665 0.0626 0.000 521 26,030
schiz1 0.4774 0.0589 0.000 2,077 10,274
schiz2 0.4685 0.0564 0.000 584 22,256
continued . . .
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. . . Table C.2 continued
Variable Coefficient Std Error p-value sample size average cost
schiz3 0.1830 0.0703 0.009 378 39,402
sickle1 1.1121 0.1356 0.000 109 16,705
sickle2 0.7573 0.3188 0.018 17 34,080
skin1 0.4735 0.0527 0.000 10,077 8,817
skin2 0.4182 0.0268 0.000 3,220 18,432
skin3 0.3375 0.0458 0.000 945 37,202
skin4 0.0969 0.0750 0.196 354 60,463
sleep1 0.0781 0.0562 0.164 3,133 2,961
sleep2 0.4378 0.0222 0.000 3,888 5,143
sleep3 0.2447 0.0221 0.000 3,955 7,409
sleep4 0.2466 0.0250 0.000 3,135 10,623
sleep5 0.1386 0.0169 0.000 7,122 21,814
sti1 0.0179 0.1064 0.866 197 3,045
sti2 0.4920 0.1110 0.000 140 7,932
sti3 0.2162 0.1527 0.157 74 10,335
sti4 0.3799 0.2219 0.087 35 14,749
sti5 0.4230 0.1842 0.022 51 46,078
strctht1 -0.0441 0.1024 0.667 221 2,730
strctht2 0.2530 0.0578 0.000 552 5,031
strctht3 0.2236 0.0447 0.000 940 8,126
strctht4 0.2302 0.0379 0.000 1,267 10,392
strctht5 0.1393 0.0175 0.000 7,576 26,894
subst1 0.1974 0.0520 0.000 18,449 4,192
subst2 0.4639 0.0158 0.000 9,648 8,736
subst3 0.3136 0.0224 0.000 4,437 14,126
subst4 0.2960 0.0322 0.000 2,024 19,788
subst5 0.2042 0.0328 0.000 1,849 33,290
tb1 -0.8281 1.3114 0.528 1 1,058
thrombemb1 0.7685 0.0830 0.000 400 27,853
valve1 0.1872 0.0582 0.001 2,290 4,953
valve2 0.3141 0.0240 0.000 3,748 8,369
valve3 0.0775 0.0157 0.000 9,402 20,683
vasc1 0.2197 0.0686 0.001 806 5,361
vasc2 0.3694 0.0383 0.000 1,255 9,684
vasc3 0.1583 0.0413 0.000 1,099 14,658
vasc4 0.2256 0.0474 0.000 846 20,569
vasc5 0.0917 0.0404 0.023 1,161 36,218
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Appendix D: Sensitivity analysis: Impact of inclusion criteria used in the
chronic conditions study
In this appendix, we investigate the impact of changing the inclusion criteria (i.e., when
a member is considered to have a chronic condition) on the cost contributions that were
estimated in the main analysis. We study the effect of stricter (see Subsection D.1), and
more flexible inclusion criteria (see Subsection D.2). In both cases, we use the same Lmax
as in the main analysis (i.e., Lmax = 5), as well as the same number of centers for the
clustering analysis (i.e., 2 centers).
D.1 Stricter inclusion criteria
We require a member to have at least one claim with a corresponding diagnoses code
in 2012, and a second claim with a diagnoses code (for the same condition) at least twelve
months apart. Thus, our inclusion criteria is stricter than it was in the main analysis. These
inclusion criteria identify 375,157 members with at least one chronic condition in 2012.
Figure D.1 shows a similar effect to that of Figure 3.1 in the main analysis, where the












Figure D.1: Counts of members with each number of chronic conditions in the stricter inclusion
criteria population.
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of chronic condition increased. In this case, the average number of chronic conditions per
member was 3.6 (with a standard deviation of 2.65), which are slightly lower numbers
compared to the main analysis.
The resulting regression model (after applying Algorithm 1) consists of 11 fewer vari-
ables, which means that some conditions correspond to a smaller number of coefficients
than they did in the main analysis. There are no members with tuberculosis in this data set,
so this condition is not included in this model.
Figure D.2, shows the slopes of the coefficients for each chronic condition consisting
of at least two coefficients. We see that there are no conditions with a negative slope. In
the main analysis, there were three conditions with a negative slope. Two of the conditions
only consist of one coefficient in this model, so we cannot draw any conclusions about
their slope. However, Parkinson’s disease still consists of two coefficients and has a small
positive slope in this case, which gives us the opposite effect of what was estimated in
the previous analysis. While all conditions have a positive slope, chronic hepatitis has a
considerably higher slope than the rest. This condition only consisted of one coefficient in
the main analysis, so we had no information about its slope.
The clusters resulting from the clustering analysis have a similar effect as the clusters
resulting from the main analysis, since one cluster included conditions with a relatively
constant increase as the order that they appear in a member increases, and the other cluster
included conditions that did not have a clear increase in cost. In total, 46 conditions were































































Figure D.2: Slopes for each chronic condition in the stricter inclusion criteria population.
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Table D.1: Conditions that switched clusters compared to the main analysis (stricter criteria).
Change Names of conditions
From 1st-type to 2nd-type cluster Chronic skin ulcer | Osteoarthritis | Non-thrombotic, non-
athlerosclerotic vascular disease
From 2nd-type to 1st-type cluster Aneurysm | Other MSK including osteoporosis | Epilepsy
| Female infertility and GU anatomic disorders | Hyperlipi-
demia | Peripheral atherosclerosis | Other central and periph-
eral nervous system disorders
long in the same type of cluster as they did in the main analysis. Note that if the number
of cost coefficients corresponding to a condition changed, but the condition continued to
belong to the same type of cluster, we assume that this condition did not change its cost
behavior. Table D.1 includes the 10 conditions that switched the type of cluster that they
were included in. Below we investigate in more detail what caused these changes.
In the main analysis, both hyperlipidemia, and peripheral atherosclerosis, had a contri-
bution that was relatively stable after an increase from being ordered first to second. While
in the main analysis they were both included in the type-2 cluster, they were an exception
compared to how the other conditions of the cluster behaved. In the model of this section,
both conditions had their coefficient decrease by 1, but their behavior remained consistent
to the conditions of a type-1 cluster. In the case of female infertility and GU anatomic dis-
orders, in the main analysis the cost contributions of this condition do not reveal any clear
patterns, as they fluctuate from one order to the next. In this section, the cost contribution
behaves more as a type-1 cluster.
In the case of aneurysm, the last coefficient affects the selected cluster (slight decrease,
compared to an increase observed in the main analysis), but the cost magnitude is similar in
both models. Similarly, in epilepsy, the last coefficient, which corresponded to 360 obser-
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vations, indicated a small decrease compared to a previously constant increase (observed
in the main analysis). This caused the condition to be included in a different cluster. Nev-
ertheless, the cost magnitude remained about the same. The same is true for other central
and peripheral nervous system disorders. For other MSK including osteoporosis, in this
version of the model there were coefficients that were not statistically significant, and the
condition consisted of five instead of three variables (as in the main analysis), with the cost
contribution in the fifth order being slightly lower than the fourth. This led the condition to
be included in a different cluster.
Regarding chronic skin ulcer, in the original analysis, the coefficient corresponding to
the last order (ranked fourth or higher in a patient), was not statistically significant. This
was the coefficient that affected the decision for entering the type-1 cluster, since it showed
a decrease compared to previous contributions. However, in this version the coefficient is
statistically significant and shows a continued increase.
For the remaining two conditions, there is a more clear difference compared to the
main analysis. In particular, for osteoarthritis, there was a different effect observed, with
an increase instead of a decrease in the contribution. Nevertheless, the magnitude of cost
was similar. Finally, for non-thrombotic, non-athlerosclerotic vascular disease, 488 patients
cause a very large increase in the last coefficient, which corresponds to the condition being
ranked third of higher in a patient. In the main analysis, the condition consisted of five














Figure D.3: Counts of members with each number of chronic conditions in the more flexible inclu-
sion criteria population.
D.2 More flexible inclusion criteria
We require a member to have at least one claim with a corresponding diagnoses code
in 2012, and at least two claims (for the same condition) in total during the 2007-2012
time period. Thus, our inclusion criteria is more flexible than it was in the main analysis.
In total, we identify 458,835 members with at least one chronic condition diagnosis in
2012. Figure D.3 shows a similar exponential decrease to that of the main analysis and the
stricter inclusion criteria version. In this case the average number of chronic conditions per
member was 4.1 (with a standard deviation of 3.1), which shows that an increased number
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of conditions were diagnosed compared to the other two versions.
The resulting regression model (after applying Algorithm 1) consists of 21 more vari-
ables than it did in the main analysis, which means that some conditions correspond to an
increased number of coefficients compared to the main analysis.
Figure D.4, shows the slopes of the coefficients for each chronic condition. The only
condition with a negative slope is Parkinson’s disease. This condition also had a negative
slope in the main analysis, but in this case the absolute value of the slope is smaller. Of
the other two conditions that had a negative slope in the main analysis, rheumatoid arthritis
now consists of only one coefficient (so a slope cannot be estimated), and pulmonary heart
disease was included in a 1st-type cluster in the clustering analysis that follows below,
which shows that even though its slope was not negative, a decrease in the cost contribution
was observed.
The two clusters had again similar characteristics to those included in the main analysis,
and the analysis of Subsection D.1. In total, 55 chronic conditions were taken into account
in the clustering analysis. While the majority of conditions were included in same type of
cluster as in the main analysis, 13 conditions were included in a different cluster. Table D.2
includes those conditions. Most conditions that switched a cluster were different than the
analysis of Subsection D.1. The only exceptions were aneurysm, hyperlipidemia, and other
central and peripheral nervous system disorders. Below we describe the changes observed
in the cost behavior of the conditions included in Table D.2.



































































Figure D.4: Slopes for each chronic condition in the stricter inclusion criteria population.
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Table D.2: Conditions that switched clusters compared to the main analysis (more flexible criteria).
Change Names of conditions
From 1st-type to 2nd-type cluster Non-cardiac congenital disorder | Conduction disorder or
cardiac dysrhythmia | Esophageal disorder and GI ulcers |
Kidney and Vesicoureteral Disorders (excl. renal failure) |
Chronic Liver Disease (excl. chronic hepatitis) | Chronic
skin ulcer | Migraines
From 2nd-type to 1st-type cluster Aneurysm | Behavior disorders | Bipolar disorder | Other
central and peripheral nervous system disorders | Immunity
disorder | Hyperlipidemia
first to the second order. While in the main analysis it was included in the type-2 cluster,
it was an exception compared to the other conditions of the cluster. In the case of chronic
skin ulcer, the last coefficient was not statistically significant in the main analysis, which
led to a different result (the same that this condition was in a different cluster in the stricter
version of Subsection D.1).
Non-cardiac congenital disorder has a similar cost magnitude as in the main analysis,
but in the main analysis there is a slight decrease observed in the last coefficient which is
not present here. Similarly, for conduction disorder or cardiac dysrhythmia, in the main
analysis there is a decrease observed in the last coefficient which is not present here (the
cost contribution is similar). In the main analysis, for kidney and vesicoureteral disorders
(excl. renal failure), only the last coefficient shows a small decrease, which is not present
here (the cost contribution continues to increase). The result was based on 893 observations
in the main analysis. Bipolar disorder has a similar cost magnitude to the results of the main
analysis, but one additional coefficient, which corresponds to a slight decrease. This moved
the condition to a different cluster. For esophageal disorder and GI ulcers, the magnitude is
the same, but the increase is more gradual compared to the main analysis. For other central
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and peripheral nervous system disorder, the last coefficient changes to a slight decrease,
but other than that the effect is very similar.
Behavior disorders have similar cost magnitude to the main analysis, but one additional
coefficient, which corresponds to a slight decrease Immunity disorder have a similar cost
magnitude, but the highest cost is reached in the fourth order and then remains stable. in
the main analysis the cost cost contribution had a more gradual increase. In the case of
migraines, the cost magnitude is very similar to the main analysis, but the second and third
order contributions are reversed in this analysis.
Aneurysm has similar cost contributions, but in this case there is a large increase from
the first to the second order and then the cost remains relatively stable. Finally, for chronic
liver disease (excl. chronic hepatitis), in this model there is a constant increase, while in
the main analysis there is a decrease after the second condition.
From this sensitivity analysis we see that in the majority of cases, the conditions con-
tinue to behave in a similar manner. While small changes may affect the type of cluster that
some conditions are included in, with only very few exceptions the cost magnitude con-
tinues to be the same. Thus, we see that the proposed methodology can be used to obtain
good estimates of the cost contributions of conditions, in patients with multiple chronic
conditions.
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Appendix E: Conversational agent scripts used in the technology adoption
study
Tables E.1 and E.2 include the script followed by the conversational agents. In particu-
lar, Table E.1 includes the questions asked of the patient, and the corresponding action of
the conversational agent based on the patient’s answer (i.e., what to comment, and which
question to ask next). Table E.2 includes the comments that the conversational agent makes












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix F: Regression output from the technology adoption study
Table F.1 includes the linear regression model for predicting the number of times that
the patient used the conversational agent technology, after excluding all race variables from
the options of the best subsets method.
Table F.1: Regression output, adjusted R2 = 15%.
Variable Coefficient 95% CI P-value
(intercept) 20.3136 -13.7409 54.3680 0.2338
Age 0.6798 -0.0032 1.3628 0.051
Household income higher than $100,000 3.2320 -14.2304 20.6944 0.7092
Some high school/ High school graduate -17.9758 -34.6146 -1.3371 0.035
Number of medications to manage HF -2.3482 -5.7876 1.0912 0.1743
Avatar study participant -19.3634 -38.3248 -0.4019 0.0456
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Appendix G: Procedure diagrams used in the multi-appointment schedul-
ing study
In this appendix, we include the procedure diagrams (Figures G.1 through G.5), a short
description of the procedures that the patients go through in each step, and the resources
required.











Figure G.1: Procedure diagram for TMVR patients.





Figure G.2: Procedure diagram for PFO patients.
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Figure G.4: Procedure diagram for Watchman patients.









Figure G.5: Procedure diagram for elective surgery patients.
A transthoracic echocardiogram (TTE) uses sound waves to generate moving images of
the heart. Another type of echocardiogram is the transesophageal echocardiogram (TEE),
which generates clearer images than the TTE. However, the procedure takes a longer time,
requires more resources and can be more difficult for the patient to go through. Some
patients are not allowed to go through a TEE due to their history. In a computed tomography
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(CT) scan, multiple X-ray images are combined to create tomographic images of the heart.
A carotid ultrasound uses sound waves to create images of the inside of the carotid arteries.
Pulmonary function tests (PFT) are a group of tests that determine how well the lungs of the
patient are functioning. During the procedure readiness evaluation and preparation (PREP),
the patients go through a number of tests to ensure that they are ready to go through the final
interventional procedure or surgery. All of the aforementioned diagnostic tests take place in
labs and use personnel and equipment resources specifically dedicated to the corresponding
test. These resources are shared among many departments in the hospital.
In the consultations the patients usually get examined by the physician that will perform
the final procedure. Two surgeons, an interventional cardiologist, and a nurse practitioner
participate in the consultation of the TAVR patients. A surgeon, an interventional cardiol-
ogist, and a nurse practitioner participate in the first consultation of a TMVR patient. The
second consultation of a TMVR patient is with a heart failure cardiologist. In the case of
the PFO closure and the valvuloplasty, the consultation is with an interventional cardiolo-
gist, and in the case of the elective surgery patients, the consultation is with the surgeon.
Finally, the consultation of the Watchman patients is with an electrophysiologist and a sur-
geon. It is important to point out that the physicians specialize in a particular program, and
therefore an interventional cardiologist who performs a TAVR procedure, for example, will
not do a TMVR procedure. The only exception is in the case of the PFO closure and the
valvuloplasty procedures, which can be performed by the same interventional cardiologist.
During the cardiac catheterization (Cath) a catheter is inserted to a blood vessel leading
209
to the heart, where it is possible to evaluate the function of the heart and open any blocked
arteries. The procedure is performed by an interventional cardiologist and takes place in
a cardiac catheterization lab. The TAVR and the TMVR procedures take place in a hybrid
operating room (OR) by a team that includes a surgeon and an interventional cardiologist,
the PFO closure is performed in a hybrid OR by an interventional cardiologist, and the
valvuloplasty is performed in a cardiac catheterization lab by an interventional cardiolo-
gist. The Watchman takes place in a electrophysiology (EP) lab, with a team including an
electrophysiologist and an echocardiogram doctor. Finally, surgeries take place in a OR.
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Appendix H: Example of decision variable values used in the multi-appointment
scheduling study
In this appendix, we use the example presented in Figure H.1 and Table H.1 in order
to better illustrate the differences between the various decision variables of the IP. Figure
H.1 provides an example of the appointments scheduled for a TAVR patient i. The top part
of the figure shows the procedure diagram for this patient, who has to follow one of the
two paths. The procedure diagram also shows the indexing for the positions (parameter
s) and the procedures (parameter p) that this patient may have to go through. The bottom
part of the figure includes part of the patient’s schedule. In particular, the appointment for
the TAVR procedure has been excluded. The schedule also shows the values for some of
the parameters of the problem. It includes the corresponding p and s values, which are
generated based on the possible paths that the patient can follow. Also, each day includes
the corresponding d value. For illustrative purposes, we assume that Monday is the first day
of the planning horizon, and therefore d = 1. The h values are also included in the figure.
Not all times included in each day can be seen in the schedule. Nevertheless, by the values
of h it can be understood that in a complete schedule each day would include 48 different
























Monday (d=1) Tuesday (d=2) Wednesday (d=3) Thursday (d=4)
Time h h h h
... ... ... ... ...
9:30 19 67 115 163
10:00 20 CT Scan (s=2, p=1) 68 116 164
10:30 21 69 117 165
11:00 22 70 118 166 PFT (s=10, p=5)
11:30 23 71 119 167
12:00 24 72 120 168
12:30 25 73 121 169
13:00 26 74 122 170





14:30 29 77 125 173
15:00 30 78 126 174
15:30 31 79 127 175
... ... ... ... ...
Figure H.1: Part of appointments scheduled for TAVR patient i.
Table H.1 provides the values that some of the variables would take in the example
presented in Figure H.1. It can be observed that variable whi,s takes the value 1, once the
time that a specific procedure is scheduled for comes, and for all future times after that.
On the other hand, variable yhi,s only takes the value 1 during the times that the patient is
scheduled to go though a specific procedure s. Variable xdi,p takes the value 1 only for the
day that a patient is scheduled to go through a procedure p, while variable xdi takes the
value 1 only for the days that the patient has an appointment scheduled. Finally, variables
udi and v
d
i give the earliest and the latest time that a patient is scheduled to be in a procedure
on day d. Note that time in this case counts from the beginning of each day, and not form
the beginning of the planning horizon.
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Table H.1: Values that the variables take in the example illustrated in Figure H.1.
Variable Value Position Time/Day
whi,s 0 s = 2 h≤ 19
1 h≥ 20
0 s = 4 h≤ 27
1 h≥ 28
0 s = 10 h≤ 165
1 h≥ 166
yhi,s 0 s = 2 h≤ 19, h≥ 21
1 h = 20
0 s = 4 h≤ 27, h≥ 31
1 h = 28, h = 29, h = 30
0 s = 10 h≤ 165, h≥ 167
1 h = 166
xdi,p 0 p = 1 d 6= 1
1 d = 1
0 p = 2 d 6= 1
1 d = 1
0 p = 5 d 6= 4
1 d = 4
xdi 0 d = 2, d = 3
1 d = 1, d = 4
udi 0 d = 2, d = 3
20 d = 1
22 d = 4
vdi 0 d = 2, d = 3
30 d = 1
22 d = 4
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Appendix I: Simulation parameters used in the multi-appointment schedul-
ing study
In this appendix, we include the parameters used in the simulations. In particular, Table
I.1 includes the number of resources of each type that are present in the hospital. Based on
these numbers, we generate the initial availability of resources.
Table I.1: Number of each type of resource present in the hospital.
Lab # Personnel #
TTE 1 Electrophysiologist 1
Carotid ultrasound 1 Heart failure cardiologist 1
PFT 1 Cardiothoracic surgeon (x 6 types) 2
Cardiac catheterization 3 Interventional cardiologist (x 3 types) 1
CT scan 1 Nurse practitioner (x 3 types) 1
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